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housed in a flexible arm (Acrobat HD ultra-long arm/ Enhanced Vision 
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Enhanced Vision – USA, cost: £1,831) (Enhanced Vision, 2015). 
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2.6 A mouse video magnifier. The camera is incorporated within the 
mouse that can be attached to a computer or TV screen (Max mouse 
electronic magnifier, Enhanced Vision – USA, cost (not including the 
screen): £125) (Enhanced Vision, 2015). 
 
73 
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Enhanced Vision – USA, cost: £930) (Enhanced Vision, 2015). 
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2.8 Kindle (Kindle, USA) and Sony (Sony Corporation, Japan) readers 
(Mariosundar, 2007). 
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3.1 A PELVA (Compact+) is used by people with visual impairment to 
magnify a text or an object and to enhance contrast. The image 
contrast relationship is the same as the target; in the example a black 
target on a white background (Left). The image contrast relationship 
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is opposite to the target (contrast reverse); in this example a white 
target against a white background (Right). 
 
3.2 A PELVA (Compact+) incorporates: 1) a display screen, 2) a collapsible 
handgrip, 3) an on/off switch, 4) a snapshot button to freeze an image 
on the display screen temporarily, 5) a power adaptor for 
rechargeable batteries, 6) a camera unit: auto-focus camera, 7) a 
battery compartment, 8) a mode button for a contrast viewing mode 
selection (e.g. a black letter on a white background or a white letter 
on a black background),  and 9) a magnification dial: a control to 
change magnification levels. 
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3.3 The travelling microscopes (MA and MB) used to measure image sizes. 
Left, Microscope (MA) by PTI (England), and right, Microscope (MB) 
by Griffin and George (England). 
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display screen to the opposite corner, was measured by using an inch 
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3.5 Small “L” letter sized N8 on a Bailey-Lovie near acuity chart was used 
as a viewing object in order to measure the image size. The image is 
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3.6 The measured screen diameter (the mean of 3 measurements in 
inches) and reported screen diameter of 12 PELVA.  All values lie close 
to the reference (no change) line. Pearson Correlation Coefficient = 
0.998 (p < 0.001).   
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3.7 Bland-Altman plot shows the differences in magnification 
measurements between Microscope MA and Microscope MB.  
Magnification was measured for 4 PELVAs (B, C, D and E) by 2 
observers (3 measurements each (n=6), at each zoom level). Mean 
difference (0.035) (bold black line); limits of agreement 0.54 and -0.47 
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3.8 Bland-Altman plot shows the differences in magnification 
measurements between observers 1 and 2 using microscope MB.  
Mean difference -0.004 (black bold line), limits of agreement 0.43 and 
-0.43 (grey lines), 95% confidence intervals 0.34 and 0.52 (dashed 
lines) for the upper limit, and –0.52 and -0.34 (dashed lines) for the 
lower limit. 
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3.9 Bland-Altman plot shows the differences in magnification 
measurements between observers 1 and 3 using microscope MB.  
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Mean difference -0.57 (bold black line), limits of agreement 3.23 and 
-4.37 (grey lines), 95% confidence intervals 2.43 and 4.03 (dashed 
lines) for the upper limit, and -5.17 and -3.57 (dashed lines) for the 
lower limit. The poorest agreement was for PELVA C (12X).  
 
3.10 Bland-Altman plot shows the differences in magnification 
measurements between observers 2 and 3 using microscope MB.  
Mean difference -0.57 (bold black line), limits of agreement 3.30 and 
-4.37 (grey lines), 95% confidence intervals 4.30 and 2.50 (dashed 
lines) for the upper limit, and –3.57 and -5.17 (dashed lines) for the 
lower limit. The poorest agreement was for PELVA C (12X), and PELVA 
E (24X). 
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3.11 Measured magnification versus reported manufacturer’s 
magnification for 13 PELVAs (A-M) at different zoom levels.  Dots 
show the mean measured magnification (3 measurements at each 
zoom level) by observer 1 using microscope MA. Pearson Correlation 
Coefficient = 0.818, p < 0.001. PELVAs F, G, H, I, K, and M were outliers. 
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magnification tolerance. PELVAs D, E, and L do have one zoom level 
that lies within tolerance, but not all levels within tolerance, see Table 
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3.12 Bland-Altman plot using the absolute difference shows agreement 
between measured magnification (by observer 1 using microscope 
MA) and the reported manufacturer magnification.  Mean difference 
-0.70 (black line) Limits of agreement 10.50 and -9.10 (grey lines) 95% 
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10.9 for the lower limit (dashed line). Poor agreement was for PELVA 
G. PELVAs F, I and K were outliers.  
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PELVAs (A-M), by 1 observer (1) using 1 microscope (MA) [3 
measurements at each zoom level]. Black dots show the mean of 
measured magnification (3 measurements) at each zoom level by 1 
observers using 1 microscope. Error bars show the standard deviation 
of measured magnification at each zoom level.  Horizontal axis show 
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= 7.5 is the value of the 1st magnification level of PELVA ‘B’, 12x (C2) 
= 12 is the value of the 2nd magnification level of PELVA ‘C’ as 
reported by manufacturers, etc. 
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4.1 Illumination measurements: the laboratory was divided into 16 small 
rectangles (1 x 0.83 metres) each and illumination was measured at 
the centre of each rectangle. 
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4.2 Konica Minolta LS-100 luminance meter (Konica Minolta INC, 2015). 143 
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4.3 ISO 12233 chart 
http://www.graphics.cornell.edu/~westin/misc/ISO_12233-
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4.9 The estimated resolution limit in 100*Lw/Ph of 12 PELVAs using 3 
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a lower resolution limit using the diagonal grating target. The poorest 
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SUMMARY/ ABSTRACT 
 
 
Student ID Number: 1136101 
               
Summary of Thesis 
 
Pocket and portable electronic low vision aids (PELVAs) are relatively new devices 
designed to enhance vision of people with visual impairment. Therefore, the aim of this 
thesis was to evaluate their use and prescribing patterns for PELVAs for patients with visual 
impairment and to inform clinicians of the functions or attributes that are most important 
when considering their prescription.  
Firstly, the parameters (including magnification screen size, luminance contrast, and 
resolution) of PELVAs were assessed. Magnification and screen size were also compared 
with the manufacturers’ data.  
Secondly, data (age, gender, ocular condition, visual acuity, living situation, registration of 
visual impairment, type of low vision aid prescribed) from 6,668 patients who attended the 
Low Vision Service for Wales were analyzed to assess the clinicians’ prescribing patterns 
for PELVAs.  
Thirdly, reading frequency and duration, and self-reported effectiveness of PELVAs and 
optical low vision aids for patients with visual impairment were evaluated by using a 
telephone interview based upon the Manchester Low Vision Questionnaire.  
Finally, reading speed was measured for normally sighted subjects with simulated visual 
impairment who used a PELVA and an optical low vision aid. The factors that could predict 
reading speed were investigated. 
PELVAs enhanced the luminance contrast of high and low contrast letters which may be 
beneficial for patients with contrast reduction, for example due to cataracts. Variations were 
found between reported and measured magnification of the PELVA. 
Only 10% of adult patients were prescribed a PELVA, and younger males were more likely 
to use them.  A larger proportion of children (36.5%) were prescribed a PELVA. Patients 
who used PELVAs rated them highly for near vision tasks and were more likely to use 
PELVAs for reading once a day but for a long duration, whereas optical low vision aids were 
used more frequently and for a shorter duration. It was found that the reading speed was 
significantly improved using PELVA and optical low vision for subjects with simulated visual 
impairment; Bailey-Lovie near visual acuity, high and low contrast Colenbarnder near visual 
acuity, and number of visible characters were significant predictors of reading speed.  
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CHAPTER 1: General introduction 
 
Electronic low vision aids have been available for patients with low vision since 1950s 
(Potts et al. 1959, Genensky et al. 1972). Table mounted electronic low vision aids 
(commonly known as CCTVs) have existed for many years (Potts et al. 1959, Genensky 
1969). Reading speed and duration have been found to be significantly greater with the 
CCTV systems than with optical devices (Goodrich and Kirby 2001, Peterson et al. 2003). 
However, their high price and lack of flexibility and portability limited their use (Harper 
et al., 1999). Head-mounted devices have also been available but the benefits of these 
over traditional devices have not been demonstrated (Harper et al., 1999). 
 
Pocket and portable electronic low vision aids (PELVAs) have been found to have 
advantages over other electronic devices and optical low vision aids: 1) they are more 
portable than other electronic low vision aids (their small size makes them easy to carry 
and for some to fit in a pocket),  2) they are more affordable than larger electronic 
devices (less expensive), 3) they are easy to operate (fewer buttons to switch on/ off 
and to manipulate zoom and luminance), 4) they have flexible focus (some PELVAs can 
be used at variable distances), 5) they have variable magnification/ zoom levels, 6) larger 
PELVAs (not mini versions) have a larger field of view than optical devices, 7) they offer 
contrast manipulation, and 8) they offer different object-background colour 
combinations.  
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PELVAs have now become a prescribing option in the National Health Service (NHS) Low 
Vision Service in Wales (LVSW) (Charlton et al., 2011). With the current pace of 
technological development, it is likely that in the near future electronic low vision aids 
will be used by more patients with a visual impairment, especially when conventional 
low vision aids (e.g. optical magnifiers) are no longer sufficient to meet their 
requirements (Taylor et al., 2014). 
  
Available literature has evaluated the effectiveness of different low vision aids in 
assisting patients with a visual impairment to perform daily life tasks (Bullimore and 
Bailey 1989, Whittaker and Lovie-Kitchin 1993, Bailey et al. 1994, Lighthouse National 
Survey on Vision Loss 1995, Goodrich and Kirby 2001, Wolffsohn and Peterson 2003, 
Peterson et al. 2003, Culham et al. 2004, Crossland and Silver 2005, Jutai et al. 2005, 
Nguyen et al. 2009, Culham et al. 2009, Virgili and Acosta 2009). However, none of these 
evaluated the effectiveness of PELVAs for people with a visual impairment.  
 
Moreover, agreement between the reported PELVAs parameters' and those found in 
independent settings has not been evaluated yet. Bullimore and Bailey (1989) reported 
that manufacturers do not necessarily provide accurate information about the optical 
parameters of stand magnifiers. Also, Bailey et al. (1994) reported that information 
provided by manufacturers about low vision magnifiers may not be sufficient to 
estimate the resolution improvement that they actually provide for visually impaired 
people. Clinicians have to determine the key parameters of devices used in their 
practice, as they might be misreported or not reported at all by manufacturers (Bailey 
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et al., 1994). The authors recommended that ''until manufacturers provide the required 
technical information about their devices, clinicians must determine these parameters 
for themselves or obtain the information from other sources” (Bailey et al., 1994). 
  
An important part of studying the effectiveness of a particular management option for 
patients with a visual impairment, such as PELVAs, was to investigate what a device 
could actually provide i.e. 'its actual parameters', then to examine if patients 
requirements can be met by the chosen device. This is important in order to help people 
and clinicians, to enhance evidence-based decisions to choose the most appropriate 
device, and to save time, effort and money; by avoiding too much 'trial and error' until 
they reach a cost-effective decision. 
 
This thesis compliments a randomized control trial being conducted currently by Taylor 
et al. (2014) to determine the impact and cost effectiveness of prescribing PELVAs. We 
evaluated PELVAs from different aspects: 1) agreement between the reported PELVAs 
parameters' (including display screen size and magnification), and those measured in an 
independent setting, 2) estimation of PELVAs contrast enhancement features and 
resolution, 3) the prescribing patterns for PELVAs by clinicians already using them, 4) the 
use and satisfaction of these devices among patients with a visual impairment, and 5) 
reading performance of patients with a visual impairment using PELVAs.  
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1.1. Aims/ Objectives 
This thesis aims to inform those who prescribe or choose PELVAs about the functions or 
attributes that are most important when considering their use for patients with a visual 
impairment.  
 
Thesis objectives include:  
 To compare the reported manufacturers’ magnification and screen size of 
PELVAs to that measured in an independent setting.  
 To measure the luminance contrast that PELVAs could provide in different 
independent settings. 
 To estimate the resolution limit of currently available PELVAs.  
 To describe the clinicians’ prescribing patterns for PELVAs for patients with a 
visual impairment attending a NHS Low Vision Service in Wales. 
 To determine the characteristics of patients with a visual impairment who 
would benefit from PELVAs. 
 To assess patients’ self-reported satisfaction of PELVAs compared to optical 
devices.  
 To evaluate what patients with a visual impairment use low vision aids 
(PELVAs and optical) for.  
  To evaluate the usefulness of low vision aids for a group of visual tasks such 
as reading a newspaper, and reading price labels. 
  To evaluate the frequency and duration of reading that can be achieved with 
low vision aids (PELVAs and optical).  
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 To compare PELVAs and optical low vision aids from the patients’ perspective 
in terms of purpose of use, rating their use and satisfaction, and reading 
frequency and duration.  
 To determine the factors (visual functions and/or devices parameters) that 
affect reading performance of patients with a visual impairment who are 
using PELVAs.  
 
This thesis includes eight chapters:  The first chapter provides a general introduction to 
the thesis.  
 
The second chapter titled ‘Visual impairment and low vision aids’ includes a literature 
review on visual impairment in terms of definition(s), prevalence, aetiology, impact, 
management modalities/ options, and the effectiveness of available management 
options. 
 
The third chapter titled ‘Pocket and portable electronic low vision aids: Do 
manufacturers provide an accurate description [Magnification and Screen diameter]?’ 
describes an experiment in which the reported manufacturers magnification and display 
screen size of PELVAs were evaluated in an independent setting. 
  
The fourth chapter titled ‘Luminance contrast and resolution limits of pocket and 
portable electronic low vision aids measured in independent settings.’ describes an 
experiment in which the luminance contrast of PELVAs was measured in independent 
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settings and different room illumination, and the resolution limits using an ISO 12233 
resolution chart. 
  
The fifth chapter titled ‘The clinicians’ prescribing patterns for pocket and portable 
electronic low vision aids for patients with a visual impairment who attended the Low 
Vision Service Wales’ includes an analysis of 6,668 records of patients with a visual 
impairment who attended the Low Vision Service Wales (LVSW) in the year 2011/ 2012. 
The data set includes demographics of patients such as age, gender, ocular conditions, 
living situation, registration of visual impairment, and whether a PELVA was prescribed 
or not. The data set did not include information about whether low vision aids (optical, 
non-optical, electronic (except PELVA) or substitution aids) were prescribed if any.   
 
The sixth chapter titled ‘The use and self-reported satisfaction of pocket and portable 
electronic low vision aids, and optical low vision aids for patients with a visual 
impairment’ describes a pilot study that evaluated the use, satisfaction, reading 
frequency and duration of previously prescribed PELVAs and/ or optical devices for 88 
patients with a visual impairment using the Manchester Low Vision Questionnaire 
(MLVQ) phone interview.  
 
The seventh chapter titled ‘Investigation of the factors (visual functions and/ or devices 
parameters) that affect reading performance of people with simulated visual 
impairment using low vision aids (pocket and portable electronic low vision aids, and 
optical low vision aids)’ describes a pilot study, in which normally sighted people with 
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simulated visual impairment undergo a clinical-based assessment of visual functions and 
reading performance using both PELVAs and optical low vision aids.  
 
The eighth chapter titled ‘Summary of the thesis findings’ includes findings and future 
work. 
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CHAPTER 2: Visual impairment and low vision aids  
 
2.1. Introduction 
Visual impairment is considered one of the major public health issues. It is becoming 
increasingly important because of the high prevalence, the projected increase in the 
number of people who are expected to become visually impaired as populations are 
ageing, and the significant impact that it has on social, economic, daily life skills 
performance levels, physical well-being, mental health and psychosocial status 
(Resinkoff et al. 2004, Lamoureux et al. 2007, Binns et al. 2012, Court et al. 2014). 
  
Moreover, visual impairment impacts on a country's economy as the productivity of 
people reduces, and more importantly, because of the large amount of direct and 
indirect expenditure that is required to cover the different types of services for people 
with a visual impairment (Taylor et al. 2006, Frick et al. 2007, Access Economic 2010, 
Binns et al. 2012). 
  
Visual impairment affects people of all age groups, it is becoming more prevalent, and 
the risk of being visually impaired increases as people become older (Eye Disease 
Prevalence Research Group 2004, WHO 2014). As people age, some causes of visual 
impairment become more prevalent, such as age-related macular degeneration (AMD) 
and cataract (Eye Disease Prevalence Research Group 2004, WHO 2014).  
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This literature review includes a background about visual impairment and low vision 
aids. Firstly, it introduces the reader to visual impairment in terms of its definitions, 
classifications, prevalence, aetiology and impact. Then, it describes different 
management modalities of visual impairment, such as optical and electronic visual aids. 
Next, it describes electronic low vision aids as new emerging technology including the 
definition, history of development, classification, advantages and disadvantages of 
electronic low vision aids. It also includes a review of literature on the prescription 
pattern of low vision aids and the effectiveness of different management options for 
patients with a visual impairment; particularly the effectiveness of using low vision aids 
in improving reading performance for patients with a visual impairment.  In addition, it 
explores methods of assessing reading performance. 
 
2.2. Definition of visual impairment 
‘Visual impairment’, throughout the text, will be used to refer to ‘blindness’ and ‘low 
vision’ (Resinkoff et al., 2004), this description includes the full spectrum of sight loss.  
 
Different definitions have been adopted for visual impairment. Some of these 
definitions use descriptions of the residual visual function (e.g. visual acuity and visual 
field) (WHO ICD-10, 2010) whereas other definitions describe the functional limitations 
caused by visual impairment such as reading, outdoor activities or shopping (Brabyn et 
al. 2001, Crews and Campbell 2001, Crews and Campbell 2004, Haymes et al. 2002, 
Lamoureux et al. 2004, Jutai et al. 2005). 
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Low vision is defined as a permanent visual impairment which cannot be corrected with 
a conventional optical correction (spectacles or contact lenses) or a surgical intervention 
(Lueck 2004, Vision Australia 2006b). 
 
According to the World Health Organization (WHO, 1992): "A person with low vision is 
one who has impairment of visual functioning even after treatment, and/ or standard 
refractive correction, and has a visual acuity of less than 6/18 to light perception or a 
visual field of less than 10 degrees from the point of fixation, but who uses, or is 
potentially able to use, vision for the planning and/ or execution of a task” (WHO, 1992). 
 
The WHO has defined visual impairment (i.e. low vision and blindness) in the 
International Statistical Classification of Diseases (WHO ICD-10, 2003). Categories of 
visual impairment, based on the best corrected visual acuity, according to ICD-10 are 
shown in Table 2.1 (WHO ICD-10 2003, WHO 2004, Dandona and Dandona 2006, and 
WHO ICD-10 2010).  
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Categories of Visual 
Impairment (Depending 
on Best Possible 
Corrected Visual Acuity) 
Categories of Visual 
Impairment (Depending on 
Presenting Distance Visual 
Acuity) 
Visual Acuity (Log MAR equivalent) 
Worse than Equal to or better 
than 
--- 0 Mild or no visual 
impairment 
 0.48 
1 Low vision 1 Mild visual impairment 0.48 1.00 
2 Low vision 2 Severe visual impairment 1.00 1.30 
3 Blindness 3 Blindness 1.30 1.80 
4 Blindness 4 Blindness 1.80 Light perception 
5 Blindness 5 Blindness No light perception 
9 Unqualified vision loss 9 Unqualified vision loss Undetermined or unspecified 
 
Table 2.1: Categories of visual impairment based on best corrected visual acuity 
(Column1) and categories of visual impairment based on presenting visual acuity 
(Column2) (Adapted from WHO ICD-10 2003, WHO 2004, Dandona and Dandona 2006, 
WHO ICD-10 2010).  Visual acuity was converted into Log MAR visual acuity. 
 
 
 
It can be clearly seen from Table 2.1 that categories of visual impairment in the first 
column are defined based on the best possible distance correction. This might lead to 
an underestimation of the number of people with visual impairment due to uncorrected 
refractive errors. Accordingly, the Resolution of the International Council of 
Ophthalmology and the WHO Consultation on “Development of Standards for 
Characterization of Vision Loss and Visual Functioning” have recommended that visual 
impairment should be based on the presenting visual acuity (WHO, 2004) (Table 2.1).  
 
The United States has different definitions for visual impairment. For example, a person 
would be described as blind if he/ she has visual acuity of equal to or less than 6/60 and 
as a low vision patient when his/ her visual acuity is less than 6/12 (NEI, 2008). Studies 
by Klaver et al. (1998), Congdon et al. (2004), and Gunnlaugsdottir et al. (2008) used 
definitions’ from the United States and the WHO ICD-10.  
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Jutai et al. (2005) [the Vision Rehabilitation Evidence Based Review VREBR] have defined 
low vision as: "Any condition of diminished vision uncorrectable by standard glasses, 
contact lenses, medication or surgery that disrupts a person’s ability to perform common 
age-appropriate visual tasks. Irresolvable low vision results from uncorrectable and 
untreatable conditions, whereas unresolved low vision results from correctable but 
uncorrected, and treatable but untreated, conditions" (Jutai et al., 2005).  
 
The Low Vision Services Consensus Group of the Royal National Institute of Blind People 
(RNIB), in the UK, defined a low vision patient as: "...one who has an impairment of visual 
function for whom full remediation is not possible by conventional spectacles, contact 
lenses, or medical intervention and which causes restrictions in that persons everyday 
life... This definition includes but is not limited to those who are registered as blind and 
partially sighted" (Low Vision Services Consensus Group 1999, Sinclair and Ryan 2012). 
  
This means that considering patients to be eligible for low vision services or 
rehabilitation should not rely only on the basis of clinical measures such as visual field 
or visual acuity, but there should be consideration given to the impact that visual 
impairment has on people with visual impairment (Binns et al., 2012). Rahi et al. (2009) 
employed the term 'socially significant visual impairment' to refer to people who are not 
eligible to legally drive (visual acuity of less than 6/12).  
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2.3. Prevalence of visual impairment 
2.3.1. Global prevalence of visual impairment  
Globally, the number of people with a visual impairment of all age groups, was estimated 
to be 285 million; 39 million blind and 246 million with low vision (Pascolini and Mariotti 
2012, RNIB 2013, WHO 2014). Visual impairment is unequally distributed throughout 
the world; with the least developed countries being more affected (WHO, 2014). About 
90% of people with a visual impairment live in developing countries (WHO, 2014).  
 
Visual impairment is also unequally distributed among age groups; 65% of people with 
visual impairment and 82% of people with blindness are aged 50 years and older (WHO, 
2014).  
 
Worldwide, the population is increasing with a shift toward a higher percentage of older 
people (UN, 2013). The increase in life expectancy because of improved sanitation, 
health care and food supply, and the noticeable decrease in birth rate as women have 
become more educated, and there has been a decline in the mortality rate of children:  
all these factors could lead to a situation where there are more elderly compared to 
children (UN, 2013).  It has been estimated that by 2050 the life expectancy at age 60 is 
projected to increase from 20 to 22 years in the more developed countries and from 17 
to 19 in the least developed countries (UN, 2013). Globally, the proportion of people 
aged 60 years and older is expected to increase from 12%, in 2013, to 21%, in 2050 (UN, 
2013).  It has been projected that the proportion of people aged 60 years and older will 
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continue to increase by three folds, while the proportions of younger ages become 
constant (UN, 2013).  
 
Prevalence of visual impairment varies with gender; with females having a more 
significant risk of developing visual impairment, with ratios range from 1.5 to 2.2 
(Resinkoff et al., 2004). About 57% of people with a visual impairment (n=230 million) in 
2010 and 60% of blind people (n=36.5 million) were females (Stevens et al., 2013). 
 
2.3.2. Prevalence of visual impairment in developed countries   
In developed countries, the prevalence of low vision as well as its social and economic 
impact cannot be accurately estimated (Bailey et al., 2006).  In Europe, it is estimated 
that there were 30 million people living with sight loss (RNIB, 2013). 
 
The prevalence of self-reported visual impairment in the adult American population was 
about 9% (Ryskulova et al., 2008). According to Bailey et al. (2006), the prevalence of 
legal blindness was about 0.2% of the total population, in the United States. The vast 
majority (about 80%) of people that were eligible to be defined as legally blind had some 
residual vision that can be used in a way to improve the performance of their daily life 
tasks, over 50% of the legally blind people were over the age of sixty (Bailey et al., 2006). 
  
In Canada, there were 836,000 people with a visual impairment: 1) 243,000 over the age 
of 75, 2) 367,000 over the age of 65, 3) 688,000 over the age of 45, 4) 128,000 between 
15 and 45 years old, and 5) 19,700 younger than 15 years old (The Elderly Working Group 
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of the World Blind Union, 2011). People with a visual impairment were defined as having 
difficulty seeing ordinary newsprint or an inability to recognize faces at four meters with 
habitual spectacles. It was also found that more than one in eleven Canadians over the 
age of 65, and more than one in eight over the age of 75 experience severe vision loss 
that cannot be corrected with standard eyeglasses (The Elderly Working Group of the 
World Blind Union, 2011). 
 
2.3.3. Prevalence of visual impairment in the UK 
Two million people in the UK are estimated to have a visual impairment and 360,000 are 
registered as sight impaired or blind (Access Economic 2009, NHS 2013, RNIB 2014). A 
total of 80,000 of UK adults (working age 18-64 years) have a visual impairment (RNIB, 
2014). There were 25,000 children aged 16 years and under blind or partially sighted 
(RNIB, 2014).  
 
A larger proportion of older people have a visual impairment (Access Economic 2009, 
RNIB 2012). In the UK, according to RNIB UK statistics (2012), one in five people aged 75 
years and older have sight loss, but one in two people aged 90 years and older are 
affected (RNIB, 2012).  However, this figure includes those with correctable/ treatable 
visual impairment such as refractive error or cataract.  
 
Evans et al. (2002) reported that out of 14,600 people aged 75 years and older from 53 
GP practices in the UK, there were 12.4% (1,803) with a visual impairment. Of them, 
10.3% (1,501) were recognized as having low vision (binocular visual acuity < 6/18), 
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whereas 2.1% (302) were recognized as blind (binocular visual acuity < 3/60). In their 
study, 6.2% of people aged 75 to 79 years, and 36.9% of people aged 90 years and older 
had a visual impairment. Also, for people aged from 75 to 90 years, there were around 
0.6% with blindness, this ratio was increased to 6.9% for people aged 90 or older (Evans 
et al., 2002). They also found that about 20% of people aged 75 years and older had a 
binocular visual acuity of less than 6/12 (Evans et al., 2002).   
 
Out of 2 million people with a visual impairment in the UK; only 360,000 people were 
registered (Access Economic, 2009). Out of 34,410 certificates received in the year 1999/ 
2000, 32,895 were registered (13,788 were registered as blind and 19,107 as partially 
sighted) (Bunce and Wormald, 2006). As people become older they are more likely to 
be registered. Bunce and Wormald (2006) reported that 83% of people who were 
registered as blind and 82% of people who were registered as partially sighted were 
aged 65 years and older. In England, there were 143,385 people who were registered as 
blind and 147,715 people were registered as partially sighted; 61.3% of them aged 75 
years and older (Health and Social Care Information Centre, 2014). The proportion of 
people with a visual impairment, who were registered by age in England, in 2014, is 
shown in Figure 2.1.  
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Figure 2.1: The proportion of people on the register of visual impairment in England, 
in 2014, by age (years) [n=143,385]. Data obtained from Health and Social Care 
Information Centre (2014). 
 
 
2.3.4. Variation in the reported prevalence of visual impairment 
Different studies have reported different statistics regarding the prevalence of visual 
impairment (Binns et al., 2012). That may be attributed to the following factors: 1) 
different definitions of visual impairment that were employed in collecting data, 2) 
different methods of collection data and different sample sizes, 3) regions of study 
whether in developed or developing country, and 4) the age of the study population 
(Binns et al., 2012).  
 
As previously mentioned in Section 2.2, the definition of visual impairment differs which 
will affect the estimates (Binns et al., 2012). For example, the Lighthouse National 
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Survey on Vision Loss (1995) and the National Health Interview Survey in the United 
States (Ryskulova et al., 2008), described visual impairment according to the self-
reported visual difficulties experienced by individuals. Others have described visual 
impairment on the basis of visual acuity and clinical measures (Klaver et al. 1998, 
Congdon et al. 2004, Gunnlaugsdottir et al. 2008, Rahi et al. 2009). For example, an MRC-
funded trial of assessment and management of older people in the community defined 
visual impairment based on the presenting visual acuity of < 6/18 (Evans et al., 2002). 
Van-Der Pols et al. (2000) defined visual impairment based on pin hole visual acuity of < 
6/18, and the Blue Mountain Eye Study defined visual impairment based on the optimal 
subjective refraction after objective refraction (Attebo et al., 1996).  
 
Also, the size of study population and the study method affect the prevalence estimates 
(Binns et al., 2012). Large population studies try to collect data from the community 
(Buch et al. 2004, Gunnlaugsdottir et al. 2008, Klaver et al. 1998), whereas other studies 
investigated the registration of visual impairment (Bunce and Wormald, 2006). The 
number of people that are registered as visually impaired will depend on a number of 
factors/ criteria (e.g. definition of visual impairment in a particular country, age, gender, 
the willingness of people to be registered, the cause of visual impairment, and the 
presence of concurrent disabilities) (Binns et al., 2012).  
 
In the UK, registration of patients with a visual impairment as 'severely sight impaired' 
(i.e. blind) or 'sight impaired' (i.e. partially sighted) is voluntary and is initiated through 
certification of visual impairment by an ophthalmologist (Bunce and Wormald, 2006). In 
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addition, people who gain a certificate of visual impairment from ophthalmologists 
choose if they want to be included in their local authorities’ register of visual impairment 
(Health and Social Care Information Centre, 2014). Therefore, this approach will lead to 
underestimation of the number of visually impaired as not all people who are eligible 
are registered (Barry and Murray 2005, Binns et al. 2012).   
 
2.4. Aetiology of visual impairment and prevalence of visual impairment by cause 
The most common eye conditions that cause visual impairment worldwide are age-
related macular degeneration (AMD), cataract, diabetic retinopathy, glaucoma and 
uncorrected refractive error (AMD Alliance International, 2010).  
 
However, the distribution of causes of visual impairment is not similar for all 
populations. The main causes of visual impairment in a particular population might 
depend on different factors or inclusion criteria such as 1) age group (elderly, adults, 
and children); for example elderly have a greater prevalence of age-related ocular 
diseases such as AMD and cataract whereas children have a greater prevalence of 
cortical visual impairment, 2) liability of treatment of eye conditions (i.e. treatable 
causes e.g. cataract and refractive errors, irreversible e.g. glaucoma, or treatable but not 
treated e.g. uncorrected refractive errors), 3) whether the study population from a 
developed or a developing country, and 4) participants generic health (Bunce and 
Wormald 2006, Binns et al. 2012).    
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Globally, Pascolini and Mariotti (2012) and WHO (2010) estimated that the major causes 
of visual impairment in 2010 were uncorrected refractive errors (43%) and cataract 
(33%), and the major cause of blindness was cataract (51%). Other causes of visual 
impairment included glaucoma (2%), AMD (1%), diabetic retinopathy (1%), trachoma 
(1%), and corneal opacities (1%).  
 
Developed countries have higher prevalence of irreversible or untreatable causes such 
as AMD, compared to developing countries where there is a higher prevalence of visual 
impairment due to treatable or preventable causes such as refractive error and cataract 
(Pascolini et al., 2004).  
 
In Canada, the major causes of visual impairment have included age-related macular 
degeneration, diabetic retinopathy, glaucoma, cataracts, and refractive errors (The 
Elderly Working Group of the World Blind Union, 2011).  The prevalence of vision loss in 
Canada, by cause is shown in Table 2.2.  
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Cause All ethnicities White AVM* 
Number % total Number % total Number % total 
AMD** 89241 10.9 84641 10.8 4380 12 
Cataract 133836 16.4 120685 15.5 13151 36.1 
Diabetic Retinopathy 29920 3.7 20992 2.7 8928 24.5 
Glaucoma 24937 3.1 22565 2.9 2373 6.5 
Refractive error/ 
other 
539236 66 531650 68.1 7586 20.8 
All vision loss 817171 100 780534 100 36417 100 
* Aboriginal and Visible Minorities (AVM) 
**Age-related Macular Degeneration 
 
Table 2.2: The prevalence of vision loss in Canada, by cause (The Elderly Working 
Group of the World Blind Union, 2011). 
 
 
In the UK, there are approximately 2 million people with sight loss; the five major causes 
include refractive error, AMD, cataract, glaucoma, and diabetic retinopathy (Access 
Economic 2009, RNIB 2013). It is estimated that half of sight loss in the UK could be 
prevented (Access Economic 2009, RNIB 2013).  Table 2.3 shows the estimated 
percentage of the main causes of sight loss in the UK adults. 
 
Sight loss (partial sight loss and blindness) Blindness only 
Main Causes Percentage (Number) Main Causes Percentage (Number) 
AMD 16.7% (300,000) AMD 50.5% (110,000) 
Cataract 13.7% (246,000) Cataract 12.5% (27,000) 
Glaucoma 5.3% (95,000) Glaucoma 16.6% (36,000) 
Diabetic retinopathy 3.5%  (62,000) Diabetic retinopathy 8.7% (19,000) 
Refractive error 53.5%  (960,000) Refractive error 2.1%  (5,000) 
Other causes 7.4% (133,000) Other causes 9.7% (21,000) 
 
Table 2.3: The main causes of sight loss (partial sight loss and blindness) in the UK 
(Access Economic, 2009).  
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Causes for certification/ registration of visual impairment in the UK: 
The main causes for certification of visual impairment in England and Wales in 
1999/2000 were AMD followed by glaucoma and diabetic retinopathy; blindness was 
due to AMD (57.2%), glaucoma (10.9%), diabetic retinopathy (5.9%) and partial sight 
was due to AMD (56%), glaucoma (10.2%), diabetic retinopathy (7.4%) (Bunce and 
Wormald, 2006). Bunce et al. (2015) reported that out of 23,616 visual impairment 
certificates in England in 2011/2012, 11,546 (57%) people had AMD (geographical, 
neovascular, or mixed). The much higher percentage of people with AMD in both studies 
of causes of certification of sight impairment compared to that reported by Access 
Economic (16.7%) (Table 2.3) (Access Economic, 2009) was because if the main reason 
for sight loss is correctable e.g. caused by refractive error or cataracts, a person is usually 
not offered certification of sight impairment. 
 
 Liew et al. (2014) compared causes of blindness certification in working age adults in 
England and Wales. The authors reported that the main causes for certification of 
blindness in 1999/ 2000 were diabetic retinopathy/ maculopathy (17.7%), hereditary 
retinal disorders (15.8%) and optic atrophy (10.1%) (Liew et al., 2014). The main causes 
for certification of blindness in England and Wales working age adults in 2009/ 2010 
were hereditary retinal disorders (20.2%), diabetic retinopathy/ maculopathy (14.4%), 
and optic atrophy (14.1%) (Liew et al., 2014). The increased certification for inherited 
retinal disorders might be due to an improvement in the certification of existing sight 
impairment because of increased community awareness or due to an increase in the 
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prevalence of these disorders (Liew et al., 2014). On the other hand, the decreased 
certification for diabetic retinopathy/ maculopathy might be related to the introduction 
of nationwide diabetic retinopathy screening programmes in England and Wales and 
improved glycaemic control (Liew et al., 2014). 
  
Children with visual impairment usually develop it before their 2nd month of life (Blohme 
and Tornqvist, 1997). In the UK, aetiology of visual impairment in children is variable and 
‘visual impairment’ is often considered a small part of other conditions and disabilities 
that children may have (Bodeau-Livinec et al., 2007). More than 75% of visually impaired 
children have additional disorders or diseases, and about one-tenth of them die within 
one year of diagnosis (Rahi and Cable 2003, Bodeau-Livinec et al. 2007). It has been 
suggested that prenatal factors could be the cause of 60% of visual impairment cases in 
children, and three quarters of visual impairments in children cannot be prevented or 
treated with the current knowledge (Flanagan et al. 2003, Rahi et al. 2009). In the UK, 
the main causes of severe visual impairment in children include: cerebral defects such 
as cortical visual impairment, disorders of the optic nerve, and retinal disorders (Rahi 
and Cable 2003, Access Economic 2009).  
 
2.5. Impact of visual impairment 
Visual impairment is one of the major global health problems; the preventable causes 
contributed to as much as 80% of the total global burden (WHO, 2011).  
 
  
47 
 
Visual impairment has a significant impact on people’s lives at all age groups. People 
with a visual impairment find it more difficult, or even impossible, to perform daily life 
activities independently (Crews and Campbell 2001, Brabyn et al. 2001, West et al. 2002, 
Haymes et al. 2002, Lamoureux et al. 2004, Chia et al. 2004, Cacciatore et al. 2004, 
Langelaan et al. 2007), and they have restricted mobility and orientation (Turano et al. 
2004, Ballemans et al. 2011). This may result in a higher incidence of falls, hip fractures, 
depression, and social isolation and lower productivity which in turn may affect a 
country’s economy (Rajala et al. 2000, Lord and Dayhew 2001, McCarty et al. 2001, 
Wang et al. 2001, Ivers et al. 2003, Colenbrander 2003, De-Boer et al. 2004, Chia et al. 
2004, Freeman et al. 2005, Taylor et al. 2006, Frick et al. 2007, Nazroo and Zimdars 2010, 
Pawar et al. 2010, Brown and Barrett 2011, Chou et al. 2013).  
  
Social and functional, as well as psychological, disabilities due to visual impairments 
have a significant negative impact on people’s quality of life (Brown et al. 2002, Chia et 
al. 2004, Thiagarajan et al. 2005, Langelaan et al. 2007), and increase the risk of mortality 
(Rajala et al. 2000, Wang et al. 2001, McCarty et al. 2001, Lee et al. 2002, Freeman et al. 
2005).  
 
In developed countries, daily life activities such as reading, driving vehicles, and 
watching television are mainly restricted by the level of vision that people have (West 
et al. 2002, Lamoureux  et al. 2004, Vu et al. 2005, Varma et al. 2006, Ramulu et al. 2012, 
Bailey 2012, Rubin 2013).  
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In this section, the impact of visual impairment has been divided into: daily living tasks, 
psychosocial impact, impact on health, and impact on economy.   
 
2.5.1. Daily living tasks 
Activities of Daily Living (ADLs) include tasks that people do on a normal daily basis such 
as self-care, social activities, mobility, driving, reading and sporting (Kane and Kane, 
1981). This might be divided into ‘basic ADLs’ (i.e. necessary self-care tasks) such as 
eating and personal hygiene, and ‘instrumental ADLs’ that include tasks that are not 
necessary for basic existence but they allow people to live independently in the 
community such as checking telephone numbers. These make independent living and 
integration with the community more achievable (Kane and Kane, 1981).  
 
To which level a patient with visual impairment is independent can be evaluated by 
referring to his/ her ability to perform daily living tasks (Binns et al., 2012). Adults with 
a visual impairment have less functional abilities in terms of both basic and instrumental 
ADLs than those without (Crews and Campbell 2001, Brabyn et al. 2001, West et al. 2002, 
Lamoureux et al. 2004, Hassell et al. 2006, Alma et al. 2011, Alma et al. 2012).  
 
Reading, outdoor mobility, shopping and leisure activities were found to be the greatest 
limitations in people with a visual impairment (Lamoureux et al. 2004, Chia et al. 2004, 
Rubin 2013). The risk of falls and hip fractures increases significantly due to restricted 
mobility and orientation skills among people with a visual impairment (Lord and Dayhew 
2001, Ivers et al. 2003, Chia et al. 2004, Patino et al. 2010, Ballemans et al. 2011). 
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The ability to perform basic and instrumental ADLs among patients with a visual 
impairment can be reduced due to reduced contrast sensitivity, visual acuity and visual 
fields (Haymes et al., 2002).  Tabrett and Latham (2011) reported that visual functions, 
particularly distance and near visual acuities without the use of low vision aids, were the 
best predictors among visual function of 'self-reported vision related activity 
limitations'. Harper et al. (1999) found that a reduction in visual acuity, loss of contrast, 
and visual field scotomas could impact on patients' ability to read, to write, to recognize 
faces and to watch television . 
 
However, the evaluation of both ability and dependence of performing daily living tasks 
might also be required to understand the functional abilities such as orientation and 
mobility in people with a visual impairment (Binns et al., 2012). For example, mobility 
(i.e. the physical ability to move in a typical, safe and organized way through the 
surrounding environment) and orientation (i.e. as the ability of an individual to 
recognize and to locate a position of an object relative to the environment) are 
restricted in people with a visual impairment and they can affect independent travelling 
and movement (Ballemans et al., 2011). 
 
On the other hand, the Vision Rehabilitation Evidence Based Review VREBR (Jutai et al., 
2005) suggested that there might be different considerations (e.g. how patients 
perceived their visual impairment or how it affected their living) that would affect the 
functional performance of patients with a visual impairment. Jutai et al. (2005) have 
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summarised the possible interpretations of the impact of visual impairment on 
functional performance in Table 2.4.  
 
There is impact on functional performance No impact on functional performance 
Visual impairment results in a loss of function of 
limited consequence to the individual. 
Visual impairment affects one eye only 
Visual impairment results in a loss of function of 
significant consequence to the individual. 
Visual impairment affects measurable dimensions 
of vision, but these do not result in any perceived 
impact on functional performance of the 
individual 
 
Table 2.4: The possible impact of visual impairment on functional performance [The 
Vision Rehabilitation Evidence Based Review VREBR (Jutai et al., 2005)].  
 
 
2.5.2. Psychosocial impact 
Visual impairment has a significant impact on the psychosocial aspect of people’s lives 
(Rovner and Ganguli 1998, Evans et al. 2007, Binns et al. 2012). For example, Evans et 
al. (2007) found that there was a correlation between visual impairment and depression 
in 13,900 visually impaired over 75 years old. They reported that about 13.5% of the 
sample was found to have depression, compared to only 4.9% of the control group 
(people with normal vision). After adjusting for age and gender, Evans and colleagues 
also found that there was a high correlation between visual impairment and limitation 
of performing daily activities that may result in depression (Evans et al., 2007).  Brody et 
al. (2001) reported that the prevalence of depression was 32.5% in 151 older American 
adults as a result of age related macular degeneration, which is almost twice the 
prevalence in the normally sighted American older adults. 
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Also, in a study of 584 American people with a visual impairment who attended 
rehabilitation services, 7% had 'major depression’ and about 27% had ‘sub-threshold 
symptoms’ (Horowitz et al., 2005). Van-Der et al. (2015) found that visual impairment 
increased the incidence of major depression, sub-threshold depression, and anxiety 
disorders.  
 
As it can be clearly seen, there is a variation in the prevalence of depression 
(psychosocial impact) among the visually impaired; this variation has been explained by 
Evans et al. (2007) to be a result of differences in ‘confounding factors controlled’ of the 
sample involved in each study.  
 
Psychological status also has been found to have an impact on people’s functional 
disabilities (Shmuely-Dulitzki et al. 1995, Rovner and Ganguli 1998, Brody et al. 2001, 
Lamoureux et al. 2004). For example, Brody et al. (2001) found that there were higher 
disability scores for self-reported functional ability for all measures among people 
diagnosed with depression. Moreover, Tabrett and Latham (2011) found that 
depression and adjustment to vision loss had a significant impact on 'self-reported vision 
related activity limitations' without regards to the severity of visual impairment. On the 
other hand, Lamoureux et al. (2004) found that mental and physical health as well as 
distance vision were independent predictors for limitation in ADLs.  
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2.5.3. Impact on general health 
Visual impairment was found to affect the level of people's general health, and increase 
the risk of falls, injuries, hip fractures, and death rate, described earlier in this chapter. 
According to a report from the Landmark Framingham Eye Study, visual impairment was 
responsible for about 18% of hip fractures of older Americans (Kahn et al., 1977). Studies 
also found that that visual impairment can cause an increase in mortality (death) rate 
(Rajala et al. 2000, McCarty et al. 2001, Wang et al. 2001, Lee et al. 2002, Freeman et al. 
2005). Also, Cimarolli et al. (2012) found that vision impairment could preclude patients 
with a visual impairment from using occupational therapy. 
  
Jacobs et al. (2005) found that older patients with a visual impairment had significantly 
poorer self-rated health and increased visits to the emergency room, hospitals 
admission, tiredness, and mortality. Also, visual impairment was associated with 
reduced well-being with impact on health and life similar to the impact of major diseases 
such as stroke (Chia et al., 2004). Older people who have cataract had poorer perceived 
health and well-being compared to controls (Polack et al., 2010).  
  
It has been estimated that other disabilities or disorders and health problems occur in 
about two third of patients with a visual impairment (Mahoney et al., 2008). In children 
with a visual impairment the risk of traumatic injuries to the teeth and mouth was higher 
compared to normally sighted children (Mahoney et al., 2008). 
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Cupples et al. (2012) suggested that visual impairment adversely affected the health and 
well-being of patients, and patients with a visual impairment were more likely to have 
limited access to health care facilities and information.  
 
It was found that patients with a visual impairment were more likely to have more 
multiple disorders or disabilities compared to normally sighted people (Court et al., 
2014). Also, the prevalence of physical health conditions and the prevalence of mental 
health conditions were higher in patients with a visual impairment (Court et al., 2014).  
 
2.5.4. Economic impact 
The impact of visual impairment on the economy is attributed by direct costs (related to 
illness) including medical, non-medical expenses, and health related costs (Drummond, 
2005) and indirect costs (e.g. productivity loss due to illness) (Ament and Evers, 1993). 
  
Globally, the estimated total cost (i.e. direct and indirect costs) of visual impairment has 
been estimated to be 2,954 billion US dollars ($), in 2010.  This was $2,302 billion as a 
direct cost, and $652 billion as indirect costs. About 12% ($343 billion) was attributed as 
visual impairment due to AMD (AMD Alliance International, 2010). 
 
“Disability adjusted life years” (DALY) is a concept that has been adopted by WHO in 
2000 to explain the overall disease burden; it is expressed as years of life lost due to ill 
health, disability or early death (Suttie et al., 2011). Globally in 2010, mild and moderate 
visual impairment contributed to about 51million DALYs, while blindness contributed to 
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68 million DALYs. Six million DALYs were attributed to AMD alone (AMD Alliance 
International, 2010).  
  
Koberlein et al. (2015) reviewed studies of the cost of visual impairment prior to 2012, 
and reported that the global mean annual direct medical costs per patient, in US dollar 
purchasing power parities ($ PPP), was $ PPP12,175-14,029 for moderate visual 
impairment, $ PPP13,154-16,321 for severe visual impairment, and $ PPP14,882- 24,180 
for blindness. Purchasing Power Parities (PPP) is a technique used to determine the 
relative value of different currencies. It converts local currencies into international 
dollars by taking the purchasing power of different national currencies into account and 
eliminating differences in price levels between countries (Koberlein et al., 2015). Direct 
costs are the actual expenses related to visual impairment and include medical costs, 
non-medical costs and other direct costs (medical costs are the cost of resources used 
for treating visual impairment; non-medical costs include costs caused by visual 
impairment but not attributed to medical treatment e.g. residential care or 
transportation; other direct costs include informal care, time spent in treatment by 
patients or caregivers) (Koberlein et al., 2015).  
 
Globally, the mean annual direct non-medical costs including the provision of assistive 
aids, home modifications and home based nursing, per patient, were higher for a patient 
who’s visual acuity was ≤ 20/80 ($ PPP 608.71) compared to a patient with a visual acuity 
of ≥ 20/20 ($ PPP 53.90) (Schmier et al. 2009, Koberlein et al. 2015).  
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The annual estimates of the indirect costs (such as productivity loss and absence from 
work) of visual impairment and blindness in Canada and the USA was $ PPP 4,974 to 
5,724 million (Rein et al. 2006, Cruess et al. 2011, Koberlein et al. 2015).  
 
Frick et al. (2007) assessed the excess costs associated with visual impairment. They 
found that there were $2.8 billion excess costs. Home care was the main contributor to 
this figure, and when they considered the additional costs of the loss of quality of 
adjusted life years the estimated total annual impact of visual impairment was $16 
billion. Moreover, the annual cost of treatment of hip fractures due to visual impairment 
in older Americans was $2.2 billion (Kahn et al., 1977).  
 
In terms of cost and economic impact, visual impairment was ranked seventh (after 
cardiovascular diseases, musculoskeletal disorders, injuries, mental disorders, cancer, 
and dementia) and ahead of coronary heart disease, diabetes, depression and stroke 
(Taylor et al., 2006). The estimated total cost of visual impairment in Australia was 9.85 
billion Australian dollars (the loss of wellbeing 4.8 billion Australian dollars) (Taylor et 
al., 2006).    
 
In the UK, the total direct NHS expenditure on eye health was £2.64 billion (£496 million 
as primary care costs, £536 million as inpatient costs, £677 as outpatients’ costs, and 
£370 million as the cost of care including residential and community care) and the 
indirect cost was £5.3 billion (RNIB, 2013). 
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In the UK in 2008, the total health expenditure on visual impairment, in adults, was 
estimated to be £22 billion (£2.15 billion as direct costs, £4.34 billion as indirect costs, 
and £15.5 billion as burden of disease costs i.e. years lost due to morbidity and years of 
life lost due to premature death) (Access Economic, 2009). Also, the total annual 
expenditure on visual impairment due to AMD was estimated to be £1.6 billion 
(Minassian and Reidy, 2009). Table 2.5 shows the estimated annual costs of the major 
causes of visual impairment, in the UK between 2010 and 2020. 
 
Cause of visual impairment Total cost (£) 
AMD 1.6 billion 
Cataract 995 million 
Diabetic retinopathy 680 million 
Glaucoma 542 million 
 
Table 2.5: The estimated annual cost of visual impairment by cause, in the UK between 
2010 and 2020 (Minassian and Reidy, 2009).  
 
 
Meads and Hyde, in 2003, analysed the ‘main cost factors’ that were associated with 
blindness due to AMD in the United Kingdom. They found that the cost of blindness for 
the first year ranged between £1,375 and £17,100 with an average of about £6,455 per 
person, this number was reduced to £6,295 per subsequent year. They found that the 
cost of residential care was the highest, and that 30% of people with visual acuity of 
6/60 would require residential care services within one year from diagnosis (Meads and 
Hyde, 2003). The authors reported that the costs associated with visual impairment vary 
depending on patient's age and his/ her diagnosis (Meads and Hyde, 2003).  
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2.6. Management modalities of visual impairment 
Different visual functions can be affected in a person who has a visual impairment such 
as distance and near visual acuity, contrast sensitivity, and/ or visual fields. However, 
near vision and reading ability are often the most affected (Dickinson 1998, Rubin 2013). 
Management modalities (e.g. aids/ devices, and rehabilitation and training) for people 
with a visual impairment vary according to the severity of visual impairment, the nature 
and cause of the underlying condition, the age of the patient, the extent of impact of 
visual impairment on visual-related tasks such as reading, and the available 
management options in a specific clinic (Freeman and Jose 1997, Freeman et al. 2007).  
 
The goals of visual impairment management could include ,but are not limited to,: 1) 
improving visual acuity (at near and distance), 2) enhancing reading performance, 3) 
reducing the effect of photophobia, 4) improving patients' independence, and 5) 
enabling patients to perform daily tasks (Freeman and Jose 1997, Dickinson 1998, 
Freeman et al. 2007).  
 
A brief description of the available management modalities (optical and non-optical low 
vision aids/ devices, sight substitution aids/ devices, patients training, and vision 
rehabilitation) for patients with a visual impairment follows; classified according to the 
aim/ objectives of use. Electronic low vision aids/ devices descriptions are covered in 
more details in section 2.6.2.  
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2.6.1. Low vision aids/ devices 
There are a variety of devices/ aids available for people with a visual impairment, and 
there are different ways of classifying or categorizing these devices. Classifications could 
be based on the aim of using certain devices such as improving contrast or visual acuity, 
or the technical characteristics of the devices. For example, Ilango (2003) has 
categorised low vision aids into optical and non-optical aids, as shown in Table 2.6. 
 
Optical aids Non-optical aids Substitution aids 
Telescopes Large print books Mobility canes 
Aspheric lenticular spectacle lenses Reading stands Talking books 
Hand magnifiers Illumination devices  
Stand magnifiers Writing devices  
Fresnel prisms Medical devices e.g. insulin 
syringes with bold letters 
 
Prismospheres*   
Paper-weight magnifiers   
Bar magnifiers   
Pocket magnifiers   
Electronic aids e.g. CCTV systems   
Anti-glare glasses   
 
Table 2.6: Aids to enhance vision (adapted from Ilango, 2003). * A prismosphere is a 
prism with a spherical lens. 
 
 
 
2.6.1.1. Optical aids to compensate for reduced distance visual acuity 
 
Telescopes 
Telescopes include optical systems for magnifying the apparent size of a distant object, 
which consists of an objective lens that forms a real image of the object and an ocular 
lens or eyepiece that magnifies the image formed by the objective (Freeman and Jose, 
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1997). Two main types of telescopes are available to people with a visual impairment 
these include hand-held or spectacle-mounted and they can be used monocularly or 
binocularly (Freeman and Jose 1997, Freeman et al. 2007, Schurink et al. 2011). Hand-
held telescopes can be more convenient for short-term use such as spotting, and reading 
signs. Spectacle-mounted telescopes (full diameter, bioptic, reading or surgical) can 
leave hands free. Issues such as restricted field of view, weight and alignment should be 
considered when prescribing spectacle-mounted telescope (Cole 1993, Nowakowski 
1994, Dickinson 1998, Freeman et al. 2007, Schurink et al. 2011).  
 
2.6.1.2. Optical aids and devices to compensate for reduced near visual acuity 
A range of optical magnifiers are available, and are used to enlarge and enhance viewing 
of a near task such as reading a text, these include:  
 
High addition spectacle lenses  
Spectacle-mounted reading lenses are high plus lenses (high plus lenses more than +3.00 
dioptres/ high plus prescription relative to the patient’s refractive error) that provide 
magnification from 1.5 to 6 times. They provide a wide field of view (Bailey 1979, Bither 
1987, Cole 1991, Cohen and Waiss 1991, Williams 1991, Freeman and Jose 1997, 
Dickinson 1998). However, the higher the magnification, the shorter the working 
distance.  
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Near telescopes 
Near telescopes and distance telescopes can be modified by adjusting focus or adding a 
reading cap in order to enhance near viewing. Compared to high addition plus lenses 
with equivalent power, they have a larger viewing distance, but a restricted field of view 
(Bailey 1981, Mancil 1986, Reich 1991, Cole 1996, Freeman and Jose 1997, Freeman et 
al., 2007).  
 
Hand-held magnifiers 
Hand-held magnifiers consist of a lens that gives a magnified image that is encircled by 
a lens holder with a handle (Freeman and Jose, 1997). Hand-held magnifiers can be used 
at different viewing distances; the magnification can be changed by changing the 
distance between the magnifier and the viewed object and/ or by changing the distance 
between the magnifier and the eye (Freeman and Jose 1997, Dickinson 1998, Freeman 
et al. 2007, Schurink et al. 2011). They can be useful for short term reading such as spot 
reading, reading a price labels, reading a telephone directory (Dickinson, 1998). The 
power range of hand-held magnifiers is 1.5-10 times. Versions of hand-held magnifiers 
are available with lights.  
 
Stand magnifiers  
Stand magnifiers can be controlled by hand for navigation while resting on the viewed 
object (Cole 1991, Freeman and Jose 1997, Dickinson 1998, Schurink et al. 2011). Stand 
magnifiers are mainly fixed focus, but in lower powers variable focus options are also 
available (Dickinson, 1998). Patients with difficulties holding objects often prefer the use 
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of stand magnifiers over hand-held magnifiers for reading because they do not need to 
find an appropriate distance as the lens-to-text distance is constant (Freeman and Jose 
1997, Dickinson 1998, Freeman et al. 2007, Schurink et al. 2011). In fixed focus stand 
magnifiers, the lens to object distance can be less than the focal length of the lens. An 
example of the optics of the stand magnifier is described in Chapter 7 of this thesis. The 
power range of stand magnifiers is approximately 1.5-15 times, most of them have an 
illumination system.  
 
2.6.1.3. Visual aids/ devices to compensate for visual field defects 
 
Visual aids/ devices to compensate for defects in the peripheral visual field: 
Patients with peripheral visual field defects find it more difficult to perform tasks that 
require navigation through the environment (Kuyk et al. 1996, Kuyk et al. 1998). 
Compensation for scotomas in the peripheral visual field can be achieved by training 
(e.g. visual scanning to improve patients ability to be aware of the surrounding), 
environment adaptations, prisms, mirrors, reversed telescopes, and negative lenses 
(Coeckelbergh et al. 2001, Anderson 2002).  
 
Prisms  
Prisms are used to displace the retinal image toward the prism apex. They are usually 
prism segments that are placed on the lens with the prism base towards the visual field 
defect, but off centre so a patient is unable to see it once in the primary gaze position 
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(Dickinson, 1998). Prisms that are used are Fresnel prisms and ground prisms within the 
lens (Dickinson 1998, Szlyk et al. 2005).  
     
Mirrors 
Mirrors are available either as clip-on devices or can be fixed to the spectacles (Cohen, 
1993). Mirrors are placed on the same side of the affected visual field which helps to 
reflect the image from the non-seeing retina towards the intact retinal area (Bailey, 
1982). These have proved to be useful for patients with hemianopia involving the 
temporal visual field but not for overall constriction of the visual field (Dickinson, 1998).  
 
Reversed telescopes and minus lenses 
Reversed telescopes and minus lenses enable patients to use their remaining visual field 
(Dickinson, 1998). They also increase the field of view, but make the image smaller 
(Dickinson 1998, Brilliant and Ginsburg 1999, Freeman et al. 2007).  
 
2.6.1.4. Non-optical low vision aids 
Non-optical aids are devices or appliances that enhance the independence of people 
with a visual impairment and improve their vision related tasks by using relative size 
magnification (i.e. enlarging the viewed object while maintaining the same viewing 
distance) or enhancing contrast, or substituation (Dickinson 1998, Freeman et al. 2007). 
These might be aids to improve the visibility of the retinal image (e.g. writing frames), 
or aids that optimise the use of magnifiers (e.g. maintaining a fixed distance between 
magnifier and object) (Dickinson, 1998). Examples of the non-optical low vision aids 
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include large print texts, bold-lined papers, fiber-tip pens, reading stands, and typo-
scopes, etc. (Dickinson, 1998).  
       
Enhancing contrast and reducing glare 
For people with a visual impairment, lighting is considered a critical factor to achieve the 
optimum level of visual functions (Dickinson, 1998). Functional performance of daily 
activities, such as reading, face recognition and mobility, in people with a visual 
impairment is limited once contrast sensitivity is reduced (Marron and Bailey 1982, Peli 
et al. 1991, Whittaker and Lovie-Kitchin 1993, Peli 1994, Leat and Woo 1997, Dickinson 
1998, Kuyk et al. 1998, West et al. 2002, De-Boer et al. 2004). Also, patients' visual 
comfort when carrying out different vision related tasks is affected by glare sensitivity 
(Waiss and Cohen, 1991). 
  
Different management options can be employed to reduce the effect of glare sensitivity 
and reduced contrast sensitivity. These include adjusting the light level for optimum 
viewing, using filters, electronic low vision aids, and using non-optical aids (e.g. hats, 
typoscopes, and side shields) (Rosenberg 1984, Lawton 1989, Waiss and Cohen 1991, 
Peli et al. 1991, Peli 1994, Dickinson 1998, Freeman et al. 2007). 
 
2.6.1.5. Sight substitution aids/ devices 
These include aids/ devices that assist patients with a visual impairment to use other 
senses than vision. These include auditory devices such as talking watches, talking 
books, voice activated typewriters or audio materials; tactile aids such as Braille code 
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books, drug box labels or watches; and mobility devices such as guide dogs or mobility 
canes (Cook and Polgar, 2012).  
 
2.6.2. Electronic low vision aids 
'Closed Circuit Televisions' (CCTVs) was the first term that has been used to describe 
electronic low vision aids (Kay, 1984). Electronic devices (also called electronic 
magnifiers, video magnifiers, closed circuit television systems CCTVs (Kay, 1984), and 
electronic vision enhancement systems (EVES) (Wolffsohn and Peterson, 2003) are 
devices that incorporate a video camera, a display screen, lenses and digital 
magnification. These devices allow people with a visual impairment to put reading 
material or objects to be viewed under the camera and then the formed image of the 
viewed object is displayed on an electronic display screen that could be a computer 
screen or a standard television screen (Kay 1984, Wolffsohn and Peterson 2003). 
Throughout the text, they will be referred to as 'Electronic low vision aids', unless 
necessary to use another term.  
 
Electronic low vision aids are an important potential management option for patients 
with a visual impairment. They have the potential to provide more features and greater 
flexibility compared to conventional low vision aids aids such as hand-held or stand 
magnifiers, and telescopes (Kay 1984, Wolffsohn and Peterson 2003). An electronic low 
vision device provides a wide range of magnification, contrast manipulation, colour 
change ability, auto and variable focus, and a  larger field of view (if they have a large 
display screen) (Kay 1984, Wolffsohn and Peterson 2003).  
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2.6.2.1 The history of the development of electronic low vision aids 
Wolffsohn and Peterson (2003) reviewed the 'current knowledge of Electronic Vision 
Enhancement Systems (EVES)'. The review includes classification, hardware, and 
software, development of technology, magnification, the size of field of view, contrast 
and the enhancement of the image. They also reviewed the devices from the users' 
perspective for example usage of the devices including the speed and duration of 
reading, and the training required. In addition, they highlighted the potential for future 
development (Wolffsohn and Peterson, 2003). 
 
Electronic low vision aids incorporate the concept of 'transverse magnification' which 
was firstly conceived to be incorporated in the application of low vision aids in the 1950s 
(Potts et al. 1959, Wolffsohn and Peterson 2003).  They were introduced in the 1970s 
(Fletcher 1979, Wolffsohn and Peterson 2003), however they were firstly described in 
1959 (Potts et al., 1959).  
 
In 1969, Genensky described modifications, for example, variable magnifications, 
reverse contrast, a 'Gestalt system' (to provide a wider field of view, with a small area 
of interest magnified), high-speed line return and self-focusing (Genensky 1969, 
Wolffsohn and Peterson 2003). However, due to limited technology development such 
as lack of portability, higher cost, and electrical faults (Goodrich et al., 1976) electronic 
low vision aids have not been commonly used or prescribed until recently (Wolffsohn 
and Peterson, 2003).  Goodrich et al. (1976) reported that one third of EVES developed 
electrical faults after 2 to 4 years of use; however these faults were often easily rectified.  
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It was predicted in the 1980s that electronic low vision aids would become more 
important in the rehabilitation of patients with a visual impairment (Brown, 1981). 
Mouse-style electronic low vision aids (a computer mouse-like unit with a camera 
incorporated within it) were firstly described in the 1970s (Fletcher, 1979). Recently, 
Harvey (2004) and Macnaughton (2005) suggested that the use of electronic 
magnification in low vision for all age groups should be considered.  
 
2.6.2.2. Classifications of electronic low vision aids 
Electronic low vision aids are available as hand-held, mouse operated, head-mounted or 
stand-mounted devices. The common features of these devices include a video-camera, 
a monitor (a display unit), and an illumination system. If they are stand-mounted devices 
they will include an XY-table to position books on (Schurink et al., 2011).  Stand-mounted 
electronic aids work by electronically magnifying the viewed object, and are usually used 
to improve reading (Schurink et al., 2011). Books have to be placed on the adjustable 
table to enhance reading, the magnified image of a book or text is displayed on a 
monitor (e.g. television screen) (Schurink et al., 2011).   
 
Hand-held electronic low vision aids can come on rollers that make it easy to move them 
on a flat surface (Schurink et al., 2011). In mouse operated devices there is a computer 
mouse with an electronic camera that records the image; the image is then presented 
on a computer screen (Schurink et al., 2011).   
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Different classifications have been developed for electronic low vision aids. Figure 2.2 
describes the classification of electronic low vision aids, according to Wolffsohn and 
Peterson (2003). In the USA, electronic aids can be classified into two major categories, 
these include devices in which the camera and/ or display are mounted on a stand and 
devices that incorporate a hand-held camera (in other words, stand electronic devices 
and hand-held electronic devices). Stand-mounted devices were subdivided into in-line 
or side-by-side configuration, and other features including colour options and 
magnification ranges were listed. Hand-held systems were sub-divided into small or 
normal size displays, and head-mounted displays (Uslan et al., 1996). 
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Figure 2.2: Classification of electronic low vision aids. CRT: Cathode Ray Tube, LCD: 
Liquid Crystal Display, TFT: Thin Film Transistor (Wolffsohn and Peterson, 2003). 
 
Currently, there is a variety of electronic low vision aids. This might be because of the 
increased demand for these devices, due to the improvement and the simplicity of 
currently available devices (Wolffsohn and Peterson, 2003). The American Foundation 
of the Blind (2010) described five main types of electronic low vision aids these include: 
1) desktop (Figure 2.3), 2) flex-arm camera (Figure 2.4), 3) head-mounted display (Figure 
2.5), 4) hand-held camera to TV (Figure 2.6), and 5) pocket and portable models (Figure 
2.7).  
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Desktop video magnifiers (Figure 2.3) consist of a computer screen, a video camera, a 
variable contrast control, a moveable platform (14x16 inches) and an illumination 
source (The American Foundation of the Blind, 2010). The viewed object/ text should be 
placed on the platform under the camera while the individual is watching the display 
screen. Desktop video magnifiers enable features such as automatic and manual focus, 
contrast reverse, magnification range from 3x to > 60x, and adjustment of magnification, 
brightness, contrast and colour (The American Foundation of the Blind, 2010).  They 
have some limitations such as lack of portability (Harper et al., 1999), and platform 
manipulation restrictions. Locating the beginning and the end of a line on reading text 
was solved by adding a 'margin stop' (The American Foundation of the Blind, 2010). The 
approximate cost of a desktop video magnifier is £1,252-£2,192 (The American 
Foundation of the Blind, 2010).  
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Figure 2.3: A desktop electronic magnifier (Merlin LCD desktop electronic magnifier/ 
Enhanced Vision – USA, cost: £1,766). It has a display screen and a moveable reading 
table (platform) (Enhanced Vision, 2015). 
 
Flex-arm video magnifiers (Figure 2.4) are similar to desktop video magnifiers, but the 
video camera is housed in a flexible (moveable) arm (The American Foundation of the 
Blind, 2010). Flex-arm video magnifiers have similar features to desktop magnifiers such 
as variable magnification controls, contrast enhancement and reversal controls, etc. But 
they do not have the X-Y table so they can be more difficult to use, and are also not 
portable (The American Foundation of the Blind, 2010). They are cheaper than desktop 
electronic magnifiers, with approximate cost of £1,252-£1,879 (The American 
Foundation of the Blind, 2010).  
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Figure 2.4: A flex-arm electronic magnifier with a computer display and a camera 
housed in a flexible arm (Acrobat HD ultra-long arm/ Enhanced Vision – USA, cost: 
£1,307) (Enhanced Vision, 2015).  
 
Head-mounted video magnifiers (Figure 2.5) incorporate a display that is mounted on 
a unit worn on the patient’s head (The American Foundation of the Blind, 2010). The 
magnification of the image displayed on the head-mounted display can be manipulated 
until the patient finds the required magnification (The American Foundation of the Blind, 
2010). Head-mounted video magnifiers have features such as colour mode, high 
contrast and contrast reverse viewing modes, and distance and near viewing (The 
American Foundation of the Blind, 2010). They are limited by being large and heavy, 
have a poor appearance, provide only low resolution and require the user to move the 
camera over the viewed object. This can be problematic for people with physical 
limitations, motion sickness, and claustrophobia (Culham et al. 2004, The American 
Foundation of the Blind 2010, Schurink et al. 2011). The approximate cost of a head-
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mounted video magnifier is £1,565-£2,192 (The American Foundation of the Blind, 
2010).  
 
 
Figure 2.5: A head-mounted electronic low vision aid with camera incorporated on a 
head-mounted unit (Jordy head-mounted electronic magnifier, Enhanced Vision – 
USA, cost: £1,831) (Enhanced Vision, 2015). 
 
Mouse video magnifiers (Figure 2.6) include a computer mouse-like unit with a camera 
incorporated within it connected to a display screen. The mouse-like unit can be moved 
over the viewed object (The American Foundation of the Blind, 2010). Features of mouse 
video magnifiers include high contrast and contrast reverse viewing modes (The 
American Foundation of the Blind, 2010).   Limitations of these magnifiers include less 
adjustable features such as magnification and image characteristics (The American 
Foundation of the Blind, 2010).  The approximate cost of a mouse video magnifier ranges 
from few hundred pounds to £1,879 (The American Foundation of the Blind, 2010).  
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Figure 2.6: A mouse video magnifier. The camera is incorporated within the mouse 
that can be attached to a computer or TV screen [Max mouse electronic magnifier, 
Enhanced Vision – USA, cost (not including the screen): £125] (Enhanced Vision, 2015).  
 
 
Pocket and Portable video magnifiers (Figure 2.7) are very small, light-weight electronic 
pocket-size magnifiers which have been developed recently. Features of pocket and 
portable electronic video magnifiers include adjustable magnification (up to 42x), 
autofocus, high contrast, contrast and colour manipulation, snapshot, and chargeable 
batteries. Pocket and portable video magnifiers are limited when reading longer 
passages (The American Foundation of the Blind, 2010). The approximate cost of these 
magnifiers ranges from £100 to £1,252 (The American Foundation of the Blind, 2010).  
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Figure 2.7: A pocket and portable electronic magnifier. It has a small display screen 
with few buttons (Amigo portable electronic magnifier, Enhanced Vision – USA, cost: 
£930) (Enhanced Vision, 2015). 
 
Other electronic devices such as electronic book-readers (e.g. Kindle, and Amazon 
readers) (Figure 2.8), i-Pads, i-phones or tablets can be used as portable magnifiers as 
they can enhance and magnify the viewed objects (The American Foundation of the 
Blind, 2010).  Features of electronic book-readers include internal memory that can hold 
from 150-2000 full-text novels, a text-to-speech option, and a flexible active matrix ink 
display that consists of the electronic paper which has a wide viewing angle of almost 
180 degree (Chen et al. 2003, Crossland et al. 2010, The American Foundation of the 
Blind 2010). However, electronic book-readers are limited by low contrast (about 60% 
Michelson contrast) and a slow refresh rate of approximately 250 ms (Crossland et al., 
2010).  
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Figure 2.8: Kindle (Kindle, USA) and Sony (Sony Corporation, Japan) readers 
(Mariosundar, 2007). 
 
 
2.6.2.3. Advantages and disadvantages 
Electronic low vision aids have been considered more user-friendly and interactive than 
conventional optical devices. The advantages of using electronic low vision aids for 
people with a visual impairment, in general, compared to conventional low vision aids 
such as hand-held/ stand magnifiers, include the following: 1) larger field of view, 2) 
large magnification range, 3) magnification can be manipulated according to user's 
requirements and comfort, thus in a later stage of the disease in which a patient might 
need different magnification, the device can still be used (Goodrich et al., 1980), 4) 
provide adjustable features such as balck-on-white and white-on-black viewing modes, 
brightness, and colours, 5) enable freeze frame feature, 6) more comfortable posture; 
they have flexible focus (some PELVAs can be used at variable distances), 7) maintain 
binocularity , and 8) they are easy to operate (few buttons to switch on/ off and to 
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manipulate zoom and luminance) (Mehr et al. 1973, Kay 1984, Uslan et al. 1996, Harper 
et al. 1999, Wolffsohn and Peterson 2003, Culham et al. 2004, Schurink et al. 2011). 
 
In comparison, magnification cannot be adjusted and contrast cannot be manipulated 
in optical low vision aids. Therefore, patients  with a visual impairment may require more 
than one device to accomplish the list of tasks that they may require to do during the 
day, or in the later stages of the disease they might need additional devices or to replace 
the existing ones (Culham et al., 2004). Also, as the magnification increases, aberration 
increases and field of view constricts (Culham et al., 2004).   
 
On the other hand, the disadvantages of electronic low vision aids include; neck and 
back-pain which might be experienced by some users (Zabel et al. 1982, Wolffsohn and 
Peterson 2003). Goodrich et al. (1976) reported that one third of electronic low vision 
aids developed electrical faults (Wolffsohn and Peterson, 2003).  
 
Optical magnification is achieved by the optics of lenses where a viewed object appears 
closer or bigger, whereas digital magnification is achieved by making parts (pixels) of an 
image appear larger (similar to zoom-in for an image on a computer screen) (Perlman, 
2011). The image quality using digital magnification may not be as good as image quality 
using optical magnification (Perlman, 2011). When using digital magnification, the new 
enlarged image is based on the same number of pixels; also the image quality might be 
worse with digital magnification at higher zoom levels, although optical aberration is a 
downside of optical magnification (Dickinson 1998, Perlman 2011).  
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Culham et al. (2004) suggested that ideally, electronic aids should provide a wide and a 
continuous range of magnification. Moreover it has to facilitate the manipulation of 
image quality factors such as contrast and brightness. It would be also important for the 
ideal electronic visual aid to be light-weight, portable, cosmetically acceptable, and easy 
to use (Culham et al., 2004).   
 
2.6.3. Patient's training and education 
'In-office training' is important for patients to be familiar with the device(s) they have 
been prescribed, in terms of how they should be used and the limitations that they might 
encounter once they use the prescribed devices (Goodrich 1997, Freeman and Jose 
1997, Dickinson 1998). Some optical low vision aids might be more complex to use and 
they may require additional training, to make sure that patients are able to use these 
devices (Goodrich 1997, Freeman and Jose 1997).  
 
The visual performance of people with a visual impairment could be improved with 
practice and training on the use of the devices.  Training was found to be helpful in 
improving reading speed and duration (Dickinson 1998, Nilsson et al. 1998, Backman 
1999, Nilsson et al. 2003, Kuyk et al. 2008). Also, patients' preference or satisfaction with 
the devices may change after using them for everyday tasks (Spitzberg and Goodrich, 
1995). Training also may be useful in some cases in which patients are required to 
efficiently use their residual vision, for example by using eccentric viewing, fixation, 
scanning, and saccade and pursuit eye movements etc. (O'Connell 1996, Waiss and 
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Cohen 1996). Kuyk et al. (2008) and Culham et al. (2009) found that home experience of 
the prescribed devices could be beneficial for users to have a perspective on the 
practicability of using the device for a range of tasks and it could provide realistic 
expectations of what can be achieved.  
 
2.6.4. Visual rehabilitation 
Low vision rehabilitation services can be defined as “a rehabilitative or habilitative 
process, which provide a range of services for people with low vision to enable them to 
make use of their eyesight to achieve maximum potential” (Low Vision Services 
Consensus Group, 1999). 'Habilitative' means that people with visual impairment learn 
new skills that they have not acquired before (Low Vision Services Consensus Group, 
1999).  'Rehabilitative' means that people who have lost the ability to do some skills due 
to visual impairment are rehabilitated in order to enable them to resume doing these 
tasks (Low Vision Services Consensus Group, 1999).  
 
Rehabilitation services can be standard hospital-based services provided by 
optometrists, or low vision therapists (Virtanen and Laatikainen 1991, Crossland et al. 
2007, Binns et al. 2012), and/ or multidisciplinary services where additional services can 
be provided by other health professional such as occupational therapists, mobility and 
training specialists (McCabe et al. 2000, Haymes et al. 2001, Lamoureux et al. 2007, 
Stelmack et al. 2008), psychologists (Needham et al., 1992), in association with social 
services (Binns et al., 2012).  
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Low vision rehabilitation has been found to be effective to improve visual functions and 
quality of life (Stelmack et al.  2006, Stelmack et al. 2007, Lamoureux et al. 2007, 
Stelmack et al. 2008, Binns et al. 2012, Ryan et al. 2012, Stelmack et al. 2012).  However, 
other studies found that low vision rehabilitation did not improve visual functions or 
quality of life (Scott et al. 1999, Reeves et al. 2004, De-Boer et al. 2006).  
 
Ryan et al. (2012), found a significant reduction in self-reported visual disability, 
between baseline and 18 months post intervention by −0.28 logits (IQR −1.24 to 0.52), 
of patients with a visual impairment who attended low vision rehabilitation services in 
180 optometry practices in Wales. This was less than that found between baseline and 
3 months; −0.61 logits (IQR −1.81 to 0.02) post intervention (Ryan et al., 2012). The 
authors also found that there was a decrease in patients’ satisfaction with the low vision 
aids 18 months after intervention (Ryan et al., 2012).  
 
Outcomes of the Veterans Affairs Low Vision Intervention trial suggested that low vision 
rehabilitation with the Veterans Affairs Low Vision service significantly improved visual 
functions including reading ability, visual information processing, mobility, and visual 
motor skills (Stelmack et al., 2008).  
 
2.7. Prescribing patterns for low vision aids  
Very few studies have assessed the prescribing patterns for low vision aids, particularly 
as new emerging technology impacts on low vision practice.   
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Crossland and Silver (2005) aimed to determine the types of low vision devices 
prescribed by clinicians in the low vision clinic at Moorfield Eye Hospital in London and 
to investigate changes in the prescribing habits over a 30 years period from 1973 until 
2003.  They reported that the median age of patients attending the clinic did not change 
significantly over this period. Eighty four percent of the patients who attended the clinic 
for the first time were prescribed at least one low vision device (Crossland and Silver, 
2005). The devices that were more frequently prescribed for new patients included: 
non-illuminated hand magnifiers, illuminated hand magnifiers, and illuminated stand 
magnifiers (Crossland and Silver, 2005). Between 1973 and 2003, there was a linear 
increase in the number of the prescribed hand magnifiers and a corresponding decrease 
in the number of prescribed near spectacle mounted telescopes (Crossland and Silver, 
2005). According to the authors, this could be due to the increased availability of 
electronic magnifiers, and the development of illuminated hand magnifiers (e.g. LED 
illumination and a higher range of magnification). The authors also found that even 
though there was a decline in the number of prescribed non-illuminated hand 
magnifiers, they contributed to a larger portion of the prescribed devices, particularly 
when compared to spectacle mounted telescopes; which might be due to the fact that 
spectacle mounted telescopes are more expensive than the non-illuminated hand-held 
magnifiers (Crossland and Silver, 2005). CCTVs were not included in the study, because 
the hospital did not provide these devices to patients, however clinicians did explain the 
use of CCTVs and they provided information about CCTVs suppliers (Crossland and Silver, 
2005). CCTVs were provided for school-children by local education authorities. Figure 
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2.9 shows the low vision aids that were included in the Crossland and Silver study and 
the differences in the prescription patterns over a 30 years period (1973-2003).  
 
 
Figure 2.9: The prescription pattern of low vision aids between 1973 and 2003. 
(Crossland and Silver, 2005) HM: Hand Magnifiers, Spec: Spectacle Mounted, HRA: 
High Reading Addition, Stm: Stand Magnifiers. 
 
Nguyen et al. (2009), in a Low Vision Clinic and Research Laboratory-Germany, reported 
that visual rehabilitation was achieved mostly by optical low vision aids (58% of study 
subjects) and less by electronic low vision aids (42% of patients). These findings are 
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significantly different to the results obtained by Crossland and Silver (2005). The 
National Health Scheme did not provide electronic devices for low vision patients in 
England. So, Nguyen et al. (2009) results may represent the prescription pattern in a 
private eye clinic.   
 
Results from the Lighthouse National Survey on Vision Loss (1995), in the USA, showed 
that of study populations of those aged 45 years and older; 30% of people with self-
reported visual impairment used optical visual aids such as magnifiers or telescopes, 
whereas 21% used large print texts, and less than 5% used adaptive visual aids such as 
talking books and clocks (Lighthouse National Survey on Vision Loss 1995, Jutai et al. 
2005). However it is not clear whether electronic low vision aids were included. 
  
Even though there are several types of electronic low vision aids, prescribing for children 
with visual impairment is considered limited  (Corn et al. 2002, Leat 2002, Ruddeck et al. 
2004, Lennon et al. 2007, Haddad et al. 2009, Schurink et al. 2011). 
 
2.8. Effectiveness of low vision aids for people with a visual impairment 
Currently, there are a variety of optical and electronic low vision aids. With the 
development of different low vision aids, there might be important changes in the 
trends or approaches to prescribing. The increased demand for electronic vision aids 
and the simplicity of these devices have increased the likelihood that they will be 
considered in clinical practice (Wolffsohn and Peterson, 2003). The most appropriate 
device is the device which meets patient's goals and objectives, and improves functional 
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abilities. Thus, it might be difficult to find the most appropriate low vision aid for a 
particular patient with visual impairment. A patient may require more than one device 
to accomplish the required list of tasks that they may require to do during the day, or in 
the later stages of the disease they might need additional devices or to replace the 
existing ones (Culham et al., 2004). “In the absence of adequate assessment of visual 
function, the choice of rehabilitation options has depended heavily on trial and error 
with different devices and interventions. Although trial and error might be expected to 
lead eventually to an adequate solution, trials consume time, require a large inventory 
of expensive devices, and frustrate clients” (Whittaker and Lovie-Kitchin, 1993). 
 
The effectiveness of different low vision aids has been evaluated in different studies 
based on the improvement of clinical visual factors (e.g. visual acuity, and contrast 
sensitivity), the improvement of functional abilities, the improvement of perceived 
quality of life and patients’ satisfaction, the devices’ characteristics (e.g. magnification) 
and improvements in reading performance  (e.g. rate, duration and comprehension) of 
people with a visual impairment (Brown 1981, Whittaker and Lovie-Kitchin 1993, 
Beckmann and Legge 1996, Watson et al. 1997, Lovie-Kitchin et al. 2000, Dickinson and 
Fotinakis 2000, Culham et al. 2004, Stelmack et al. 2006, Culham et al. 2009, Nguyen et 
al. 2011, Rubin 2013). People with a visual impairment particularly those who have 
difficulty or inability to read because of vision loss tend to use devices that improve their 
reading performance.  
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There have been very few publications regarding the effectiveness of pocket and 
portable electronic low vision aids (PELVAs), and there is no literature available (to our 
knowledge) that evaluates the accuracy of electronic low vision aids parameters (e.g. 
magnification, resolution and contrast sensitivity). Bullimore and Bailey (1989) reported 
that manufacturers' specifications in terms of optical parameters of stand magnifiers 
may not necessarily be accurate, also Bailey et al. (1994) advised that both the 
equivalent power and the image location should be verified to achieve the most 
appropriate prescription (Bullimore and Bailey 1989, Freeman et al. 2007). Moreover, 
many companies that sell electronic devices may not have a background in low vision 
rehabilitation (Wolffsohn and Peterson, 2003). The next section highlights the 
prescription patterns of different low vision aids, and it summarises the available 
literature about the effectiveness of low vision aids in improving the abilities of people 
with a visual impairment; however there will be more emphasis on reading 
performance.  
 
To our knowledge, little has been published regarding the efficiency of different low 
vision devices or interventions, very few studies compared electronic low vision aids 
with conventional low vision aids aids such as hand-held/ stand magnifiers, and very few 
studies compared different electronic low vision aids.  Peterson et al. (2003) compared 
the effect of three different electronic vision enhancement systems (EVES) (‘mouse-
based EVES with monitor viewing’, ‘mouse-based EVES with head-mounted display 
(HMD) viewing’, and ‘stand-based EVES with monitor viewing’) and optical magnifiers 
on near task performance for people with a visual impairment.  They compared different 
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visual tasks which include reading speed, reading acuity, time taken to track between 
columns of print, following a route map, locating a specific feature, and identification of 
specific information from medicine labels (Peterson et al., 2003).  
 
Peterson et al. (2003) found that: 1) reading speed using all of ‘mouse-based EVES with 
monitor viewing’, ‘mouse-based EVES with HMD viewing’, and ‘stand-based EVES with 
monitor viewing’ was faster compared to optical magnifiers, 2) reading speed using 
‘stand-based EVES with monitor viewing’ was higher compared to ‘mouse-based EVES 
with HMD viewing’, 2) the column location task was faster using optical magnifiers 
compared to the three types of EVES,  3) the map tracking and identification of medicine 
labels was slower using ‘mouse-based EVES with HMD viewing’ compared to other 
devices (Peterson et al., 2003). The authors concluded that although electronic low 
vision aids could provide objective advantages to people with a visual impairment such 
as in reading speed and acuity as well as some near tasks, some of them can perform no 
better than optical low vision aids.  
  
The authors found that previous experience of using EVES had no effect on the 
performance when undertaking visual tasks (reading speed, column location task, map 
tracking, or identification of medicine labels), but patients with previous experience of 
these devices found it easier to use optical magnifiers compared to patients with no 
previous EVES experience (Peterson et al., 2003). Previous optical magnifiers experience 
had no significant effect on reading speed, column location task or map tracking, but 
patients with previous experience of these device were slower at identification of 
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medicine labels compared to patients with no previous experience (Peterson et al., 
2003).  
 
Culham et al. (2004) studied the clinical performance of electronic head-mounted 
devices (Jordy (Enhanced Vision, USA, http://www.enhancedvision.com), Fliperport 
(Enhanced Vision, USA, http://www.enhancedvision.com, Maxport (Enhanced Vision, 
USA, http://www.enhancedvision.com, and NuVision (Keeler Limited, UK, 
http://www.keeler.co.uk). A head-mounted device is shown in Figure 2.5. They aimed 
to compare the 'laboratory based clinical measurements' and practical visual tasks 
among 20 people with macular degeneration. They measured near visual acuity using a 
Bailey-Lovie near acuity chart, intermediate visual acuity using a Bailey-Lovie near acuity 
chart fixed at 2/3 metres, and distance visual acuity using an Early Treatment Diabetic 
Retinopathy Study (ETDRS) Log MAR acuity chart at 4 metres. Contrast sensitivity was 
assessed using a Pelli-Robson chart at 1 metre. Visual task assessments included 
performance at writing a cheque, reading three different text sizes (N5, N10, and N20) 
using passages of text, and identifying grocery items on a shelf.  After initial evaluation 
each patient took home two devices (randomly selected) for two weeks. After home-
loan of devices patients were evaluated for reading performance. Culham et al. (2004) 
reported that generally none of the four devices stood out as the best device. However 
1) Flipperport and Jordy provided better distance and intermediate visual acuities 
compared to previously prescribed optical low vision aids, 2) for all devices in this study, 
near acuity and contrast sensitivity were similar to that with optical low vision aids, 3) 
practice at home improved the performance, 4) optical low vision aids were the best 
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devices for the majority of tasks, and 5) younger patients and people with better 
distance visual acuity were found to be more likely to benefit from the use of head-
mounted devices compared to optical low vision aids particularly in reading small print.  
 
The authors also tried to correlate users' opinions with patients' performance of the 
devices (using VF-14 modified questionnaires to evaluate patients' performance) 
(Culham et al., 2009). During the laboratory assessment, the Flipperport was the best 
device overall in terms of: rating, the score of image quality and the ability to magnify, 
but after home loan there was no significant difference between the four devices. 
Authors reported that the comfort of device was important, but it was not predictive of 
rating the device if the magnification was taken into account (Culham et al., 2009).  
 
In this study, the actual performance of devices for patients was measured by reading 
speed (Culham et al., 2009). However authors found that patients' impression or 
satisfaction of a given device was affected by a number of factors such as performance, 
ergonomics, cost, size, weight, appearance, portability, ease of use of controls of the 
devices, age of users, type of diagnosis, and time since diagnosed with vision loss 
(Culham et al., 2009). 
 
Culham et al. (2009) found that home experience of the prescribed devices could be 
beneficial for users to have a perspective on the practicability of using the device for a 
range of tasks and it could provide realistic expectations of what can be achieved. 
However, they suggested that extensive training is not necessary for the users to begin 
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to manage using devices alone, but continuous support and training at home may 
impact on the users experience, satisfaction and ability in addition to the final decision 
of clinicians. Goodrich et al. (1977) found that practice and training for CCTVs over a 
period of 10 days improved reading speed and the duration of using devices; this might 
be because not too many people were aware of using computer technology at that time 
(Culham et al., 2009). Culham et al. (2009) found also that more success with EVES was 
noticed in younger patients and patients who have been recently diagnosed with an eye 
disease or disorder. 
 
Goodrich and Kirby (2001) conducted a study that aimed to provide comparative 
information for practitioners to assist patients to select the most cost-effective reading 
devices. They compared reading speed and duration, and subjects' preference for two 
types of CCTVs with optical devices. They found that reading speed and duration were 
greater with CCTV systems than optical devices, but they did not find a significant 
difference in the performance between the two types of CCTVs. Patients preferred the 
stand-mounted system, but when they were asked to take the device price into 
consideration their preference were equal for both CCTV systems. The authors 
concluded that clinicians could expect better initial reading performance for patients 
with central visual field defects when reading with CCTVs compared to optical devices. 
They also found that hand-held CCTVs are less expensive than stand-mounted systems 
however the hand-held CCTVs had a lower subjective preference rating, but provide 
equal performance (Goodrich and Kirby, 2001).  
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Optical low vision aids are highly task-specific (e.g. devices for improving distance vision 
only such as telescopes, and devices for improving near visual acuity only such as 
magnifiers), that means a low vision patient could require more than one optical device 
in order to meet his/ her objectives of seeking low vision services (Culham et al., 2009). 
Studies indicate that at least 80-91% of patients attending low vision services were 
provided with a low vision aid (Leat et al. 1994, Shuttleworth et al.1995, Watson et al. 
1997, Harper et al. 1999). However some patients discontinue the use of low vision 
devices after prescription (Leat et al. 1994, Watson et al. 1997, and Harper et al. 1999). 
Causes that could make patients discontinue the use of the prescribed devices include: 
1) changes of their vision, 2) the ergonomic of the device, 3) frustration with limitations 
imposed by the use of optical devices where patients try to find another device (Watson 
et al. 1997).   
 
It has been found that patient's age and the visual acuity achieved with devices are not 
predictive of the continued use of low vision aids (Leat et al. 1994, Watson et al. 1997, 
Harper et al. 1999). A smaller group of patients wanted low vision devices to be less 
noticeable (Harper et al., 1999). Watson et al. 1997 suggested that patients would like 
to see a range of improvements in low vision aids such as wider field of view, higher 
resolution, automatic focus, additional image brightness, and clear near and distance 
view.   
 
Harper et al. (1999) reviewed and described the new devices (i.e. electronic) and 
discussed their current and future potential in comparison with conventional low vision 
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aids. However, the authors explained that comparing patients' performance with 
conventional low vision aids and CCTVs is difficult, because not all patients are equally 
familiar with both types of devices.  
 
Goodrich et al. (1980) tested 96 US veterans who had been CCTVs users for two years. 
They found that 50% of their patients use both types of devices (optical and CCTVs) in 
combination. The optical aid is used to find a specific item and the CCTVs for detailed 
viewing. Conventional aids were useful in "spotting" tasks or in cases where portability 
is important.  When comparing the reading speed using the two types of devices, there 
was no difference however the duration of use was three times longer with CCTVs 
(Goodrich et al., 1980). Therefore this suggests that CCTVs should be considered when 
prescribing for longer reading tasks.  
 
Harper et al. (1999) suggested that the measurement of dynamic visual acuity is 
important because it measures the effectiveness of retinal image stabilization and gaze 
stability in all planes of head movement. Dynamic visual acuity is the threshold of visual 
resolution achieved during relative motion of the visual target or the observer head. It 
is a measure of visual vestibular interaction (Demer and Amjadi, 1993). All spectacle 
mounted telescopes caused a decrease in dynamic visual acuity, regardless of their 
magnification (Demer and Amjadi, 1993).   
 
Harper et al. (1999) suggested that it remains a priority to identify patients’ factors that 
predict successful use of devices. For example, Whittaker and Lovie-Kitchin (1993) found 
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that the image contrast should be 10 times more than the patient’s contrast threshold 
in order to increase reading speed to a level called "read for pleasure" i.e. high fluent 
reading (174 words/ minute).  
 
Li et al. (2002) aimed to study the clinical effectiveness of optical and video low vision 
aids and to analyze the characteristics of the people with a visual impairment at Chang 
Gung Memorial Hospital low vision clinic. The sample included 203 patients who were 
evaluated for improvement in near and distance visual functions when using low vision 
aids. Spectacles were only able to meet both near and distance visual requirements in 
21 patients, but 3 of them were prescribed Fresnel prisms with their spectacles. Eighty 
four of 121 patients with distance visual requirements benefited from telescopes. Only 
one patient benefited from adding a Jordy head-mounted device (Li et al.,  2002), 118 
out 136 patients who could not read newsprint, benefited from optical magnifiers, and 
125 benefitted from using a MagniCam CCTV (Li et al.,  2002). They concluded that low 
vision patients could benefit from video magnifiers if optical low vision aids failed to 
improve their vision. However, they reported that their patients can accomplish their 
tasks using traditional low vision aids (Li et al., 2002).  
 
Also, the authors found that older patients preferred simple rather than complex low 
vision aids. This might explain why 82% of study subjects preferred optical low vision 
aids (Li et al., 2002).   
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2.9. Reading performance: Factors affecting reading performance with low vision aids 
Reading difficulty is the most common complaint in people with visual impairment 
(Rubin, 2013). Rubin (2013) found that reading difficulty was the reason for 60% of 
patients to be referred to low vision practices. Literature available about the 
effectiveness of low vision aids has focused on improvement in reading ability or speed 
(Rubin, 2013). This was done by comparing the reading ability and/ or performance (e.g. 
critical print size, reading acuity and reading speed) with and without visual aids.  
 
Reading tests such as the Minnesota Low Vision Reading Test (MNREAD) (Mansfield et 
al. 1993, Ahn et al. 1995, Ahn and Legge 1995, Mansfield et al. 1996, Rubin 2013), the 
Neale Analysis of Reading Ability (Revised British Edition), the New Reading Analysis 
(Neale 1989, Bowers 2000), the International Reading Speed Text (IReST) (Hahn et al. 
2006, Ramulu et al. 2013, Rubin 2013), the Bailey-Lovie near acuity chart (Bailey and 
Lovie, 1980), the Colenbrander mixed contrast cards (Dexl et al., 2010), the sustained 
reading performance test  (Ramulu et al., 2013) and text passages for reading such as 
the Flesh Kincaide Scale (Dickinson and Shim, 2007), etc. are often used in such studies 
(Schurink et al., 2011). 
 
The Bailey-Lovie near reading chart is widely used to measure the acuity threshold which 
can be used to determine the magnification level that is required for reading print of 
any given size (Bailey and Lovie 1980, Rubin 2013). The letter size is decreased by a 
constant percentage on the following line. The text size is specified in Log MAR units 
(Bailey and Lovie 1980, Rubin 2013).  
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The Colenbrander mixed contrast card consists of high contrast and low contrast lines. 
The size of letter in each line decreases by a constant ratio (Dexl et al., 2010). The 
importance of the Colenbrander chart is that the test can be used to screen for reduction 
in both contrast and reading (Rubin, 2013).   
 
The MNRead test is a continuous-text reading acuity chart. Each sentence consists of 60 
characters, the sentences decreases in size by 0.1 log unit (Legge et al. 1989, Rubin 
2013). The advantage of using the MNRead test is the fact that all of reading acuity, 
critical print size, and reading speed can all be measured using one chart. It is also 
available in different languages. However, having only two charts per language makes 
sentences easier to remember if the test is required to be repeated, it also requires 
calibrating the external lighting (Rubin, 2013).  
 
The IREST is available in different languages; the English version consists of 10 plates 
(about 170 words each, Times Roman 12 font) (Hahn et al. 2006, Trauzettel-Klosinski 
2012, Rubin 2013). Having 10 plates (170 words each), enables the assessment of 
reading speed without repeating the passages (Rubin, 2013). The limitation of the IREST 
is that it is available in one size (Rubin, 2013).  
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Factors affecting reading performance in patients with a visual impairment:  
From summary of the available literature regarding reading performance, it is clear that 
several factors may affect reading performance, or can be predictive of reading 
performance. The factors are as follows:   
 
1) Age: 
Akutsu et al. (1991) found that reading rate was lower for normally sighted older people 
compared to young people, for characters with angular sizes of < 0.3 degree and > 1 
degree (Akutsu et al., 1991).The authors explained that this was attributed to reduced 
contrast and dynamic visual acuity, and oculomotor limitations due to ageing (Akutsu et 
al., 1991). On the contrary, some studies found that age was not predictive of reading 
performance (Cummings et al. 1985, Legge et al. 1992, Fletcher et al. 1999, Ergun et al. 
2003, Sunness et al. 2007).  
 
2) Ocular conditions: 
 Legge et al. (1992) found a slower reading rate in patients who had AMD compared to 
other conditions. Brown (1981) found that patients who had AMD needed more 
magnification and more time to recognize texts compared to cataract patients. In 
contrast, central visual field status and ocular media status were not predictors of 
reading speed (Ahn and Ledge, 1995). In older patients, glaucoma was associated with 
a lower reading speed (Ramulu et al., 2009). Mohammed and Omar (2011) found a lower 
reading speed in young patients (aged 13-19 years) with visual impairment (different 
ocular conditions) compared to a normally sighted age matched group. 
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3) Type of magnifier: 
Nguyen et al. (2009) found that low vision aids (CCTVs and optical low vision aids) 
significantly improved reading ability, and no difference was found in reading ability 
between optical and electronic low vision aids. Reading ability was improved using low 
vision aids and there was no reported difference between a variety of low vision aids 
(Margrain 2000, Bowers 2000). On the contrary, Dickinson and Shim (2007) found a 
lower reading speed with low vision aids compared to reading speed without low vision 
aids in older participants (60 – 85 years old), but not in younger participants (18 – 30 
years old). The authors reported that lower reading speed with low vision aids in older 
participants was not attributed to age, but it might be attributed to the poorer manual 
dexterity compared to younger participants. The authors did not report if there was any 
difference in reading speed with different types of low vision aids (Dickinson and Shim, 
2007). Also, with low vision aids, there was no significant difference in reading speed 
between moving the magnifier and moving the text (Dickinson and Shim, 2007). Ahn and 
Legge (1995) found a lower reading speed with low vision aids however a higher reading 
speed was found with spectacle mounted magnifiers, then hand-held magnifiers, 
followed by CCTVs and then stand magnifiers.  Beckmann and Legge (1996) reported 
that page navigation was more problematic with hand-held magnifiers and electronic 
vision enhancement systems.  Cheong and Lovie-Kitchin (2007) found that with hand-
held magnifiers and electronic vision enhancement systems few characters were visible 
which requires moving magnifiers between words in order to increase visibility.  
Peterson et al. (2003) found a higher reading speed with mouse and stand-mounted 
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electronic vision enhancement systems compared to the reading speed with optical 
magnifiers. The reading speed with stand-mounted electronic vision enhancement 
systems was higher compared to the reading speed with mouse electronic vision 
enhancement systems. Goodrich and Kirby (2001) reported a higher reading speed and 
duration with CCTVs compared to optical low vision aids. There was no difference in 
reading speed between CCTVs or mouse devices in patients with a visual impairment 
and the normally sighted (Harland et al., 1998). 
 
4) Visual acuity: 
Whittaker and Lovie-Kitchin (1993) found that when reading the print size needed to be 
larger than acuity threshold, and the effectiveness of a low vision aid depended largely 
on acuity reserve. The authors found that an acuity reserve of 1.5:1 was required for 
‘fluent’ reading (88 words/ minute), and an acuity reserve of 3:1 was required for ‘high 
fluent’ reading (174 words/ minute). Lovie-Kitchin et al. (2000) found that near visual 
acuity was predictive of higher rauding rate (i.e. reading for understanding). ‘Rauding’ is 
derived from ‘reading’ and ‘auding’, which means to be attending to words and 
comprehending each consecutively encountered thought contained in the words 
(Carver 1985, Carver 1993). In other words, an individual should read each word to 
comprehend the complete thought of each sentence. Rauding rate is the fastest rate 
that an individual can accurately comprehend relatively easy material/ text (Carver 
1985, Carver 1993). Rauding accuracy is the highest level of text difficulty that an 
individual can accurately/ correctly comprehend (Carver 1985, Carver 1993). Rauding 
efficiency is the ability to comprehend efficiently, i.e. the number of thoughts that can 
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be comprehended per the amount of time allowed for reading (Carver 1985, Carver 
1993). Rauding efficiency (E) can be calculated by applying the equation (E = A*R), where 
A is the rauding accuracy, and R is the rauding rate (Carver 1985, Carver 1993). 
 
Latham and Tabrett (2012) found that an acuity reserve of 2:1 was sufficient to achieve 
a reading speed of 118 words/ minute. The authors referred to the reading speed of > 
80 words/ minute as fluent reading speed, and the reading speed of 133 words/ minute 
as the maximum reading speed. Harper et al. (1999) found that reduced visual acuity 
was associated with lower reading ability. On the other hand, visual acuity was not 
predictive of reading performance (Cummings et al. 1985, Legge et al. 1992, Fletcher et 
al. 1999, Ergun et al. 2003, Sunness et al. 2007).  
 
5) Contrast: 
 Whittaker and Lovie-Kitchin (1993) found that, in patients with visual impairment, a 
letter contrast of less than 4 times the patient’s contrast threshold impaired reading rate 
and accuracy, whereas a letter contrast of less than 10 times the patient’s contrast 
threshold only reduced reading speed. A contrast reserve of 4:1 was required for ‘fluent’ 
reading (88 words/ minute), and contrast reserve of 10:1 was required for ‘high fluent’ 
reading (174 words/ minute) (Whittaker and Lovie-Kitchin 1993, Crossland et al. 2010). 
Whittaker and Lovie-Kitchin (1994) suggested that a letter contrast threshold of higher 
than 9% is considered poor and indicate a need for lighting adjustment, higher 
magnification or a CCTV. A contrast threshold of higher than 25% can be considered very 
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poor and a CCTV or non-visual intervention is needed for fluent reading (Whittaker and 
Lovie-Kitchin, 1994).  
 
Studies (Rubin and Legge1989, Whittaker and Lovie-Kitchin 1993) found that letter 
contrast correlates more accurately with reading speed than grating contrast. Ginsburg 
(1978) reported that small characters need increased contrast for identification rather 
than detection. Van-Nes and Jacobs (1981) found that the accuracy of letter recognition 
did not decrease until the contrast was below 0.12 Michelson contrast. Crossland et al. 
(2005) found that the baseline contrast measurements were predictive of future reading 
speed for patients with AMD.  Legge et al. (1987) found that reading rates were highest 
for letters ranging in size from 0.25 to 2 degrees at 40cm, within this range, reading was 
very tolerant to contrast reduction for 1 degree sized letters, reading rate decreased by 
less than a factor of two for a tenfold reduction in contrast.  
 
Brown (1981) reported that higher contrast was more critical to cataract patients when 
compared to AMD patients, in terms of reading performance with CCTVs. The authors 
also found that word recognition speed in patients with visual impairment was more 
predicted by contrast sensitivity (measured by Arden plates) than visual acuity. In 
patients with visual impairment who had cloudy ocular media, there was a higher 
reading speed for white text on a black background compared to black text on a white 
background and this could be due to light scatter (Legge et al., 1985), but no effect of 
contrast polarity (reverse) on reading performance in normally sighted people (Legge et 
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al., 1985). On the other hand, Bauer and Cavonius (1980) reported more errors when 
subjects read white text on a black background. 
  
Leat and Woo (1997) found that contrast measured with Pelli-Robson charts, 
Cambridge grating charts, Regan charts, University of Waterloo charts (UW charts), and 
Vistech charts was predictive of reading speed. The authors found that Cambridge 
grating charts and Pelli-Robson charts were the best charts to measure medium to low 
contrast; UW charts and Regan charts for medium to high contrast whereas the Vistech 
chart is useful for testing contrast at all levels (Leat and Woo, 1997).    
 
6) Visual field: 
A lower reading speed for patients with central visual field defects was found compared 
to normally sighted people (Legge et al. 1985, Legge et al. 1987, Lovie-Kitchin and Woo 
1988, Legge et al. 1992). Ergun et al. (2003) found that the size of the absolute scotoma 
was significantly correlated with reading speed and reading acuity. Whittaker and Lovie-
Kitchin (1993) suggested that to achieve ‘fluent’ reading (88 words/ minute), the central 
scotoma must be less than 22 degrees. The authors also reported that ‘high fluent’ 
reading (174 words/ minute) can be achieved with a central scotoma of 4 degrees. On 
the contrary, scotoma size was not predictive of reading performance in patients with 
visual impairment (Legge et al. 1992, Cummings et al. 1985, Fletcher et al. 1999, Ergun 
et al. 2003, Sunness et al. 2007). Nguyen et al. (2011) suggested that the pattern of 
eccentric viewing that patients with visual impairment develop differs according to the 
aetiology behind the central field scotoma.  
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7) Field of view: 
As magnification increases to the maximum the field of view will be restricted to the 
minimum (Schurink et al., 2011). Den-Brinker and Bruggeman (1996) reported that the 
field height and width had a significant effect on reading speed. The window size was 
found to affect reading speed with and without navigation in patients with visual 
impairment (Legge et al. 1985, Fine et al. 1996, Fine and Peli 1996). Legge et al. (2001) 
suggested that if the visual span is reduced the reading rate will be lower. A field of view 
of 4 to 5 characters was found sufficient for fluent reading (88 words/ minute) (Legge et 
al. 1985, Whittaker and Lovie Kitchin 1993). However, Rayner et al. (1982) found that a 
window size of 15 characters to the right of the fixation point increased the reading 
speed. Also, Den-Brinker and Bruggeman (1996) reported that a large field of view was 
required for page navigation. In optical low vision aids, high magnification levels restrict 
the field of view which significantly reduced reading speed (Dickinson and Fotinakis, 
2000). This might be attributed to higher magnification that was not accompanied with 
a proportional increase in the number of saccades (Dickinson and Fotinakis, 2000). In 
comparison, Lowe and Drasdo (1990) suggested that the field of view of patients with a 
visual impairment using CCTVs was approximately equal to the normal field of view, for 
manual scanning.  Den-Brinker and Bruggeman (1996) found that when the window size 
(width and height) with CCTVs was increased the time required to read a line was 
decreased, and the number of the required saccades was decreased. 
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9) Ocular movements:  
Dickinson and Fotinakis (2000) suggested that patients with visual impairment had a 
slow reading speed compared to normally sighted people because the limited size of the 
saccades. Also, Rumney and Leat (1994) found shorter saccades in patients with visual 
impairment (different ocular conditions) using the optimal low vision aids. Bowers and 
Lovie-Kitchin (2001) found that the regressive saccades were decreased using low vision 
aids.  
 
10) Page navigation requirements: 
Page navigation refers to the movement of the low vision aid during reading (Harland et 
al., 1998). This might be restricted by the low vision aids ergonomics. Page navigation 
was found to be more problematic with hand-held magnifiers and EVES (Beckmann and 
Legge, 1996), and a larger field of view was required for page navigation (Beckmann and 
Legge 1996, Den-Brinker and Bruggeman 1996). Reading and page navigation were 
affected by the window size (Fine et al., 1996). CCTVs did not affect the field of view 
when manual scanning was required (Lowe and Drasdo, 1990). Harland et al. (1998) 
compared the reading performance with four different text presentation methods 
(CCTVs, mouse devices, drift, and Rapid Serial Visual Presentation RSVP). With CCTVs, 
the text is moved on an X-Y table to be viewed by a camera mounted to a monitor. With 
mouse devices, the mouse within which a camera is incorporated is moved over the text.  
With drift, a line of text drifts/ moves from right to left across the screen. With RSVP, a 
computer presents words, one at a time, at the same place on the monitor. They found 
that RSVP and sensomotoric training (SM) presentation methods increased reading rate. 
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There was no difference in reading speed using CCTVs or mouse devices (both required 
manual navigation) in normally sighted and patients with visual impairment (Harland et 
la., 1998). Drift and RSVP methods had less navigational requirements which resulted in 
higher reading speeds (85% and 169% faster, respectively) in normally sighted people. 
Significant differences between different presentation methods were not found among 
people with central visual field loss, but drift and RSVP methods improved reading 
performance in patients with intact central fields (Harland et la., 1998).  It was suggested 
that a larger field of view could be required for page navigation.  
 
11) Reading text characteristics: 
Legge et al. (1985) reported that reading rate can be affected by text characteristics such 
as text size and contrast. Large text size resulted in slower reading speed because of the 
decreased number of saccades (Bullimore and Bailey, 1995). Lovie-Kitchin et al. (2000) 
found that rauding (Carver, 1993) rate was associated large print size without low vision 
aids and large print size was more predictive of oral reading speed with low vision aids. 
In peripheral vision, reading speed was increased with increasing text size until the 
critical font size was reached; then the maximum reading rate becomes constant at 
larger letter sizes (Chung et al., 1998). In patients with visual impairment, reading rate 
was higher using Courier font compared to Times New Roman font, and the critical print 
size was smaller for Courier font (Mansfield et al., 1996).  
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12) Media clarity: 
Legge et al. (1985) findings suggested that patients with visual impairment who had 
ocular media opacity had higher reading speed using a white letter on a black 
background (i.e. contrast reverse). This suggests that contrast reversal has potential to 
improve performance in patients with cataract. However, Legge et al. (1987) found that 
patients with ocular media opacities did not show a better reading speed using white 
letters on a black background.  
 
13) Ocular dominance: 
Zeri et al. (2011)  studied the effect of ocular dominance on the visual functions, and 
found that ocular dominance had no effect on the visual functions including reading 
performance.  
 
14) Reading rate and comprehension:  
Carver (1990) found that reading rate and comprehension were positively related;  
Legge et al. (1989) found that slow reading rate was a predictor of poor reading 
comprehension. On the other hand, Watson et al. (1992) found that reading rate was 
not predictive of reading comprehension in adults with visual impairment who 
demonstrated good comprehension before becoming visually impaired.  
 
In summary, there has been no literature that evaluated the use of, and prescribing 
trends for PELVAs in patients with a visual impairment. Therefore, this thesis aims to 
inform those who prescribe or choose PELVAs about the functions or attributes that are 
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most important when considering their use for people with a visual impairment. Also, 
we aim to evaluate PELVAs from different perspectives including their parameters and/ 
or features, their use, their prescribing patterns, and factors that affect reading 
performance with these devices. The objectives of this thesis were: to compare the 
reported manufacturers’ magnification and screen size of PELVAs to that measured in 
an independent setting, to measure the luminance contrast that PELVAs could provide 
in different independent settings, to estimate the resolution limit of currently available 
PELVAs, to describe the clinicians’ prescribing patterns for PELVAs for patients with a 
visual impairment attending the Low Vision Service Wales, to determine the 
characteristics of patients with a visual impairment who would benefit from PELVAs, to 
assess patients’ self-reported satisfaction of PELVAs compared to optical devices, to 
evaluate what patients with a visual impairment use PELVAs and optical low vision aids 
for, to evaluate the usefulness of low vision aids for a group of visual tasks such as 
reading a newspaper, and reading price labels, to evaluate the frequency and duration 
of reading that can be achieved with PELVAs and optical low vision aids, to compare 
PELVAs and optical low vision aids from the patients’ perspective in terms of purpose of 
use, rating their use and satisfaction, and reading frequency and duration, and to 
determine the factors (visual functions and/ or devices parameters) that affect reading 
performance of patients with a visual impairment who are using PELVAs.  
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CHAPTER 3: Pocket and portable electronic low vision aids: Do 
manufactures provide an accurate description? [Magnification and Screen 
Diameter] 
 
3.1. Introduction 
PELVAs are a relatively a new type of low vision aids. They are easy to operate, feature 
few buttons and/ or controls to operate and manipulate the devices, are small (often 
pocket sized) which might make them convenient to be used at different places such as 
in the office, school, bus, etc. They have a smart appearance which may draw less 
attention to people with a visual impairment when they use them compared to optical 
magnifiers.  
 
The image for a viewed text or an object is displayed on a small display screen. These 
devices provide a magnified image for which there are different zoom levels available. 
The image can also be viewed with different contrast settings/ modes.  PELVAs have 
features such as a variable contrast control. This allows the users to vary the way in 
which the image is displayed. For example, if viewing black writing on a white 
background the users can view the image where the image contrast relationship is the 
same as the target; in this example a black target on a white background (Figure 3.1, 
Left). Alternatively, they could choose contrast reverse (where the image contrast 
relationship is opposite to the target); in this example a white target against a black 
background (Figure 3.1, Right). There are also options for various colour combinations 
e.g. yellow target against blue background. PELVAs enable a refreshed image and a 
snapshot view, by which the image can be frozen temporarily. The brightness of some 
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PELVAs can be manipulated via an on/ off brightness button.  The power is provided by 
chargeable batteries. Common features of PELVAs are shown in Figures 3.1 and 3.2.  
 
 
Figure 3.1: A PELVA (Compact+) is used by people with visual impairment to magnify 
a text or an object and to enhance contrast. The image contrast relationship is the 
same as the target; in the example a black target on a white background (Left). The 
image contrast relationship is opposite to the target (contrast reverse); in this example 
a white target against a white background (Right).  
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Figure 3.2:  A PELVA (Compact+) incorporates:  1) a display screen, 2) a collapsible 
handgrip, 3) an on/off switch, 4) a snapshot button to freeze an image on the display 
screen temporarily, 5) a power adaptor for rechargeable batteries, 6) a camera unit: 
auto-focus camera, 7) a battery compartment, 8) a mode button for a contrast viewing 
mode selection (e.g. a black letter on a white background or a white letter on a black 
background),  and 9) a magnification dial: a control to change magnification levels.  
 
From Chapter 2, it is clear that very few studies have evaluated the effectiveness of low 
vision aids in assisting people with a visual impairment to perform daily life tasks 
(Bullimore and Bailey 1989, Whittaker and Lovie-Kitchin 1993, Bailey et al. 1994, 
Lighthouse National Survey on Vision Loss 1995 , Goodrich and Kirby 2001, Wolffsohn 
and Peterson 2003, Peterson et al. 2003, Culham et al. 2004, Crossland and Silver  2005, 
Jutai et al. 2005, Culham et al. 2009, Virgili and Acosta 2009, Nguyen et al. 2009). None 
have evaluated the effectiveness of PELVAs for people with a visual impairment, 
however the Wales Council for the Blind evaluated children’s response regarding the 
use of 11 pocket electronic magnifiers for school activities in focus groups (Dyment, 
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2009). They reported children comments and concerns about the use of these 
magnifiers in order to recommend the most effective electronic magnifier for school-
age children (Dyment, 2009).  
 
An important part of studying the effectiveness of a particular management option for 
people with a visual impairment is to investigate the properties of the devices 
prescribed, and thereafter to examine if the patients requirements can be met by the 
chosen device. This is important in order to help patients and clinicians to choose the 
most appropriate device, and to save time, effort and money by avoiding too much 'trial 
and error' in reaching a decision. Bullimore and Bailey (1989) reported that 
manufacturers do not necessarily provide accurate information about the optical 
parameters of stand magnifiers. Also, Bailey et al. (1994) reported that information 
provided by manufacturers about optical low vision magnifiers may not be sufficient to 
estimate the resolution improvement that they actually provide. Clinicians have to 
determine the key parameters of devices used in their practice, as they might be 
misreported or not reported at all by manufacturers. Bailey et al. (1994) recommended 
that ''until manufacturers provide the required technical information about their 
devices, clinicians must determine these parameters for themselves or obtain the 
information from other sources".  
 
In their study, Bailey et al. (1994) measured the image distance, the equivalent power 
of the lens system, and the enlargement ratio for optical magnifiers (92 stand magnifiers 
and 53 hand-held magnifiers). They used three different eye-to-lens distances for each 
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magnifier (i.e. at 2.5, 10 and 25cm). The equivalent viewing distance (EVD), the eye to 
image distance and the predicted width of field were calculated. The authors explained 
that EVD is important in predicting the resolution performance. For an individual 
patient, the resolution limit will be directly proportional to the EVD. The eye-to-image 
distance is useful to indicate if the patient will have appropriate focus or whether the 
reading addition has to be adjusted (Bailey et al., 1994). The EVD for hand-held 
magnifiers is equal to the equivalent focal length, if the lens is used to form the image 
at or close to infinity. Accommodation demand in a given situation is determined by the 
sum of the image-to-lens distance and the lens-to- eye distance (Bailey et al., 1994).  
 
The EVD is the distance at which the object would subtend an angle that is equal to the 
angle that the image subtends at the patient's eye. In stand magnifiers, EVD = eye-to-
image distance/ enlargement ratio (Bailey et al., 1994). Bailey et al. (1994) found that 
the threshold print size will be directly proportional to EVD (e.g. if the EVD is halved, the 
size of the smallest resolvable print is also halved). They reported that for 'any viewing 
system with known EVD' the resolution limit can be predicted by the equation 
Resolution unit (M units) = EVD for initial resolution/ initial viewing distance (Bailey et 
al., 1994).  They defined the field size as the lens size multiplied by the equivalent power 
(Fe) and divided by the eye-to-lens distance and all of these variables are available in 
tables for optical magnifiers (Bailey et al., 1994), examples of stand magnifiers optical 
parameters are shown in Table 3.1.  
  
110 
 
 
 
 
 
 
Manufacturer ID No. 
 
Description 
Illum 
Adjust. 
Code 
Lens 
Size 
(mm) 
Measured Predict Performance (Z= Eye/ Lens distance cm) EVD-EVP 
Fe 
D 
I 
Cm 
ER 
X 
Z= 2.5 Z= 10 Z= 25  
 
 
Peak 8-16X 
Mattingly 22X Ill a 
Peak #1996 L 
 
 
8X-16X zoom 
22X Illum 
30X Illum 
 
 
Zoom 
be ih 
b i 
 
 
10 
17 
8 
 
 
68.7 
66.4 
120.4 
 
 
## 
## 
10.0 
 
 
## 
## 
13.0 
EVD Ey/Im Fld EVD Ey/Im Fld EVD Ey/Im Fld  
 
1.25-80 1.5 
1.5 
1.0 
## 
## 
12.5 
6 
10 
3 
1.5 
1.5 
1.5 
## 
## 
20.0 
1 
3 
1 
1.5 
1.5 
2.7 
## 
## 
35.0 
1 
1 
1 
Mattingly 22X Ill b 22X Illum be ih 17 66.4 21.3 15.1 1.6 23.8 11 2.1 31.3 4 3.1 46.3 2 2.0-50 
 
Table 3.1: Examples of stand magnifiers optical parameters.  Fe = equivalent power in dioptres (D), I = image location, ER = enlargement ratio. EVD’s 
and eye to image distance (Ey/Im) are calculated for eye-lens distances (z) of 2.5, 10, and 25 cm (EVD = Eye-to-image dist/ER). Each double-ruled 
divider represents one line of visual acuity assuming size progression ratio = 5/4. Equivalent Viewing Power (EVP) and Equivalent Viewing Distance 
(EVD) conversion benchmarks are shown on the right at each horizontal divider. Field sizes (Fld) in millimetres are based on thin lens and small pupil 
assumptions. Field may be limited further by aberrations or base of stand. Illumination codes: b = battery, r = rechargeable, e = electrical, I = 
incandescent, h = halogen (or xenon), f = fluorescent, ## = no data available (Bailey et al., 1994).
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To date, no studies have investigated agreement between the manufacturers’ PELVA 
parameters and those found in an independent setting. The aim of this study is to 
answer a question "Do manufacturers provide accurate and clear descriptions of pocket 
and portable electronic low vision aids?”. This will be assessed by comparing the 
reported manufacturers' description of these devices with independent measurements.  
 
There were four parts to this study: 
1) The first part involved a comparison of actual PELVAs display screen size with the 
manufacturers quoted size. 
2) The second part compared the magnification levels acquired with the PELVAs to 
the manufacturers quoted levels.  
3) The third part involved measurements of luminance contrast of the image that 
PELVAs could provide for a high and low contrast letter acuity card under 
different levels of illumination, different viewing conditions, and black-on-white 
and white-on-black contrast viewing modes. 
4) The fourth part describes estimates of the resolution limits that these devices 
may provide by employing an ISO 12233 chart as a viewing target. 
 
This chapter describes the first and second parts; the third and fourth will be covered in 
Chapter 4.   
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3.2. Methods 
3.2.1. PELVAs 
Almost all suppliers and manufacturers of low vision aids in the UK were contacted; 
requesting the loan of currently available PELVAs.  
 
Initially 12 PELVAs were received from suppliers which were included in this study and 
another 2 PELVAs were added later for the magnification repeated measurements. 
Devices were given symbols from A to N and symbols will be used to represent devices 
throughout the text. 
 
3.2.2. Laboratory preparation and setup 
A ruler with an inch scale was used to measure the display screen diameter of PELVAs. 
It was not possible to use a more accurate method of measurement, such as a travelling 
microscope with Vernier scale due to difficulty in applying the procedure when 
measuring devices, because the extent of movement that was required to measure the 
diagonal diameter was outside of the scope of the travelling microscope. 
 
A viewing object (a single letter sized N8) from a Bailey-Lovie near acuity chart was used 
for measuring magnification.    
 
Two travelling microscopes (MA and MB) (Figure 3.3) were used to measure the image 
sizes available from each PELVA and hence the linear or transverse magnification was 
calculated.  
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A travelling microscope is an instrument for measuring length with 0.01mm resolution. 
The travelling microscopes incorporated: 1) a rigid base, 2) two rails, 3) a knob for coarse 
adjustment, 4) screws for fine adjustment, 5) a 10X eyepiece fitted with fine cross-hairs 
to fix a precise position which is then read off the Vernier scale, 6) measuring scales, and 
7) objectives. Microscope MA was made by PTI (England), and Microscope MB by Griffin 
and George (England). Both travelling microscopes have a resolution of 0.01mm.  
Microscope MA can travel up to 16.5 cm horizontally and up to 14 cm vertically.  
Microscope MB can travel horizontally up to 22 cm and vertically up to 15 cm.  
 
 
 
Figure 3.3: The travelling microscopes (MA and MB) used to measure image sizes. Left, 
Microscope (MA) by PTI (England), and right, Microscope (MB) by Griffin and George 
(England).  
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3.2.3. Measuring the display screen size 
The display screen diameter was measured for 12 PELVAs (A, B, D, F, G, H, I, J, K, L, M, 
and N), PELVAs C and E were added at a later stage for magnification repeated measures.  
 
The visible screen diameter (Figure 3.4) was measured in inches (because this is what 
most manufacturers provided) for each PELVA, by one observer, using a ruler. 
Measurements were repeated three times and the average was calculated.  
 
 
Figure 3.4: The visible screen diameter, i.e. the distance from the corner of the display 
screen to the opposite corner, was measured by using an inch ruler. The PELVA shown 
in this figure is Compact+.  
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3.2.4. Measuring magnification 
A letter "L" sized N8 (newsprint size) (Figure 3.5) was used as a target from a Bailey-Lovie 
near acuity chart. The letter height (i.e. letter size) was measured three times using the 
travelling microscope (MA) with Vernier scale and found to be 1.90 mm, standard 
deviation (SD) < 0.004.  
 
 
Figure 3.5: Small “L” letter sized N8 on a Bailey-Lovie near acuity chart was used as a 
viewing object in order to measure the image size. The image is minified (50% of the 
actual size).  
 
The image of the N8 sized letter was taken under the static viewing mode (i.e. a snapshot 
was taken using the freeze button). The distance between the device and the viewed 
letter for each PELVA was set according to manufacturers' instructions in terms of 
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viewing distance/ angle (some PELVAs require a particular viewing angle and these were 
supplied with a stand).  
 
The letter image height on each PELVA, under different magnification levels, was 
measured at each zoom level (zoom levels were different for different PELVAs); each 
measurement was repeated three times in order to ensure repeatability of 
measurements.  
 
The average image size for each magnification level was calculated and divided by the 
letter size to get the transverse magnification (Transverse magnification = Image size / 
Object size), i.e. enlargement ratio (Dickinson and Fotinakis, 2000).  
 
i. Agreement of magnification measurements made using different microscopes 
Measurements of the magnification levels provided by 4 PELVAs (B, C, D, and E) were 
made by 2 observers, using two microscopes (MA and MB). Each observer made 3 
measures for each magnification level, using each microscopes. A 3rd observer could 
not finish the measurements using microscope MA, but did finish the measurements 
with microscope MB. Therefore, we had measurements from two observers for both 
microscopes and three observers for microscope MB.    
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 ii. Agreement of magnification measurements made by different observers 
Measurements of the magnification provided by 4 PELVA (B, C, D, and E) were made by 
3 observers (observer 1 i.e. the author, observer 2, and observer 3) using microscope 
MB. Each observer made 3 measures for each magnification level. Agreement between 
the three observers was assessed using only one microscope (MB).  
 
Agreement between the travelling microscopes MA and MB, and between three 
observers (1, 2, and 3) was assessed using Bland-Altman plots. Bland-Altman plots assess 
agreement and were more useful in this context than the use of correlation coefficients. 
Correlation between two sets of measurements can be high but agreement may be poor 
(Chan 2003, McAlinden et al. 2011).  
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3.3. Results 
3.3.1. Display screen size  
The difference between measured and reported diameter for 12 PELVAs is shown in 
Table 3.2 and Figure 3.6. Reported manufacturer diameter for the 12 PELVAs (A, B, D, F, 
G, H, I, J, K, L, M, and N) ranged from 2.80 to 6.50 inches, their measured diameter [mean 
of three measurements by 1 observer] ranged from 2.81 inches to 6.39 inches (the mean 
difference between measured and reported screen diameter was -0.03 ±0.07 inch). The 
percentage difference between measured and reported diameter ranged between 0.00 
and 4.29%.  Although differences between measured and reported diameter were small, 
they were statistically significant (One sample t-test, p < 0.05) for all PELVAs except 
PELVAs (B and I).  
 
According to the measured screen diameter, devices were divided into two sub-groups 
of PELVAs. The first can be described as small pocket size PELVAs; these include PELVAs 
with screen diameter of 3.5 inches or less (i.e. F, G, J, K, and L). The second can be 
referred to as larger PELVAs, these include PELVAs with screen size of greater than 3.5 
inches (i.e. A, B, D, H, I, M, and N). These criteria are not used by manufacturers. The 
criterion of 3.5 inches or less for the PELVA was decided, because a PELVA with a 
diameter of 3.5 inches can be fitted in a pocket. This grouping might also be important 
for clinicians to consider when a larger field of view is required possibly for a higher 
reading speed.  
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PELVA Reported screen 
diameter  
(inches) 
Measured screen diameter using 
an inch-ruler  (Mean of three 
measurements ± SD) (inches) 
Difference1 
(inches)  
Ratio 
(%)2 
Percentage 
difference3 
A 6.50 6.39±0.008 -0.11** 98.31% 1.69% 
B 4.30 4.30±0.001  0.00 100.00% 0.00% 
D 5.00 4.99±0.046 -0.01** 99.80% 0.20% 
F* 3.50 3.38±0.006  -0.12** 96.57% 3.43% 
G* 3.50 3.35±0.002 -0.15** 95.71% 4.29% 
H 4.30 4.24±0.005 -0.06** 98.60% 1.40% 
I 4.30 4.30±0.001  0.00 100.00% 0.00% 
J* 3.00 3.02±0.002 0.02** 100.67% 0.67% 
K* 3.50 3.51±0.004  0.01** 100.29% 0.29% 
L* 2.80 2.81±0.004  0.01** 100.36% 0.36% 
M 4.30 4.34±0.008  0.04** 100.93% 0.93% 
N 4.30 4.36±0.008 0.06** 101.40% 0.40% 
1 Difference = Mean measured diameter – Reported diameter 
2 Ratio (%) = Mean measured screen diameter / reported screen diameter *100% 
3 Percentage difference = (Mean measured screen diameter – Reported diameter)/ Reported diameter 
*100% 
is the difference between measured and reported diameter to the 
* small pocket size PELVAs i.e. reported screen diameter = < 3.50 inches 
** Significant difference between the mean measured and the reported screen diameter (p < 0.05). 
  
Table 3.2: The reported and measured screen diameter (the mean of 3 measurements) 
of 12 PELVAs.  
 
 
 
Figure 3.6: The measured screen diameter (the mean of 3 measurements in inches) 
and reported screen diameter of 12 PELVA.  All values lie close to the reference (no 
change) line. Pearson Correlation Coefficient = 0.998 (p < 0.001).   
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3.3.2. Magnification  
3.3.2.1. Inter-microscope differences (a comparison of two travelling microscopes    
(MA and MB)) 
 
There was no significant difference in measured magnification using both travelling 
microscopes (MA and MB) by 2 observers (3 measurements by each observer with each 
microscope i.e. 6 measurements) for 4 PELVAs (B, C, D, and E).  
 
Data (measurements using both microscopes, by two observers) were normally 
distributed (Shapiro Wilk test, p > 0.05). The mean difference in measured magnification 
between the microscope MA and the microscope MB was 0.035 ±0.25 (Paired sample t-
test, p > 0.05). Measured magnification using the travelling microscopes MA and MB is 
shown in Table 3.3.  
 
Table 3.3: Measured magnification using the travelling microscopes MA and MB (two 
observers (1 and 2), 3 measurements each at each zoom level).  
 PELVA 
Manufacturer’s 
zoom level 
MA 
Mean±SD 
MB 
Mean±SD 
Observer 1  
B 
5.00 5.77 ±0.00 5.98±0.08 
7.50 8.62±0.04 8.39±0.10 
10.00 11.87±0.02 11.68±0.04 
C 
1.70 1.38±0.04 1.54±0.10 
12.00 13.01±0.11 13.07±0.05 
D 
1.50 1.59±0.02 1.73±0.01 
18.00 19.06±0.03 18.87±0.01 
E 
2.00 2.76±0.06 2.64±0.09 
24.00 21.77±0.20 22.15±0.14 
Observer 2 
B 
5.00 5.80±0.01 6.29±0.14 
7.50 8.66±0.07 8.21±0.03 
10.00 11.79±0.04 11.62±0.07 
C 
1.70 1.50±0.01 1.57±0.05 
12.00 12.90±0.03 12.86±0.12 
D 
1.50 1.54±0.04 1.69±0.02 
18.00 18.48±0.07 18.67±0.21 
E 
2.00 2.63±0.05 2.71±0.03 
24.00 22.21±0.18 22.35±0.21 
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Bland-Altman plot showed that limits of agreement [Mean + 2*SD and Mean – 2*SD] 
were 0.54 and -0.47, measurements were distributed equally above and below the 
mean difference line, 95% confidence intervals [Limits of agreement ± Corresponding 
value of Degree of Freedom DF on t-tables * Standard Error SE] were 0.61 and 0.47 for 
the upper limit, and -0.40 and -0.54 for the lower limit (Figure 3.7). 
 
Figure 3.7: Bland-Altman plot shows the differences in magnification measurements 
between Microscope MA and Microscope MB.  Magnification was measured for 4 
PELVAs (B, C, D and E) by 2 observers (3 measurements each (n=6), at each zoom level). 
Mean difference (0.035) (bold black line); limits of agreement 0.54 and -0.47 (grey 
lines); 95% confidence intervals 0.61 and 0.47 for the upper limit, and -0.40 and -0.54 
for the lower limit (dashed lines). Poorest agreement was for PELVA B (5X and 7.5X), 
and PELVA E (24X).  
 
B (5X) 
B (7.5X) 
E (24X) 
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3.3.2.2. Inter-observer differences (a comparison of 3 observers) 
The magnification measurements made by each of the three observers were normally 
distributed (Shapiro Wilk test, p > 0.05). There was no significant difference in measured 
magnification by 3 observers (1, 2, and 3) using microscope MB i.e. 3 measurements by 
each observer at each zoom level for 4 PELVAs (B, C, D, and E) (ANOVA: F = 0.42, F critical 
= 3.11, p > 0.05). Measured magnification by three observers is shown in Table 3.4.  
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Table 3.4: Measured magnification of 4 PELVAs (B, C, D, and E) by 3 observers (1, 2, and 3) using the travelling microscope MB. The mean and 
standard deviation of three measurements by each observer at each zoom level. (††) Magnification was not measured at this zoom level by observer 
3 (i.e. missing data therefore data in the whole highlighted row were removed from inter-observers analysis). The ISO15253:2000 (BSI, 2000) for 
magnification tolerance: for equivalent power of =< 12 the tolerance is 5%, for equivalent power of > 12 and =< to 20 the tolerance is 10%, and if 
the equivalent power is > 20 the tolerance is 15%. ✔ PELVA’s magnification was within the ISO15253:2000 standard (BSI, 2000).   X  PELVA’s 
magnification deviated significantly from the ISO standard.
PELVA 
Manufacturer’s 
zoom 
 
Observer 1 
(Mean ± SD) 
 
Observer 2 
(Mean ± SD) 
 
Observer 3 
(Mean ± SD) 
 
Observer 1 vs. Observer 2  
 
Observer 1 vs. Observer 3 
 
Observer 2 vs. Observer 3 
Deviation 
from ISO 
15253:2000 
standard 
Fall within 
ISO15253:2000 
standard? 
Deviation 
from ISO 
15253:2000 
standard 
Fall within 
ISO15253:2000 
standard? 
Deviation 
from ISO 
15253:2000 
standard 
Fall within 
ISO15253:2000 
standard? 
B 5 5.98±0.08 6.29±0.14 5.46±0.36 5% ✔ -9% X -13% X 
 7.5 8.39±0.10 8.21±0.03 †† -2% ✔ †† - †† - 
 10 11.68±0.04 11.62±0.07 12.61±0.50 -1% ✔ 8% X 9% X 
C 1.7 1.54±0.10 1.57±0.05 2.14±0.02 2% ✔ 39% X 36% X 
 12 13.07±0.05 12.86±0.12 9.14±0.07 -2% ✔ -30% X -29% X 
D 1.5 1.73±0.01 1.69±0.02 2.23±0.06 -2% ✔ 29% X 32% X 
 18 18.87±0.01 18.67±0.21 19.22±0.05 -1% ✔ 2% ✔ 1%  ✔ 
E 2 2.64±0.09 2.71±0.03 2.68±0.10 3% ✔ 2% ✔ -1% ✔ 
 24 22.15±0.14 22.35±0.21 18.70±0.22 1% ✔ -16% X -16% X 
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There was no significant difference between magnification measured by observer 1 and 
observer 2. The mean difference in measured magnification between observer 1 and 2 
was -0.004 ± 0.22 (ANOVA: F = 1.72E-05, F critical = 4.03, p > 0.05), Pearson Correlation 
Coefficient = 0.97 (p < 0.001). Bland-Altman plot showed that limits of agreement were 
0.43 and -0.43; 95% confidence intervals were 0.34 and 0.52 for the upper limit, and -
0.52 and -0.34 for the lower limit (Figure 3.8). All differences between observer 1 and 
observer 2 measurements lie within the ISO15253:2000 standard (BSI, 2000) (Table 3.4).   
 
 
Figure 3.8: Bland-Altman plot shows the differences in magnification measurements 
between observers 1 and 2 using microscope MB.  Mean difference -0.004 (black bold 
line), limits of agreement 0.43 and -0.43 (grey lines), 95% confidence intervals 0.34 and 
0.52 (dashed lines) for the upper limit, and -0.52 and -0.34 (dashed lines) for the lower 
limit.  
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There was no significant difference between magnification measured by observer 1 and 
observer 3. The mean difference in measured magnification, of PELVAs B, C, D and E, 
between observer 1 and 3 was -0.57 ± 1.90 (ANOVA: F = 0.63, F critical = 4.03, p > 0.05), 
Pearson Correlation Coefficient = 0.90 (p < 0.001). Bland-Altman plot showed limits of 
agreement were 3.23 and -4.37, and 95% confidence intervals were 2.43 and 4.03 for 
the upper limit and -5.17 and -3.57 for the lower limit (Figure 3.9). However, two out of 
8 differences between observer 1 and observer 3 measurements lie within the 
ISO15253:2000 standard (BSI, 2000), and 6 differences lie outside the standard (Table 
3.4).   
 
Figure 3.9: Bland-Altman plot shows the differences in magnification measurements 
between observers 1 and 3 using microscope MB.  Mean difference -0.57 (bold black 
line), limits of agreement 3.23 and -4.37 (grey lines), 95% confidence intervals 2.43 and 
4.03 (dashed lines) for the upper limit, and -5.17 and -3.57 (dashed lines) for the lower 
limit. The poorest agreement was for PELVA C (12X).  
C (12X) 
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There was no significant difference between magnification measured by observer 2 and 
observer 3. The mean difference in measured magnification between observer 2 and 3 
was -0.57 ± 1.91 (ANOVA: F = 0.63, F critical = 4.03, p > 0.05), Pearson Correlation 
Coefficient= 0.90 (p < 0.001). Bland-Altman plot showed that limits of agreement were 
3.25 and -4.39; 95% confidence intervals were 4.30 and 2.50 for the upper limit, and –
5.17 and -3.57 for the lower limit (Figure 3.10). However, two out of eight differences 
between observer 2 and observer 3 measurements lie within the ISO15253:2000 
standard (BSI, 2000) (Table 3.4).   
 
Figure 3.10: Bland-Altman plot shows the differences in magnification measurements 
between observers 2 and 3 using microscope MB.  Mean difference -0.57 (bold black 
line), limits of agreement 3.25 and -4.39 (grey lines), 95% confidence intervals 4.30 and 
2.50 (dashed lines) for the upper limit, and –3.57 and -5.17 (dashed lines) for the lower 
limit. The poorest agreement was for PELVA C (12X), and PELVA E (24X). 
   E (24X) 
C (12X) 
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3.3.2.3. Manufacturer versus measured magnification  
 
Manufacturer magnification compared to measured magnification  
As the inter-observer and inter-microscope differences for magnification measurements 
were not significantly different as shown in Sections 3.3.2.1 and 3.3.2.2, transverse 
magnification was measured for 14 PELVAs (A-N) by 1 observer (1) using 1 microscope 
(MA) and was compared to the manufacturer reported magnification. One PELVA (N) 
was removed because it had a technical fault.  
 
Data were normally distributed (Shapiro Wilk test, p > 0.05). The reported 
manufacturers’ magnification for 13 PELVAs (A to M) ranged from 1 to 42, while the 
measured magnification ranged from 0.57 to 27.43.  The mean difference between the 
reported magnification and the measured magnification by observer 1 (3 measurements 
at each zoom level) using microscope MA for 13 PELVAs was -0.70 SD± 4.90 (Paired 
sample t-test, p < 0.05). The majority of PELVAs lie outside the ISO15253:2000 standard 
(BSI, 2000) for tolerance of optical magnifiers.  All PELVAs except PELVA A lie outside the 
ISO15253:2000 for magnification tolerance, i.e. only one PELVA (A) meets the tolerance 
expected for all zoom levels. PELVAs D, E, and L do have one zoom level that lies within 
tolerance, but not all zoom levels within tolerance. Table 3.5 and Figure 3.11 show 
manufacturers reported magnification compared to measured magnification of PELVAs.  
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PELVA Reported 
Magnificati
on 
Measured 
magnification¹ 
±SD 
P-Value³ Ratio 
(%)² 
Deviation from 
ISO 15253:2000 
standard 
Fall within ISO15253: 
2000 standard? 
✔ or X 
A 3.5                                                                  
14 
3.71±0.04
14.46±0.06 
0.028*
0.004* 
104% 
103% 
4% 
3% 
✔ 
✔ 
B 5                                                                     
7.5                                                                             
10 
5.77±0.001
8.62±0.03
11.87±0.02 
0.002* 
<0.001*
<0.001* 
115% 
115% 
119% 
15% 
15% 
19% 
X 
X 
X 
C 1.7 
12 
1.38±0.03 
13.01±0.02 
<0.001* 
0.005* 
81% 
108% 
19% 
8% 
X 
X 
D 1.5 
18 
1.59±0.01 
19.06±0.02 
0.009* 
0.009* 
106% 
106% 
6% 
6% 
X 
✔ 
E 2 
24 
2.76±0.05 
21.77±0.16 
0.003* 
0.002* 
138% 
91% 
38% 
9% 
X 
✔ 
F 2 
11 
2.99±0.03 
24.06±0.03 † 
<0.001* 
<0.001 
149% 
219% 
49% 
119% 
X 
X 
G 2 
14 
2.73±0.02 
5.36±0.02 † 
<0.001* 
<0.001* 
136% 
38% 
36% 
62% 
X 
X 
H 2 
7 
14 
4.75±0.02 †  
6.59±0.02 
9.81±0.03 
0.002* 
<0.001* 
<0.001* 
237% 
94% 
70% 
137% 
6% 
30% 
X 
X 
X 
I 42 27.43±0.03 † <0.001* 65% 35% X 
J 4 
6 
8 
11 
3.19±0.02 
4.56±0.04 
5.98±0.03  
7.7±0.03 
<0.001* 
<0.001* 
<0.001* 
<0.001* 
80% 
76% 
75% 
70% 
20% 
24% 
25% 
30% 
X 
X 
X 
X 
K 1 
20 
0.57±0  †     
5.5±0.03 † 
<0.001* 
<0.001* 
57% 
28% 
43% 
72% 
X 
X 
L 3 
5 
7 
2.86±0.02 
4.14±0.15 
5.88±0.03 
0.015* 
<0.001* 
<0.001* 
95% 
83% 
84% 
5% 
17% 
16% 
✔ 
X 
X 
M 2 
10 
4.45±0.09 † 
10.86±0.03 
0.001* 
<0.001* 
221% 
109% 
121% 
9% 
X 
X 
N†† 5 
7.5 
4.9±0.02 
6.61±0.02 
0.041* 
0.003* 
98% 
88% 
2% 
12% 
✔ 
X 
 
Table 3.5: The reported manufacturer’s magnification and the measured magnification¹ (mean 
of 3 measurements by observer (1) using microscope MA)   for 13 PELVAs using N8 size letter. 
² Ratio= Measured magnification/ Manufacturer magnification*100%. ³ P-value was calculated 
for the difference between reported and measured magnification at each zoom level 
separately using paired-sample t-test (paired sample t-test was performed for each zoom 
level). * P-value was significant (p < 0.05). ISO15253:2000 (BSI, 2000) for magnification 
tolerance: For equivalent power of =< 12 the tolerance is 5%, for equivalent power of > 12 and 
=< to 20 the tolerance is 10%, and if the equivalent power is > 20 the tolerance is 15%. ✔ PELVA 
magnification was within the ISO15253:2000 standard (BSI, 2000).   X  PELVA magnification 
deviated significantly from the standard. All PELVAs except PELVA A lie outside the 
ISO15253:2000 for magnification tolerance. PELVAs D, E, and L do have one zoom level that lies 
within tolerance, but not all levels within tolerance.  † PELVAs F, G, H, I, K, and M were outliers 
in Figures 3.11. †† PELVA N was removed from magnification analysis because it had a technical 
fault, therefore results of 13 PELVAs (A-M) are presented.  
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Figure 3.11: Measured magnification versus reported manufacturer’s magnification 
for 13 PELVAs (A-M) at different zoom levels. Dots show the mean measured 
magnification (3 measurements at each zoom level) by observer 1 using microscope 
MA. Pearson Correlation Coefficient = 0.818, p < 0.001. PELVAs F, G, H, I, K, and M were 
outliers. All PELVAs except PELVA A lie outside the ISO15253:2000 for magnification 
tolerance. PELVAs D, E, and L do have one zoom level that lies within tolerance, but 
not all levels within tolerance, see Table 3.5.  
 
 
Although, overall, correlation was high (Pearson Correlation Coefficient = 0.818, p < 
0.001) (Figure 3.11), Bland-Altman plot shows that about 13% of values lie outside 
agreement limits (Figure 3.12). Limits of agreement were 10.50 and -9.10; 95% 
confidence intervals were 12.30 and 8.70 for the upper limit and -7.30 and -10.90 for 
the lower limit (Figure 3.12).  
F 
G 
I 
K 
 
M 
H 
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Figure 3.12: Bland-Altman plot using the absolute difference shows agreement 
between measured magnification (by observer 1 using microscope MA) and the 
reported manufacturer magnification. Mean difference -0.70 (black line) Limits of 
agreement 10.50 and -9.10 (grey lines), 95% Confidence intervals 12.3 and 8.7 for the 
upper limit and -7.3 and -10.9 for the lower limit (dashed line). Poor agreement was 
for PELVA G. PELVAs F, I and K were outliers.  
 
 
Also, it was found that the difference between the reported and the measured 
magnification was greatest at higher magnification levels for some PELVAs (p < 0.05) 
(Figure 3.13).   
  
F 
G 
 K I 
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Figure 3.13: The mean and standard deviation of measured magnification of 13 PELVAs 
(A-M), by 1 observer (1) using 1 microscope (MA) [3 measurements at each zoom 
level]. Black dots show the mean of measured magnification (3 measurements) at each 
zoom level by 1 observers using 1 microscope. Error bars show the standard deviation 
of measured magnification at each zoom level.  Horizontal axis show the zoom levels 
as reported by manufacturers for example, 7.5X (B1) = 7.5 is the value of the 1st 
magnification level of PELVA ‘B’, 12x (C2) = 12 is the value of the 2nd magnification level 
of PELVA ‘C’ as reported by manufacturers, etc.  
 
 
The differences between measured magnification and manufacturers reported 
magnification can be expressed as percentages of the values (Method A – Method B) / 
Mean %) (Giavarina, 2015). Clinically, it is likely that the more useful measure would be 
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the difference in absolute magnification. For example, a 50% difference will be more 
significant at some magnifications but not others; a 50% difference of 2X magnification 
is 1X, but a 50% difference of 10X magnification is 5X. The 5X will be noticed by the 
patient, whereas the 1X may not be. Therefore, differences in absolute magnification 
are likely to be more important clinically. 
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3.4. Discussion  
In this study the manufacturers reported screen diameter was compared to the 
measured screen diameter for 12 PELVAs. Differences between measured screen 
diameter and reported diameter were small (-0.03±0.07 inch). Although they were 
statistically significant (p < 0.05) for 10 PELVAs, these differences were considered 
unlikely to have any clinical implications. 
 
Agreement between microscopes measurements, observers measurements, and 
between measured magnification and reported magnification was compared using 
Bland-Altman plot in which the difference between two measurements was plotted 
against the mean of both measurements. These showed that variations between 
reported manufacturers magnification and magnification measured in an independent 
setting were significant, and these were not attributed to inter-microscopes or inter-
observers variations.  
 
Although there was no significant difference between the mean measures for 3 
observers, the limits of agreement were greater between observer 3 and the other 
observers compared to observer 1 versus observer 2. The difference between observer 
3 and other two observers for some zoom levels were about 4 times magnification. 
Applying the ISO15253:2000 standard (BSI, 2000); a difference of 3.93X magnification 
between observers 1 and 3 for the second zoom level of PELVA C (12X) represents -30% 
deviation which lies outside the recommended tolerance (Table 3.4). Also, a difference 
of 3.65X magnification between observers 2 and 3 for the second zoom level of PELVA E 
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(24X) represents -16% deviation which lies slightly outside the standard. Observer 3 had 
presbyopia and he found it difficult to read the Vernier scale of the travelling 
microscope; this might contributed to the variations between observers 1 and 3, and 
observers 2 and 3.  
 
Statistically, large limits of agreement could reflect a small sample (Bland and Altman, 
1986), but this is less likely to be the reason because for the same sample of PELVAs the 
differences between observers 1 and 2 measurements were smaller. 
 
Reported manufacturers and measured magnification were compared for 13 PELVAs. 
Significant variations were found between manufacturers' and reported measurements 
(mean difference -0.70±4.90, p = 0.00) which can not be explained by inter-microscope 
or inter-observer differences (p > 0.05).  
 
The difference between measured and reported magnification was large (ranged from -
14.6 to 13.1X). When the tolerances for magnification from the ISO15253:2000 (BSI, 
2000) were applied to the data, the vast majority of measures fell outside these levels 
(Table 3.5).  The ISO15253:2000 standard (BSI, 2000) to tolerance of magnifiers states 
that: 1) for equivalent power of less than or equal to 12 the equivalent power for 
magnifiers should not deviate by more than 5%, 2) the equivalent power of magnifiers 
of equivalent power of greater than 12 and less than or equal to 20 should not deviate 
by more than 10%, and 3) the equivalent power of magnifiers of equivalent power 
greater than 20 should not deviate by more than 15% (BSI, 2000).  
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Only PELVA (A) falls within the standard with deviations of 3% and 4%, for the two 
magnification levels (Table 3.5). Other PELVAs (B, C, F, G, H, I, J, and M) did not fall within 
the ISO 15253:2000 for all zoom levels and the deviation of these PELVAs was up to 
137% (Table 3.5) which is large. For example, a difference between measured and 
reported magnification of 137% for a PELVA with 20X magnification would provide 27.4X 
magnification (higher than the expected) which is clinically significant. Although this 
study suggested that differences between reported and measured magnification were 
clinically significant for the majority of PELVAs (137% for some PELVAs) we preferred not 
to report PELVAs names.  
 
The PELVAs have not been identified due to the limitations of the study. The limitations 
were that only one observer assessed the 13 PELVAs, only one sample of each type of 
PELVA from each manufacturer was assessed, the manufacturers methods to measure 
the magnification were not available, despite the fact that we approached the 
manufacturers regarding this matter. In order to make the study more robust it would 
be important to assess a random sample of each type of PELVA with an increased 
number of observers and measurements, and ideally repeat the measurements using 
the manufacturers techniques (if they can be acquired). 
 
Therefore, it was felt inappropriate to identify each PELVA/ manufacturer; and a more 
robust study should be carried out before claims are made about the incorrect 
description of a device by manufactures.  In the meantime this study highlights for 
clinicians that magnification levels for PELVAs may not be as expected. 
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3.5. Conclusion 
Variations between the reported screen diameter and the measured screen diameter of 
PELVAs were small and were unlikely to have any clinical implication.  
 
Variations between the reported manufacturer magnification of PELVAs and those 
measured independently were significant. The difference between the manufactures 
reported magnification and those measured varied from 3% to 137%. This could not be 
explained by inter-observer or inter-microscope variations.  Variations between the 
reported manufacturer magnification and those measured were larger for high zoom 
levels.  The magnification was outside the ISO standard for the vast majority of PELVAs 
and it is important that clinicians are aware of these variations to ensure that the 
patients’ requirements are met.  
 
PELVAs were not identified in this study because of its limitations. In future, it is 
important to measure magnification of different samples of each type of PELVA with 
more observers and using the same methods as the manufacturers (if the information 
can be acquired).  
 
In order to prescribe the most appropriate electronic low vision aid, clinicians should be 
aware that variations may be found in magnification reported by the manufacturers and 
that found in independent settings.  
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CHAPTER 4: Luminance contrast and resolution limits of pocket and 
portable electronic low vision aids measured in independent settings.  
 
4.1. Introduction 
Luminance contrast and resolution are important factors affecting the quality of digital 
images (Peli, 1990). Many techniques have been developed to improve image contrast 
such as contrast manipulation and modifications including increasing the brightness of 
the screen (Peli, 1990).  
 
Luminance contrast is a measure of the perceived lightness or brightness difference 
between object and background. For the perception of fine detail, such as in reading, 
contrast across edges is very important (Maclntyre and Cowan, 1994). The minimum 
recommended luminance contrast ratio of text and background is 3:1 (ISO9241 Part 3, 
2008) and a contrast ratio of 10:1 is preferred (Ware, 2013).  
 
Luminance contrast is usually calculated using the Michelson contrast definition or 
Weber contrast definition as explained below. The Michelson contrast is used to 
calculate the contrast of repetitive stimuli, for example gratings. It ranges between 0.00 
(low contrast) to 1.00 (high contrast). 
 
Michelson Contrast = (L Max – L Min) / (L Max + L Min) 
 
Where L is the luminance measured by light-meter (cd/m²), L Max is the maximum 
luminance (i.e. luminance of the white background), L Min is the minimum luminance (i.e. 
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luminance of the black target) (Legge et al. 1987, Legge et al. 1990, Maclntyre and 
Cowan 1994, Crossland et al. 2010).   
 
Crossland et al. (2010) used the Michelson contrast to calculate the luminance contrast 
of Kindle and Sony electronic books. The authors did not report the method that they 
used to measure luminance.  
 
Maclntyre and Cowan (1994) used the Michelson contrast definition to calculate the 
luminance contrast of coloured areas displayed on a Cathode Ray Tube (CRT), and 
proposed a method for determining the contrast of coloured areas. For this they used a 
contrast metric that is in wide use in visual psychophysics, and showed that the metric 
can be approximated reasonably without display measurement, as long as it is possible 
to assume that the CRT has been adjusted according to usual CRT set-up standards 
(Maclntyre and Cowan, 1994). By using the average adjacency relationship and the 
optimal ‘ɛ’ value (i.e. the contribution of a pixel to its own total luminance), a metric for 
measuring luminance contrast can be determined by setting LMax and LMin in the 
Michelson contrast definition to the appropriate one of L’dbg and L’dfg (Maclntyre and 
Cowan, 1994): 
L Max = Max (L’dbg, L’dfg) 
L Min = Min (L’dbg, L’dfg) 
L’d of the average background pixel is approximated by: 
L’dbg = ɛLdbbg  + (1 - ɛ) (LdbbgNbg + Ldbfg (1 - Nbg)) 
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Ldbbg and Ldbfg are the background (bg) and foreground (fg) luminance contrast with black 
level correction (Maclntyre and Cowan, 1994). The contribution of a pixel to its own total 
luminance (ɛ) equals 0.47 (Maclntyre and Cowan, 1994). Nbg is the average number of 
background pixels adjacent to a background pixel (Maclntyre and Cowan, 1994). 
 
L’d of the average foreground pixel is approximated by: 
L’dfg= ɛLdbfg + (1 - ɛ) (Ldbbg (1-Nfg) + LdbfgNfg) 
Where Nfg is the average number of foreground pixels adjacent to a foreground pixel 
(Maclntyre and Cowan, 1994).  
 
                       Weber Contrast = (L – Lb)/ Lb 
Where L is the letter luminance, Lb is the background luminance (this has to be the 
luminance of the immediately adjacent background to the letter) (Westheimer 1985, 
Peli 1990).  
 
Weber contrast is used to calculate the contrast of a small object against a background. 
When the letter is darker than the background, it ranges from -1.00 (highest contrast) 
to 0.00 (lowest contrast); and from 0.00 to very large numbers when the background is 
darker than the letter.   
 
The contrast ratio (luminance ratio) is the ratio between the highest luminance, and the 
lowest luminance (Contrast ratio = Highest luminance / Lowest luminance). It is often 
used for high luminances and for specification of the contrast of electronic visual display 
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devices. The contrast ratio is a dimensionless number, often indicated by adding ‘:1’ to 
the value of the quotient (e.g. Contrast ratio = 1200:1) (DNP 2015, Kelly et al. 2006, 
ISO9241 Part3 2008, Ware 2013). 
 
Most commonly luminance is measured using the American National Standards Institute 
(ANSI) and full-on/ full-off methods (Powell, 2008). The full-on/ full-off method is used 
to measure the dynamic contrast where an equal size of both black and white is 
measured (Powell, 2008). The ANSI method is used to measure static contrast using a 
checker board patterned test image where the black and white luminance values are 
measured simultaneously (Powell, 2008).  
 
Reading is one of the most important daily visual tasks for patients with visual 
impairment. Several factors have been identified as affecting the reading performance 
of patients with visual impairment, including luminance and colour contrast. Legge et al. 
(1990) found that text can be ‘depicted’ by changes in character and background 
luminance i.e. luminance contrast or by differences in chromaticity i.e. colour contrast 
(Legge et al., 1990). The legibility of reading has been shown to be best predicted by the 
Michelson contrast definition (Maclntyre and Cowan, 1994). 
 
Manufacturers' descriptions of PELVAs include a contrast enhancement feature, without 
stating the level of contrast that PELVAs could provide. The aim of this study was to 
evaluate luminance contrast and to estimate resolution limits that PELVAs provide. 
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In this study, luminance contrast (under different light levels, viewing modes, viewing 
conditions for high and low contrast targets) and resolution limit was estimated for 12 
PELVAs.  
4.2. Laboratory preparation  
4.2.1. Illumination  
A laboratory was set up for three different illumination conditions: room illumination, 
dim illumination and dark conditions. The laboratory dimensions (Length x Width) was 
4.00 x 3.30 metres. It was divided into 16 small rectangles (Figure 4.1) (Length x Width= 
1 x 0.83 metres each) and illumination was measured at the centre of each rectangle 
using an ETI-8051 light meter (ETI Ltd 2015, www.eti1.co.uk) i.e. illumination meter [ETI-
8051 light meter has a measuring range of 0-30,000 lux or 0-2,788 foot candle (fc), 1lux 
or 0.1 fc resolution, and ±4% accuracy (high accuracy)]. The average of 16 measurements 
was calculated and represented the illumination level (Metrel 2002, Occupational Safety 
and Health Branch Labour Department 2008). This procedure was followed to find the 
illumination level at room illumination, dim illumination, and dark conditions.  
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Figure 4.1: Illumination measurements: the laboratory was divided into 16 small 
rectangles (1 x 0.83 metres each) and illumination was measured at the centre of each 
rectangle.  
 
 
4.2.2. Luminance 
A luminance meter i.e. Konica Minolta LS-100 luminance-meter (Konica Minolta INC 
2015, www.Konica Minolta.com) was used to measure the screen luminance (Figure 
4.2). It is a portable spot luminance meter, used for measuring the brightness of light 
sources in units of candelas per sq. meter (cd/m2). With its minimum focal distance 
(1,014 mm) it provides 1° field of view and Ø14.4 mm measurement spot size, however 
with the use of close-up lenses the minimum measuring area can reach to Ø1.3 mm at 
205 mm. It provides luminance measurements from 0.001 to 299,900 cd/m². The single-
lens-reflex (SLR) optical viewing system allows viewing through the meter to target the 
required area to be measured. It focuses the lens, on the front of the luminance meter, 
on the area under test and aligns the black spot over the required area on the light 
source. This is important to ensure that luminance meters only collect light from the 
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required area under test and do not receive light from a surrounding area in order to 
avoid stray light. Stray light can corrupt measurements of the contrast ratio of a display.  
 
 
Figure 4.2: Konica Minolta LS-100 luminance meter (Konica Minolta INC, 2015).  
 
4.2.3. Resolution 
An ISO 12233 resolution chart (Figure 4.3) was used as a target to estimate the 
resolution limit of PELVAs. The ISO 12233 Chart is designed to test resolution of 
electronic still picture cameras. It can be used for testing both monochrome and colour 
cameras. Targets on this chart can be used to evaluate visual resolution, limiting 
resolution, and can be used to obtain spatial frequency response (SFR) data (this is 
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similar to measurements of MTF for a camera). The target resolution ranges from 100 
to 2,000 line widths per picture height (Lw/Ph).  
 
 
 
 
Figure 4.3: ISO 12233 chart 
http://www.graphics.cornell.edu/~westin/misc/ISO_12233-reschart.pdf (accessed 
10 February, 2014). 
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4.3. Methods 
The same set of PELVAs, with the same coding (A-L) that were assessed in Chapter 3 
were assessed in this chapter.  
4.3.1. Measuring luminance contrast 
The luminance contrast was measured for the viewed letter and the background. In 
order to reduce/ avoid reflection from the white background of a Bailey-Lovie near 
acuity chart; a black card was covered with black felt. A circular hole was made in the 
card which was placed over the letter/ background while measuring luminance. The 
diameter of the hole (4.71 mm) was equal to the width of the viewed letter (sized N80).  
 
The circular hole (Ø 4.71 mm) made it possible to measure the same size of black letter 
and the white background so that only the required area of black or white was visible at 
a time.  
 
The viewed letters were a high contrast letter (0.90 Michelson contrast) and a low 
contrast letter (0.10 Michelson contrast), sized N80 and taken from a Bailey-Lovie near 
visual acuity chart. 
 
The high contrast letter was viewed using PELVAs under different conditions: 1) three 
illumination conditions (room (396 lux), dim (12 lux) and dark (0 lux)), 2) different 
viewing conditions; dynamic (refreshed image) and static (snapshot), and 3) using black-
on-white contrast viewing mode and white-on-black contrast viewing mode.  
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Each PELVA was set at the lowest magnification level, and on the contrast viewing mode, 
and manufacturer's instructions regarding brightness level were followed.   
 
Maximum and minimum luminance (in cd/m²) of the image obtained by each PELVA was 
measured using the Konica Minolta LS-100 luminance meter that was fixed and adjusted 
at 106.5 cm (the distance specified by the manufacturer at which luminance can be 
detected by the meter) from the PELVA display screen.  
 
Luminance using 12 PELVAs (A-L) was measured with black-on-white contrast viewing 
mode; the black letter (minimum luminance) on white background (maximum 
luminance). Due to time constraints on the loan of the devices, the luminance was 
measured with white-on-black contrast viewing mode for 7 PELVAs (the white letter 
(maximum contrast) on black background (minimum contrast)). All luminance 
measurements were repeated 10 times at each illumination level, contrast mode, and 
viewing condition and the average was recorded.  
 
The luminance contrast using a low contrast letter was measured using 3 PELVAs (B, C, 
and E) under room and dark illumination conditions; with black-on-white viewing mode 
and both static and dynamic viewing conditions. At each condition, all luminance 
measurements were repeated 10 times and the average was recorded. 
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In this experiment contrast was measured for dynamic and static contrast using a 
method similar to full-on/ full-off method where only black or only white was visible at 
a time. 
   
The Michelson contrast equation was applied to calculate the image luminance contrast 
of each PELVA, at different illumination levels and for static and dynamic viewing modes.  
 
4.3.2. Estimating resolution 
The ISO 12233 resolution chart was downloaded in a printable version, and it was 
printed on high quality photograph papers sized A3, using the maximum number of dots 
per inch to get a high quality print of this chart. Three different targets (horizontal 
grating, vertical grating, and diagonal grating) were selected to be viewed by using the 
PELVAs at three different magnification levels (low, medium and high) (Figure 4.4).  
 
The resolution limit was defined as the area where the first ‘fringing’ becomes visible. 
The unit of measurement is Line Width per Picture Height (Lw/Ph).   
 
During resolution measurements, the viewing distance was 40 cm, and magnifiers were 
placed directly on the chart unless manufacturers recommended a particular angle or 
distance for best viewing conditions. Horizontal and vertical targets measure resolving 
power from 100 to 2,000 Lw/Ph.  
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Diagonal target examine spatial frequency response at different locations. Horizontal, 
vertical and diagonal oriented wedges are included for comparison of resolving power 
at various locations.   
       
 
Figure 4.4: Central horizontal (H), vertical (V) and diagonal (D) targets used from ISO 
12233 Resolution Chart were used in order to estimate PELVAs limit of resolution.  
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4.4. Results 
Under room illumination (396 lux), the Michelson luminance contrast (as measured on 
the chart, not through the PELVA) of the high contrast letter was 0.93±0.01, and 
0.12±0.01 for the low contrast letter.  
 
4.4.1. Luminance contrast 
4.4.1.1. Luminance contrast using a high contrast letter  
The dynamic luminance contrast under room illumination of 12 PELVAs is shown in 
Figure 4.5. All PELVAs (A-L) lie within the minimum recommended luminance contrast 
ratio of text to background of 3:1 (ISO9241 Part3, 2008) except PELVA (D) (Table 4.1). 
Only PELVAs (A, B, F, I and K) lie within the preferred contrast ratio of 10:1 (Ware, 2013) 
(Table 4.1).  
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Figure 4.5: The dynamic luminance contrast of 12 PELVAs measured using a high 
contrast letter with black-on-white viewing mode, under room illumination (396 lux). 
Horizontal axis represents PELVAs, vertical axis represents the measured luminance 
contrast; Michelson contrast ranges from 0 to 1, the higher the number the higher the 
contrast. The dashed line represents the luminance contrast of a high contrast letter 
(0.93±0.01).  
 
 
 
The measured dynamic luminance contrast, with black-on-white viewing mode, of 12 
PELVAs under room illumination using a high contrast letter ranged from 0.53 to 0.99 
Michelson contrast (Table 4.1). Some PELVAs (A, B, F, G, I, J, and K) enhanced the 
contrast of the viewed target (Paired sample t-test, p < 0.05). On the other hand, other 
PELVAs (C, D, and E) produced an image with lower contrast than the high contrast letter 
(Paired sample t-test, p < 0.05). The poorest luminance contrast was seen with the 
PELVA D (Figure 4.5), which was also found to give higher than expected magnification 
compared to manufacturers reported data (106%). The luminance contrast of the high 
contrast letter did not change significantly (Paired sample t-test, p > 0.05) using PELVAs 
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(H and L) although the luminance contrast of PELVA H was slightly lower compared to 
the high contrast letter.  
 
4.4.1.2. Different illumination conditions, using a high contrast letter  
 
The measured luminance contrast of 12 PELVAs under different illumination conditions 
is shown in Table 4.1. There were no significant differences (ANOVA: F = 1.287 p > 0.05, 
Multiple paired sample t-test p > 0.05) between luminance contrast measured under 
three different illumination conditions, using a high contrast letter with black-on-white 
viewing mode, for 12 PELVAs. The mean difference in measured luminance contrast 
under three illumination conditions (room, dim, and dark) was 0.01±0.005 Michelson 
contrast (ANOVA, p > 0.05). PELVA D showed the poorest contrast among all PELVAs at 
all illumination levels (Table 4.1). All PELVAs, except D, lie within the ISO9241 Part 3 
(2008) standard for all illumination conditions. The discrepancy in PELVA D we could not 
explain. However, manufacturing or technical faults cannot be excluded because the 
same PELVA did not fall within ISO15253:2000 standard (BSI, 2000) for magnification 
tolerance.  
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PELVA 
Static Dynamic 
Contrast 
Ratio * 
Ware 2013 
standard 
ISO9241, 
Part 3 2008 
standard 
Room 
Mean±SD 
Dim 
Mean±SD 
Dark 
Mean±SD 
P-
value 
Room 
Mean±SD 
Dim 
Mean±SD 
Dark 
Mean±SD 
P-
value 
A 0.92±0.004 0.86±0.021 0.93±0.006 0.448 0.99±0.001 0.97±0.002 0.99±0.005 0.365 13.0:1 ✔ ✔ 
B 0.99±0.019 0.96±0.024 0.91±0.011 0.791 0.98±0.018 0.97±0.001 0.97±0.026 0.449 12.7: 1 ✔ ✔ 
C 0.70±0.023 0.72±0.032 0.78±0.009 0.100 0.79±0.009 0.8±0.009 0.84±0.030 0.441 7.3:1 X ✔ 
D 0.41±0.006 0.22±0.003 0.22±0.002 0.123 0.53±0.010 0.38±0.012 0.37±0.004 0.779 2.3:1 X X 
E 0.85±0.019 0.82±0.001 0.67±0.003 0.440 0.87±0.003 0.85±0.019 0.79±0.032 0.281 8.9:1 X ✔ 
F 0.95±0.002 0.94±0.002 0.95±0.014 0.630 0.98±0.001 0.99±0.032 0.99±0.01 0.231 10.2:1 ✔ ✔ 
G 0.88±0.022 0.88±0.040 0.88±0.001 0.978 0.95±0.001 0.95±0.007 0.95±0.003 0.742 9.4:1 X ✔ 
H 0.86±0.005 0.91±0.020 0.91±0.021 0.340 0.91±0.019 0.97±0.002 0.97±0.021 0.812 9:1 X ✔ 
I 0.92±0.037 0.91±0.011 0.93±0.003 0.430 0.97±0.007 0.97±0.001 0.96±0.019 0.090 11:1 ✔ ✔ 
J 0.88±0.023 0.92±0.001 0.93±0.002 0.080 0.95±0.004 0.95±0.015 0.96±0.021 0.562 9.3:1 X ✔ 
K 0.94±0.005 0.92±0.009 0.90±0.005 0.054 0.97±0.013 0.96±0.004 0.97±0.002 0.771 10.0:1 ✔ ✔ 
L 0.75±0.003 0.81±0.002 0.94±0.013 0.440 0.93±0.002 0.90±0.016 0.99±0.005 0.234 9.0:1 X ✔ 
 
Table 4.1: The Michelson luminance contrast (the mean and standard deviation of 10 measurements) of 12 PELVAs (A-L), measured under different 
illumination conditions (room, dim, and dark) using a high contrast letter (0.93±0.01 Michelson contrast) with black-on-white viewing mode, with 
static and dynamic viewing conditions. P-value (ANOVA) is significant if < 0.05. * Contrast ratio = Background luminance/ Letter luminance, as 
measured under room illumination with dynamic mode.  ✔ PELVA’s contrast ratio lie within the standard. X PELVA’s contrast ratio did not lie within 
the standard.
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4.4.1.3. Dynamic versus static viewing condition 
The measured luminance contrast with both dynamic and static viewing conditions using 
a high contrast letter with black-on-white viewing mode is shown in Table 4.1, and 
Figures 4.6 and 4.7. The measured luminance contrast of 12 PELVAs was significantly 
higher using the dynamic viewing condition compared to the static viewing condition 
under all illumination conditions. The mean measured luminance contrast using the 
dynamic viewing condition was 0.89±0.16 Michelson contrast compared to 0.83±0.18 
Michelson contrast using the static viewing condition (Paired sample t-test, p < 0.001).   
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Figure 4.6: The dynamic luminance contrast compared to the static luminance contrast 
of 12 PELVAs (A-L) under different illumination (room, dim, and dark) using a high 
contrast letter chart with black-on-white viewing mode. The horizontal axis shows 12 
PELVAs (A-L). The vertical axis (dots) shows the Michelson contrast.   The dashed line 
shows the luminance contrast of the high contrast letter (0.93 Michelson contrast). 
The poorest contrast was for PELVA D using both static and dynamic viewing under all 
illumination conditions.  
 
 
Ill
u
m
in
at
io
n
  
Static viewing 
 
Dynamic viewing 
R
o
o
m
 
 
 
D
im
 
  
D
ar
k 
  
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
A B C D E F G H I J K L
M
ic
h
e
ls
o
n
 c
o
n
tr
as
t
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
A B C D E F G H I J K L
M
ic
h
e
ls
o
n
 c
o
n
tr
as
t
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
A B C D E F G H I J K L
M
ic
h
e
ls
o
n
 c
o
n
tr
as
t
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
A B C D E F G H I J K L
M
ic
h
e
ls
o
n
 c
o
n
tr
as
t
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
A B C D E F G H I J K L
M
ic
h
e
ls
o
n
 c
o
n
tr
as
t
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
A B C D E F G H I J K L
M
ic
h
e
ls
o
n
 c
o
n
tr
as
t
  
155 
 
 
 
Figure 4.7: The luminance contrast of 12 PELVAs with dynamic viewing compared to 
the luminance contrast with static viewing conditions using a high contrast letter with 
black-on-white viewing mode (all lighting levels). The graph shows that dynamic 
contrast was higher than static contrast; most circles are clustered above the 
reference line. Arrows: The outlier (outside the standard of Ware 2013 and the 
ISO9241 Part 3 (2008) standard) was PELVA D, under different illumination conditions, 
as shown in Table 4.1. PELVA D also showed the poorest contrast at all illumination 
levels.   
 
 
 
4.4.1.4. Luminance contrast with black-on-white viewing mode versus luminance 
contrast with white-on-black viewing mode 
 
A comparison between luminance contrast using black-on-white viewing mode and 
luminance contrast using white-on-black viewing mode (contrast reverse/ polarity) is 
shown in Figure 4.8 and Table 4.2. There were no significant differences between 
luminance contrast of any of the 7 PELVAs measured with black-on-white viewing mode 
and white-on-black viewing mode using a high contrast letter. The mean difference 
D 
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between measured luminance using black-on-white and white-on-black viewing mode 
was 0.008±0.03 Michelson contrast (Paired sample t-test, p = 0.600).  
 
 
 
 
Figure 4.8: The Michelson luminance contrast of 7 PELVAs using black-on-white 
viewing mode compared to the Michelson luminance contrast using white-on-black 
viewing mode, using a high contrast letter. Data points are the mean of 10 
measurements. Most points cluster close to the reference line.  
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PELVAs 
 
Black-on-white 
(Mean±SD) 
White-on-black 
(Mean±SD) 
Static 
 
 
 
 
A 0.92±0.004 0.92±0.03 
E 0.85±0.019 0.87±0.02 
F 0.95±0.002 0.94±0.04 
H 0.86±0.005 0.86±0.08 
I 0.92±0.037 0.86±0.20 
J 0.88±0.023 0.90±0.03 
K 0.94±0.005 0.94±0.02 
Dynamic 
 
 
 
 
A 0.99±0.001 0.98±0.01 
E 0.87±0.003 0.86±0.01 
F 0.98±0.001 0.92±0.02 
H 0.91±0.019 0.93±0.01 
I 0.97±0.007 0.97±0.05 
J 0.95±0.004 0.96±0.03 
K 0.97±0.013 0.94±0.08 
 
Table 4.2: The Michelson luminance contrast (mean and standard deviation (SD) of 10 
measurements) of 7 PELVAs using black-on-white viewing mode compared to 
luminance contrast using white-on-black viewing mode, using a high contrast letter. 
 
  
 
4.4.1.5. Luminance contrast using a low contrast letter  
Some PELVAs improved the luminance contrast of a high contrast letter; in order to find 
whether PELVAs improve the contrast of a low contrast object, luminance contrast was 
measured for a low contrast letter. The Michelson luminance contrast of the low 
contrast letter was 0.12±0.005 under room illumination (396 lux). 
 
Table 4.3 shows the luminance contrast measured for 3 PELVAs (B, C, and E), these were 
same PELVAs used in the previous experiments, using the low contrast letter (0.12 
Michelson contrast) with contrast viewing mode (black-on-white), using dynamic and 
static viewing conditions. Three PELVAs only were used to measure the luminance 
contrast of a low contrast letter because of time constraints on the loan of the devices. 
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We had PELVA B at the School of Optometry, PELVAs C and E that were on extended 
loan, and all other PELVAs had to be returned to the suppliers.  
 
The luminance contrast of PELVAs of a low contrast letter (0.12 Michelson contrast) 
using PELVAs was significantly increased (almost doubled) (p < 0.05), with both static 
and dynamic viewing conditions under different illumination conditions (room and dark 
illumination). The measured luminance contrast using a low contrast letter ranged from 
0.24 to 0.26 Michelson contrast using the dynamic viewing condition and from 0.19 to 
0.22 using the static viewing condition (Table 4.3).   
 
The luminance contrast did not appear even across the screen, and a better contrast 
was seen at the middle of the screen. The measured luminance contrast in this study 
reflects the luminance contrast of the central area of PELVAs display screen.  
 
 Static Dynamic Static vs. dynamic 
PELVA Room 
Mean±SD 
Dark 
Mean±SD 
P-value Room 
Mean±SD 
Dark 
Mean±SD 
P-value P-value¹ 
B 0.21±0.001 0.22±0.013 0.068 0.25±0.001 0.26±0.002 0.128 <0.001* 
C 0.19±0.002 0.21±0.010 0.789 0.25±0.021 0.25±0.030 0.327 <0.001* 
E 0.20±0.002 0.21±0.001 0.536 0.24±0.011 0.24±0.001 0.459 <0.001* 
Table 4.3: The Michelson luminance contrast (mean and standard deviation (SD) of 10 
measurements) of 3 PELVAs using a low contrast letter (0.12±0.01 Michelson contrast) 
under different illumination and viewing condition with black-on-white contrast 
viewing mode. P value: Paired sample t-test. P-value¹ shows the significance of the 
mean difference between static and dynamic viewing under room and dark conditions 
combined. 
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There was no significant difference in the measured luminance contrast using a low 
contrast letter at different illumination conditions (room and dark). The mean difference 
in luminance contrast between room and dark conditions was 0.013±0.006 Michelson 
contrast with static viewing (Paired sample t-test, p > 0.05), and 0.005±0.005 Michelson 
contrast with dynamic viewing (Paired sample t-test, p > 0.05) (Table 4.3). Luminance 
contrast under dim illumination was not measured in this experiment because there was 
no difference in luminance contrast under different illumination conditions in the 
previous experiment.  
 
The dynamic luminance contrast was significantly higher than static luminance contrast 
using a low contrast letter (Table 4.3). The mean Michelson luminance contrast for room 
and dark conditions combined with the dynamic viewing condition was 0.25±0.008 and 
0.21±0.01 for the static viewing condition (Paired sample t-test, p < 0.001).  
 
Although the luminance contrast of PELVAs (B, C, and E) significantly increased (0.19- 
0.26 Michelson contrast) using a low contrast letter, it still far a long way short of the 
luminance contrast (0.67-0.99) using a high contrast letter. 
 
4.4.2. Estimated resolution using ISO 1233 chart 
The estimated resolution limit that each PELVA (A - L) could provide using three different 
targets (horizontal, vertical, and diagonal) from an ISO 12233 chart, under different 
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magnification levels (the lowest, medium, and the highest magnification levels) in 100 
Lw/Ph is shown in Table 4.4. 
 
The resolution of the targets on the ISO 12233 chart ranges from 1*100 to 20*100 
Lw/Ph. In general, the spatial resolution of computer monitors is 72 to 100 lines/ inch; 
this is equivalent of 8.5*100 to 16.5*100 Lw/Ph if the test chart A3 size is used. This 
means any PELVA that provided a resolution within this range can be comparable to a 
computer screen; the higher the resolution is better.  
 
Applying this on the diagonal target resolution which is the best predictor of screen 
performance (Bond, 2015), only PELVAs (B, C, F, G and L) provided a resolution equal to 
or better than 8.5*100 Lw/Ph (i.e. comparable to a general computer screen). A 
horizontal or vertical line of a specific pixels length covers a specific linear distance on 
the display screen but this is different for diagonal lines; in which the same number of 
pixels covers a larger linear distance on the display screen. This could be up to 40% larger 
in some displays and may affect the diagonal lines by making them fainter by up to 30% 
(aliasing) (Bond, 2015). 
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Table 4.4: The estimated resolution limit of 12 PELVAs (A - L) using three different 
targets (horizontal grating target, vertical grating target, and diagonal grating target) 
from ISO 12233 resolution chart (Values in 100 Lw/Ph). 
 
 
The mean estimated resolution limit using horizontal grating target was 10.9*100±3.2 
Lw/Ph (range 5.8*100-16.6*100). The mean estimated resolution limit using vertical 
grating target was 10.2*100±2.6 Lw/Ph (range 5.5*100-15*100). The mean estimated 
resolution limit using diagonal grating target was 7.9*100±1.2 Lw/Ph (range 5.6*100-
9.5*100).  
 
The poorest resolution (the outliers in Figures 4.9 and 4.10) was found using PELVA K; 
this might be because of its low cost compared to most PELVAs, which may suggest a 
poorer quality display screen. PELVA K also had lower than expected magnification.  
 
 
PELVA 
Average resolution at  different 
magnification levels *100 
Average resolution using different targets 
*100 
High 
magnification 
Medium 
magnification 
Low 
magnification 
Horizontal 
grating target 
Vertical 
grating target 
Diagonal 
grating target 
A 9.8 8.5 7.3 9.6 9.0 7.0 
B 11.6 10.2 9.16 12.1 10.3 8.5 
C 14.3 13.6 12.6 16.6 15 9.0 
D 13.1 9.6 6.3 11.0 10.6 7.5 
E 8.5 7.0 7.0 7.0 8.5 7.7 
F 11.6 10.8 9.5 12.3 10.1 9.5 
G 14.1 13.1 11.3 14.8 14.6 9.1 
H 11.5 8.8 6.3 11.6 8.3 6.6 
I 9.8 7.6 6.0 7.1 9.3 7.0 
J 10.6 9.6 8.6 11.0 10.0 8.0 
K 6.3 5.6 5.0 5.8 5.5 5.6 
L 11.6 10.6 9.6 12.3 11.0 8.8 
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The estimated resolution limits using diagonal grating target was significantly lower than 
estimated resolution limits using both horizontal and vertical grating targets (ANOVA: F 
= 102.670, p < 0.05) which was expected due to aliasing of diagonal target. There were 
no statistically significant differences (ANOVA: F = 1.932, p > 0.05) in the estimated 
resolution limits between horizontal and vertical grating targets (Figure 4.9).  
 
Figure 4.9: The estimated resolution limit in 100*Lw/Ph of 12 PELVAs using 3 different 
grating targets (horizontal, vertical, and diagonal); showing a lower resolution limit 
using the diagonal grating target. The poorest resolution was for PELVA K. 
 
 
In terms of magnification, there was a variation between resolution and magnification 
between different magnifiers (Figure 4.10). The resolution was significantly higher 
(better) with increasing magnification. The mean difference in the estimated resolution 
limits between higher and medium magnification was 1.48*100±0.88 Lw/Ph, and 
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between medium and lower magnification was 1.36*100±0.87 Lw/Ph. This was not 
expected; as with higher magnification the sharpness of targets edges deteriorated and 
pixilation was more obvious compared to medium and lower magnification levels.  
Moreover, the difference that magnification made on resolution varied between 
magnifiers and was not uniform.  
 
 
Figure 4.10: The estimated resolution limit in 100*Lw/Ph of 12 PELVAs under different 
magnification levels (high, medium, and low); showing a higher resolution limit under 
the high magnification level. The poorest resolution was for PELVA K. 
  
0
2
4
6
8
10
12
14
16
18
20
A B C D E F G H I J K L
Es
ti
m
at
e
d
 r
e
so
lu
ti
o
n
  1
0
0
 *
 (
Lw
/ 
P
h
) 
PELVAs
High magnification
Medium magnification
Low magnification
  
164 
 
4.5. Discussion 
Luminance contrast of 12 PELVAs (A- L) was measured in an independent setting 
(dynamic viewing condition, under room illumination, and using black-on-white contrast 
viewing mode, which is the conventional settings of PELVAs use) using a high contrast 
letter (0.93 Michelson contrast). Only seven PELVAs (A, B, F, G, I, J and K) significantly 
improved the luminance contrast for the high contrast letter. The measured luminance 
contrast of the high contrast letter was reduced significantly for PELVAs (C, D, and E), 
and was about the same for two PELVAs (H and L).  
 
All PELVAs (A- L) lie within the minimum recommended background to letter contrast 
ratio (Contrast ratio = Highest luminance/ Lowest luminance) of 3:1 (ISO9241 Part3, 
2008) except PELVA D which was also found to give higher than expected magnification 
compared to manufacturers reported data (106%); this might be explained by 
manufacturing error, or technical faults. Only PELVAs (A, B, F, I, and K) lie with the 
preferred contrast ratio (contrast ratio = Highest luminance/ Lowest luminance) (Ware, 
2013) of 10:1 Table (4.1).  
 
Crossland et al. (2010) found that the Michelson contrast for Sony and Kindle readers 
were 63% and 62% respectively. All PELVAs in this study except PELVA (D) had 
significantly better Michelson Luminance contrast compared to Sony and Kindle readers. 
 
The luminance contrast of images obtained by EVES that were used in the Peterson et 
al. (2003) ranged between 0.70 and 0.90 (Michelson contrast). The Michelson luminance 
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contrast of all PELVAs under three illumination conditions and using static and dynamic 
viewing  (0.70-0.99) was equal to or better than the luminance contrast of EVES [except 
PELVA D under all illumination conditions using static and dynamic (0.22-0.53), and 
PELVA E under dark illumination using static viewing (0.67)].  
 
This study found that the luminance contrast of a high contrast letter viewed by PELVAs 
was 1) not affected by different illumination conditions, 2) significantly higher using the 
dynamic viewing compared to static viewing conditions, 3) not significantly different 
using white-on-black viewing compared to black-on-white viewing modes.  
 
Luminance contrast was measured in different illumination. Room illumination is the 
illumination that most people read with; dark conditions in order to measure the actual 
luminance of the letter and the background in order to exclude the effect of surrounding 
illumination; dim illumination because not all people use the devices in an ideal room 
illumination or day illumination and it is known that ambient light can affect the 
brightness or the luminance of a screen. The actual luminance contrast can be obtained 
in dark conditions (with absolutely no other light source). In this study, there was no 
specific pattern to predict in which illumination level PELVAs performed best; there was 
no significant difference in luminance contrast between three illumination conditions.  
 
The difference between dynamic and static contrast was expected due to the fact that 
in dynamic viewing the image is refreshed continuously several times per time unit (for 
example, a movie projector runs 24 frames per second, each frame is illuminated two or 
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three times before the next frame is projected, giving a refresh rate of 72 Hertz) and the 
maximum and minimum luminance of background and letter is measured over time. In 
comparison, in static viewing in which the snapshot cannot be refreshed again, the 
luminance is measured every time at one point, and the maximum and minimum 
luminance is measured simultaneously. The refresh rate of PELVAs was not included 
with their descriptions, but the refresh rate of desktop video magnifiers is about 60 
frames per second (Digital Apex, 2015).  
 
Overall, there was no significant difference between black-on-white contrast and white-
on-black contrast. Zabel et al. (1982) found that the blur perceived using EVES systems 
when moving black-on-white print (because of update rate or refresh rate) is increased 
by white-on-black print. Although white-on-black increases perceived blur, it has the 
advantage of reduced glare and less picture flicker (Zabel et al., 1982). Therefore, 
preference for white-on-black is an individual preference (Legge and Rubin 1986, Jacobs 
1990). Mehr et al. (1973) reported a preference for white-on-black over black-on-white 
print. However, some studies (Zabel et al., 1982) reported an equal preference for both 
types of print, with 70% preferring contrast-enhanced print (Zabel et al., 1982).  
 
Finding that some PELVAs could improve the luminance contrast of a high contrast text, 
only slightly; it was important to find if the use of PELVAs is more beneficial for a low 
contrast text compared to a higher contrast text. Therefore, the luminance contrast 
using a low contrast letter was measured for 3 PELVAs. 
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It was found that the luminance contrast of 3 PELVAs using the low contrast letter was 
increased (almost doubled). This might suggest that PELVAs could be more beneficial for 
patients with a visual impairment for tasks involving lower contrast targets/ scenes. 
However, although the contrast was doubled this was still only 0.19 to 0.26 Michelson 
contrast compared to 0.67-0.99 Micheslon contrast using a high contrast letter. So, for 
people with very much reduced contrast sensitivity it may not improve it enough. 
 
All luminance measurements were repeated 10 times at each illumination, contrast, and 
viewing condition and the average was recorded. The luminance measurements were 
repeated due to possible variations in luminance readings which might be attributed to 
the small hole size (positioning of the luminance meter spot directly over the circular 
hole), exposure time (the time taken to take the luminance measurement), and the 
amount of reflected light from the PELVA light source (Konica Minolta INC, 2013). The 
variation between measurements ranged between 0.00 and 2.09 cd/m².  
 
The resolution is an important determinant of image quality. Therefore, the resolution 
limits of 12 PELVAs (A-L) were also investigated in this study.  
 
Because of the fact that PELVAs are designed to be used at a very close distance from 
the viewed target and some of them should be placed directly on the viewed target it 
was difficult to get an image of the whole chart using PELVAs. Hence, three targets with 
different grating directions were chosen from the chart to be viewed by PELVAs in order 
to find their resolution limits.   
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Three targets with different grating directions (horizontal, vertical, and diagonal) were 
chosen in order to estimate the pixilation on each direction. In manufacturing a display 
the diagonal and horizontal or vertical lines will be treated the same so they have the 
same brightness at each pixel; but this would result in a less uniform density of colours. 
This is because a horizontal or vertical line of a specific pixels length covers a specific 
linear distance on the display screen but this is different in terms of diagonal lines; in 
which the same number of pixels covers a larger linear distance on the display screen. 
This could be up to 40% larger in some displays and may affect the diagonal lines by 
making them fainter by up to 30% in some screens (Bond, 2015). Horizontal, vertical and 
diagonal grating targets are included for comparison of resolution at different locations 
on the screen. 
 
The poorest resolution was for PELVA K which had also lower than expected 
magnification, with up to 72% deviation from the ISO standard for magnification 
tolerance. This might be due to its low cost compared to most PELVAs, or it might be 
attributed to a poor quality display screen.  
 
There was no significant difference in the resolution limits using horizontal and vertical 
targets. The estimated resolution limit was significantly lower using the diagonal grating 
target compared to both horizontal and vertical which was expected due to aliasing of 
diagonal target.  
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The estimated resolution limits were significantly higher with higher magnification. This 
was not expected; it could be because of the brightness of the screen made targets 
details still clear even at higher magnification. Also, in this study resolution limit was 
defined as the first seen merging of two lines. Although, with higher magnification the 
sharpness of targets edges deteriorated and pixilation was obvious compared to 
medium and lower magnification levels.   
 
Resolution limit estimates were subjectively estimated. These could be more accurate if 
software (called SFRplus) was used rather than depending on subjective assessment. 
SFRplus/ IMAtest measures the modulation transfer function (MTF) over the whole 
image plane as well as many other image quality factors such as resolution. The software 
is very expensive; costing about £7,000 (IMAtest LLC, USA www.imatest.com). 
 
This experiment illustrated how it is important to examine low vision aids actual 
parameters, in order to assess what they might do for patients with visual impairment. 
Luminance contrast of PELVAs included in this experiment was overall good, with some 
exception as mentioned in results section. 
 
The limitations of this study were that only one observer measured the luminance 
contrast and estimated the resolution limits of PELVAs. The luminances contrast of the 
PELVAs were not reported by manufacturers, so we could not compare those with the 
PELVAs luminance contrast measured in an independent setting. No information was 
available about manufacturers’ methods of evaluating contrast and resolution of 
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PELVAs. We contacted the manufacturers regarding the techniques/ methodology used, 
but we had no replies. Therefore, the method used in this study may differ from these 
employed by the manufacturers. The luminance contrast of the low contrast letter was 
measured using only three PELVAs due to time constraints on the loan period for 
PELVAs. It might be important in the future to measure luminance contrast and 
resolution with more than one observer, using different manufacturers’ methods for 
evaluating contrast and resolution, and using SFRplus software for measuring 
resolution, and using more PELVAs. Moreover, because the luminance contrast 
appeared to vary across the screen with a better image obtained at the middle of the 
screen, we measured the luminance contrast only at the middle of the screen. 
Therefore, it would be important to measure the luminance contrast across the screen 
in a follow-up study.   
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4.6. Conclusion 
Some PELVAs significantly improved the contrast of a high contrast letter; whilst others 
significantly reduced the contrast. All PELVAs (A-L) lie within the minimum 
recommended luminance contrast ratio of text and background of 3:1 (ISO9241 Part3, 
2008) except one PELVA (D). Only PELVAs (A, B, F, I, and K) lie within the preferred 
contrast ratio by Ware (2013) of 10:1.  
 
Illumination conditions had no significant effect on the luminance contrast of PELVAs. 
There was no significant difference for different contrast viewing modes (black-on-white 
and white-on-black) on the luminance contrast of PELVAs. The dynamic viewing 
conditions (refreshed image) had an advantage over the static viewing conditions in 
terms of significant increase of luminance contrast.  
 
For a patient with reduced contrast sensitivity, such as a patient with cataract, 
glaucoma, or diabetic retinopathy, a PELVA would be useful to improve a low contrast 
scene or target.  This is an advantage that PELVAs have compared to the conventional 
low vision aids.  
 
The contrast of a low contrast letter was almost doubled using some PELVAs, although 
the contrast was not the same as a high contrast letter. So, for people with severe 
reduction in contrast sensitivity it may not improve it enough. 
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PELVAs (B, C, F, G and L) provided an estimated resolution limit of greater than or equal 
to 8.5*100 Lw/Ph (i.e. the resolution of a general computer screen). High resolution is 
an important factor to maintain a good quality image, particularly for patients with a 
visual impairment.  
  
  
173 
 
CHAPTER 5: The clinicians’ prescribing patterns for pocket and portable 
electronic low vision aids for patients with a visual impairment who 
attended the Low Vision Service Wales 
 
5.1. Introduction 
As discussed in Chapter 2, very few studies (Lighthouse National Survey on Vision Loss 
1995, Crossland and Silver 2005, Nguyen et al. 2009) have assessed the prescribing 
patterns for low vision aids, and to date no one has evaluated the prescribing patterns 
for PELVAs.  
 
Schurink et al. (2011) reported that even though there are several types of low vision 
aids, their prescription and use were low in visually impaired children. Although some 
research has investigated the use of low vision aids among children (Corn et al. 2002, 
Ruddeck et al. 2004), little is known about their use in the low vision population as a 
whole. In addition, there is little information about the type of these devices in relation 
to the type of visual impairment (Leat 2002, Corn et al. 2002, Ruddeck et al. 2004, 
Lennon et al. 2007, Haddad et al. 2009, Schurink et al. 2011). For example, Haddad et al. 
(2009) found that 36% of children used optical low vision aids for distance, and 6% used 
optical low vision aids for near, monocular telescope and stand magnifiers were the 
most prescribed aids. Lennon et al. (2007) found that 69% of children used optical low 
vision aids for near (brightfield magnifier was the most commonly prescribed aid).  A 
proportion of 25% of children were prescribed low vision aids (a CCTV, telescopes, hand-
held and stand magnifiers, brightfield magnifiers) and 82.7% of them used their devices 
on a regular basis, in the Ruddeck et al. (2004) study.   
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Wolffson and Peterson (2003) suggested that the increased demand for electronic low 
vision aids, particularly CCTVs and their simplicity have made them more frequently 
considered in clinical practice (Wolffson and Peterson, 2003).  
 
The American Optometric Association (AOA) recommended that the severity and 
stability of the underlying visual impairment should be considered when prescribing low 
vision aids, and the prescription of optical low vision aids might be better delayed until 
the visual impairment become more stable (Freeman et al., 2007). AOA also considered 
that a ‘loaner system’ of low vision aids is invaluable, particularly for patients with 
unstable visual impairment (Freeman et al., 2007). 
 
It is important to understand the prescribing patterns for available low vision aids, such 
as PELVAs, and to determine which patients are most likely to benefit from these 
devices, in addition to what factors might affect the prescribing for PELVAs. To date 
there was no published literature that describes the prescribing patterns for PELVAs. 
One PELVA (Compact+) has been available on loan for patients with visual impairment 
attending the Low Vision Service Wales (LVSW) [a National Health Service (NHS) in 
Wales] (Charlton et al. 2011, Taylor et al. 2014).Therefore, the aim of this study was to 
assess a data set of patients who attended the LVSW in the year 2011/2012 in order to 
determine the prescribing patterns for PELVAs.   
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5.2. Methods 
Data from 7,866 records of patients who attended 187 LVSW clinics across Wales in the 
year 2011/2012 (the period between 1st April 2011 and 31st March 2012) were reviewed 
and analysed using SPSS 20.0.  
 
5.2.1. Data recording and preparation 
Accredited practitioners recorded biographical and clinical information on standard 
record cards. Patients were required to sign the record and indicate if they were happy 
for their information to be used for research and/ or audit purposes. Practitioners sent 
the signed records by secure fax to the NHS central service administration. Key data 
from the records were incorporated into a computerised data set.  
 
Data set 
The required data set was downloaded from the service data set by the LVSW manager. 
It was then sent to us as an Excel spreadsheet. A sample of the data set is shown in 
Appendix I. All data were manually transferred into an SPSS 20.0 file, so that numbers 
of patients falling into each category could be analysed. The data set included 
demographic and clinical information of patients which was limited to: 1) age, 2) gender, 
3) type of visit (follow up or assessment), 4) living situation (with partner, with other 
people, sheltered accommodation, residential care, or alone), 5) registration of visual 
impairment (severely sight impaired, sight impaired, or not registered), 6) ocular 
condition, 7) binocular distance visual acuity, 8) binocular near visual acuity, and 9) 
prescribed a Compact+ (Yes/ No).  
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Limitations of the data set 
Although clinicians record the visual acuity using Log Minimum Angle of Resolution (Log 
MAR) charts, binocular distance visual acuity was recorded in the service data set in 
Snellen 6 metres notation. Therefore, distance visual acuity was converted into Log 
MAR.  
 
Data about near visual acuity were not used in this study, because information about 
the test chart used, the spectacles worn and viewing distance were not included in the 
data set.   
 
Causes of visual impairment for common conditions were ticked by practitioners on 
patients’ record cards. Often there were a number of conditions, but the principal cause 
of visual impairment was not identified in their records.  
 
The data set provided by the service included information about whether a patient was 
prescribed a PELVA or not. It did not include information about other types of low vision 
aids that were prescribed, or if patients who were not prescribed a Compact+ were 
prescribed other aids. Therefore, the ‘prescribed a PELVA’ group may contain patients 
who were also prescribed other aids. Moreover, we could not filter out patients who 
were not prescribed any low vision aids. 
 
  
177 
 
Contrast sensitivity, although on the record card, was not recorded on the service data 
set.   
 
Full records were not available for follow-up patients. Therefore, records from patients 
who had a follow-up visit with low vision aids prescribed and an assessment record in 
the same year (882 records) were merged in the data set. This resulted in a total of 6,984 
records.  
 
After review, 316 patient records were removed; those were records from follow-up 
visits for which no assessment visit information was available because they had been 
seen for assessment in the preceding year. A total of 6,668 records remained. 
 
5.2.2. Ethics 
Ethical approval was obtained as part of the on-going audit process of the service and 
all procedures followed the Declaration of Helsinki.  
 
5.2.3. Statistics  
Testing for normality of the data set was performed in order to choose the appropriate 
statistical test [SPSS: analyse  descriptive statistics  explore  descriptives and 
percentiles (confidence interval 95%)  normality plots with statistics]. Shapiro-Wilk 
test of normality is used for small sample sizes of up to 2,000 subjects; because of the 
large sample size > 2,000 in this study (n=6,668) Kolmogorov-Smirnov normality test was 
chosen.   
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Descriptive statistics and frequencies were performed for the whole data set (including: 
mean, standard deviation, median, range, interquartile range, minimum and maximum 
values, variance, etc. as where appropriate) for all variables/ factors in the data set, in 
order to describe the demographics of the patients.   
 
The data were then split into two groups: first group: prescribed a PELVA; second group: 
not prescribed a PELVA [SPSS: data  split files  compare groups]. Descriptive 
statistics and frequencies were performed for all the variables/ factors after splitting 
data to compare the demographics of the patients prescribed a PELVA versus those who 
were not prescribed a PELVA. The ‘prescribed a PELVA’ group may contain patients who 
were also prescribed other aids, and we could not filter out patients who were not 
prescribed any low vision aids, because the data set did not include information about 
types of low vision aids that were prescribed, or if patients who were not prescribed a 
Compact+ were prescribed other aids.   
 
The significance of proportion differences between those prescribed a PELVA and those 
who were not prescribed one was analysed using Chi-squared test. The significance of 
variable/ factor differences between the two groups (prescribed versus not prescribed 
a PELVA) were analysed using non-parametric tests, Mann-Whitney U (2 samples), 
because the data were not normally distributed [SPSS: analyse  nonparametric tests 
 independent samples and analyse  nonparametric tests  legacy dialogs  2 
independent samples].  
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Graphs and charts were created using either SPSS 20 or Excel 2013, where appropriate.  
 
In order to predict which factor(s) affected PELVAs prescribing, multiple regression 
analysis was carried out [SPSS: analyse  regression  linear  dependent variable 
(prescribed a PELVA)  independents (all variables/factors in the data set)  estimates, 
model fit, descriptive, confidence interval (95%)]. 
 
Adults and children analysis: 
Children have different requirements than adults. Therefore, the data set was also 
analysed for adults (> 18 years) and for children (=< 18 years).  
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5.3. Results 
A total of 6,668 patient records were included in the analysis. Data (age, gender, living 
situation, registration of visual impairment, ocular conditions, binocular Log MAR 
distance visual acuity, and prescribed a Compact+) were not normally distributed 
(Kolmogorov-Smirnov, p < 0.001). Also, the normal Q-Q plot of prescribing was not 
normally distributed; data points stray from the line in a non-linear fashion.  
 
5.3.1. Summary of the total data set 
Of the 6,668 patient records assessed, the median age of the patients was 83 years 
(interquartile range 76-88) (Figure 5.1), of whom, 65.7% (4384) were female. The 
median binocular distance visual acuity of patients was 0.60 Log MAR (interquartile 
range 0.40-1.00) (Figure 5.2). Counting fingers was not recorded in the service data set. 
A visual acuity of 2.00 Log MAR is equivalent to one letter seen at a distance of 0.5 metre, 
i.e. 1.98 which was approximated to 2.00 Log MAR in the service data set (Figure 5.2).  
Sixty six patients had a distance visual acuity worse than 2.00 Log MAR, i.e. Hand 
Movements (44), Light Perception (16), and No Light Perception (6). Patients were 
diagnosed with different ocular conditions, some patients having more than one ocular 
condition (the principle cause of visual impairment was not specified in the data set). 
The demographics of patients are shown in Table 5.1 which includes the findings for: 1) 
all patients, 2) adults (> 18 years), and 3) children (=< 18 years).   
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Figure 5.1: The age distribution of 6,668 patients (median 83 years) assessed in the 
LVSW in 2011/2012. 
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Figure 5.2: The Binocular Log MAR distance visual acuity of the study group (n=6,668) 
(median 0.60, interquartile range 0.40 – 1.00). Sixty six patients had a distance visual 
acuity worse than 2.00 Log MAR distance visual acuity (Hand Movements, Light 
Perception, and No Light Perception) and hence are not included in this histogram. 
Counting fingers was not recorded in the service data set. A visual acuity of 2.00 Log 
MAR is equivalent to one letter seen at a distance of 0.5 metre i.e. 1.98 which was 
approximated to 2.00 Log MAR in the service data set.   
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Characteristic 
 
Category 
 
All patients (i.e. 
including adults 
and children ) 
n=6,668 
 
Adults (i.e. aged > 
18 years)  
n=6,564 
 
Children (i.e. aged 
= < 18 years only) 
n=104 
Age  (Years) 
 
 Median (83.37)  
Range (0-104) 
IQR (76-88) 
Median (84) 
Range (19-104) 
IQR (76-88) 
Median (11) 
Range (0-18) 
IQR (9-15) 
Gender  
  
Female 4,384 (65.7%) 4,331(66%) 53 (51%) 
Male 2,282 (34.2%) 2,231(34%) 51 (49%) 
Visit Type  
 
Assessment 6,310 (94.6%) 6,214(94.7%) 96 (92.3%) 
Follow up 358 (5.4%) 350(5.3%) 8 (7.7%) 
Eye 
Conditions 
 
 
 
AMD Total  4,246 (63.7%) 4,246(64.7%) 0 
AMD Wet  1,167 (17.5%) 1,167(17.8%) 0 
AMD Dry   3,508 (52.6%) 3,508(53.4%) 0 
AMD Not Specified  64 (1.0%) 64(1.0%) 0 
Diabetic Eye Disease  462 (6.9%) 462(7.0%) 0 
Cataract  1,962 (29.4%) 1,958(29.8%) 4 (3.8%) 
Nystagmus   138 (2.1%) 93(1.4%) 45 (43.3%) 
Glaucoma  869 (13.0%) 867(13.2%) 2 (1.9%) 
Other Eye Conditions   1,109 (16.6%) 1,052(16.1%) 55 (52.9%) 
Diagnosis Not Known  68 (1.0%) 66 (1.0%) 2 (1.9%) 
Missing 358 (5.4%) 350 (5.3%)  8 (7.7%) 
Binocular Log 
MAR distance 
visual acuity 
 Median (0.60)  
Range (0.00- NLP†)  
IQR (0.40-1.00) 
Median (0.60) 
Range (0.00-NLP†) 
IQR (0.40-1.00) 
Median (0.50) 
Range (0.00- NLP†) 
IQR (0.30-0.80) 
Living 
Situation  
 
Alone 2,782 (41.7%) 2,782 (42.4%) NE 
With Partner/ Spouse 2,222 (33.3%) 2,215(33.7%) NE 
With other People 720 (10.8%) 641(9.8%) NE 
Sheltered Accommodation 237 (3.6%) 237(3.6%) NE 
Residential Care 182 (2.7%) 182(2.8%) NE 
Other 28 (0.4%) 26(0.4%) NE 
Missing 497 (7.5%) 481 (7.3%) 16 (15.4%) 
Registration 
of Visual 
Impairment  
 
Sight impaired 1,221 (18.3%) 1,184(18.0%) 37 (35.6%) 
Severely Sight Impaired 799 (12.0%) 793(12.1%) 6 (5.8%) 
Not Registered 3,256 (48.8%) 3,229(49.2%) 27 (26%) 
Not Known 200 (3.0%) 192(2.9%) 34 (32.7%) 
Missing 1,192 (17.9%) 1,164 (17.7%) 0 
Prescription 
of Compact+  
Prescribed 664 (10.0%) 626 (9.5%) 38 (36.5%) 
Not Prescribed 6,004 (90.0%) 5,938 (90.5%) 66 (63.5%) 
 
Table 5.1: The demographics of all patients (n= 6,668), adults aged > 18 years (n = 
6,564), and children aged =< 18 years (n = 104) who attended the LVSW during the year 
2011/2012. AMD= Age-related Macular Degeneration. Statistics includes number and 
(percentage) of the total number included, except where indicated as median, range, 
and interquartile range (IQR).  [Patients may have multiple ocular conditions (e.g. Wet 
and dry AMD; cataract and glaucoma; AMD and nystagmus)]. † No light perception 
(NLP).  NE = not evaluated; the analysis of children living situation was not appropriate 
because in the LVSW the record cards are designed for adults, and there is not an 
option 'living with family/ parents'.   
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5.3.2. The prescribing patterns for a PELVA in the LVSW in the year 2011/2012 
Of the 6,668 patients, 10% (664) of all patients were prescribed a PELVA (Compact+). 
This was similar to the percentage of adults who were prescribed a PELVA (9.5%). A 
summary of the demographics of patients who were prescribed a PELVA compared to 
those who were not prescribed a PELVA is shown in Table 5.2. 
 
Those who were prescribed a PELVA were: 
1) Younger: The median age of patients who were prescribed a PELVA was 77 years 
compared to 84 years of those who were not prescribed (Mann Whitney U, p < 
0.001) (Table 5.2,  Figures 5.3 and 5.4). These were similar to the age of adults who 
were prescribed a PELVA (median 78 years) and to the age of adults who were not 
prescribed a PELVA (median 84) (Table 5.2, Figure 5.4). 
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Table 5.2: The demographics of patients who were prescribed a PELVA versus those that were not prescribed one. IQR = interquartile range. * P-value 
significant (Chi squared, p < 0.05) ** P-value is significant (Mann-Whitney test, p < 0.05). ¹0 the age is < 1 year. ²Some patients had more than one ocular 
condition, therefore the sum of percentages of eye conditions is more than 100%. †No light perception (NLP). NE = not evaluated; the analysis of children 
living situation was not appropriate because in the LVSW the record cards are designed for adults, and there is not an option 'living with family/ parents'.   
 All patients (n=6,668) Adults  (n=6,564) Children (n= 104) 
Prescribed 
a PELVA 
(n=664) 
Not prescribed 
a PELVA 
(n=6004) 
P-value Prescribed 
a PELVA 
(n=626) 
Not prescribed 
a PELVA 
(n=5938) 
P-value Prescribed a 
PELVA (n=38) 
Not 
prescribed a 
PELVA (n=66) 
P-value 
Visit type Assessment 
Follow up 
556 (83.7%) 
108 (16.3%) 
5,563 (92.7%) 
440 (7.3%) 
<0.001* 533 (85.1%) 
93 (14.9%) 
5,681(95.7%) 
257(4.3%) 
<0.001* 33 (86.8%) 
5 (13.2%) 
63 (95.5%) 
3 (4.5%) 
<0.001* 
Gender Female 
Male 
380 (57.2%) 
284 (42.8%) 
4,004 (66.7%) 
1,998 (33.3%) 
<0.001* 361(57.7%) 
265(42.3%) 
3,970(66.9%) 
1,966(33.1%) 
<0.001* 19 (50%) 
19 (50%) 
34 (51.5%) 
32 (48.5%) 
0.845 
Age¹ (Years) Median 
Range 
IQR 
77 
5-102 
58-85 
84 
0-104 
77-89 
<0.001** 78 
19-102 
63-86 
84 
19-104 
77-89 
<0.001** 12 
5-18 
9-15 
11 
 0-18 
9-14 
0.316 
Binocular Log 
MAR distance 
visual acuity 
Median 
Range 
IQR 
0.90 
0.1- NPL† 
0.60-1.20 
0.60 
0.00- NPL† 
0.40-0.90 
<0.001** 0.90 
0.1.00-NPL†  
0.60-1.30 
0.60 
0.00-NPL† 
0.40-0.90 
<0.001** 0.50 
0.20-1.60 
0.48-0.80 
0.50 
0.00-NPL† 
0.30-0.80 
0.290 
Eye 
conditions² 
AMD not specified 
AMD WET 
AMD DRY 
Total AMD 
Diabetic eye disease 
Cataract 
Nystagmus 
Glaucoma 
Other eye conditions 
5 (0.8%) 
128 (19.3%) 
226(34%) 
315 (47.4%) 
60 (9%) 
100 (15.1%) 
40 (6%) 
72 (10.8%) 
162(24.4%) 
59 (1%) 
1,039 (17.3%) 
3,282 (54.7% 
3,931 (65.5%) 
402 (6.7%) 
1,862 (31%) 
98 (1.6%) 
797 (13.3%) 
947(15.8%) 
0.745 
0.008* 
<0.001* 
<0.001* 
0.002* 
<0.001* 
<0.001* 
0.447 
<0.001* 
5(0.8%) 
128(20.4%) 
226(36.1%) 
315(50.3%) 
60(9.6%) 
98(15.7%) 
22(3.5%) 
71(11.3%) 
145(23.2%) 
59(1%) 
1,039(17.5%) 
3,282(55.3%) 
3,931(66.2%) 
402(6.8%) 
1,860(31.3%) 
71(1.2%) 
796(13.4%) 
909(15.3%) 
0.826 
<0.001* 
<0.001* 
<0.001* 
<0.001* 
<0.001* 
<0.001* 
0.660 
<0.001* 
0 
0 
0 
0 
0 
2 (5.3%) 
18 (47.4%) 
1 (2.6%) 
17 (44.7%) 
0 
0 
0 
0 
0 
2 (3%) 
27 (40.9%) 
1 (1.5%) 
38 (57.6%) 
- 
- 
- 
- 
- 
<0.001* 
0.540 
<0.001* 
0.154 
Living 
situation 
Alone 
With partner/ spouse 
With other people 
Sheltered Accommodation 
Residential care 
Other 
Not known 
196(29.5%) 
269(40.5%) 
70(10.5%) 
13(2%) 
4(0.6%) 
2(0.3%) 
110(16.6%) 
2,586(43.1%) 
1,953(32.5%) 
650(10.8%) 
224(3.7%) 
178(3%) 
26(0.4%) 
387(6.4%) 
<0.001* 
<0.001* 
0.052 
<0.001* 
<0.001* 
0.060 
<0.001* 
196(31.3%) 
265(42.3%) 
44(7.0%) 
13(2.1%) 
4(0.6%) 
2(0.3%) 
102(16.4%) 
2,586(43.6%) 
1,950(32.8%) 
597(10.1%) 
224(3.8%) 
178(3%) 
24(0.4%) 
374(6.3%) 
<0.001* 
<0.001* 
0.071 
<0.001* 
<0.001* 
0.062 
<0.001* 
NE 
NE 
NE 
NE 
NE 
NE 
NE 
NE 
NE 
NE 
NE 
NE 
NE 
NE 
- 
- 
- 
- 
- 
- 
- 
Registration Sight impaired 
Severely sight impaired 
Not registered 
Not known 
181 (27.3%) 
176(26.5%) 
140(21.1%) 
167(25.2%) 
1,040(17.3%) 
623(10.4%) 
3,116(51.9%) 
1225 (20.4%) 
<0.001* 
<0.001* 
<0.001* 
0.421 
166(26.5%) 
173(27.6%) 
130(20.8%) 
144(23%) 
1,018(17.1%) 
620(10.4%) 
3,099(52.2%) 
1,201(20.3%) 
<0.001* 
<0.001* 
<0.001* 
0.590 
15 (39.5%) 
3 (7.9%) 
10 (26.3%) 
10 (26.3%) 
22 (33.3%) 
3 (4.5%) 
17 (25.8%) 
24 (36.4%) 
<0.001* 
<0.001* 
0.621 
<0.001* 
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Figure 5.3: The age distribution of all patients who were prescribed a PELVA (n=664) 
[median age = 77 years] and those who were not prescribed (n=6004) [median age = 
84 years].  
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Figure 5.4: A comparison between percentages of patients who were prescribed a 
PELVA and those who were not prescribed by age group. All patients who were 
prescribed PELVA were younger (median 77 years) than those who were not 
prescribed (median 84 years), this was not different for adult patients.  
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2) More likely to be “male”: Although there were more females [65.8% (4,384)] 
compared to males [34.2% (2,282)] in the data set (n=6,668), males were more likely 
to be prescribed a PELVA; 12.4% (284 out of 2,282) of males in the sample were 
prescribed a PELVA, compared to 8.7% (380 out of 4,384) females (Chi squared, p < 
0.05). There were 42.8% (284) males out of 664 patients who were prescribed a 
PELVA compared to 33.3% (1,998) males out of 6,004 of those not prescribed (Table 
5.2, Figure 5.5). On the other hand, 57.2% (380) females out of 664 patients were 
prescribed a PELVA compared to 66.7% (4,004) females out of 6,004 of those not 
prescribed (Table 5.2, Figure 5.5) (Chi squared, p < 0.001). The exclusion of children 
aged 18 years or younger did not significantly affect these results; 42.3% (265) out 
of 626 adults who were prescribed a PELVA were males compared to 33.1% (1,966) 
out of 5,938 adults who were not prescribed (Table 5.2).  
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Figure 5.5: Percentage of all patients (n=6,668) who were prescribed a PELVA (n=664) 
compared to those who were not prescribed (n=6,004) by gender.  
 
3) More likely to live with “a partner/ spouse” and less likely to live “alone”, in “a 
residential care” or in “a sheltered accommodation”): There were 40.5% (269) out 
of 664 patients who were prescribed a PELVA compared to 32.5% (1,953) out of 
6,004 not prescribed live “with a partner or a spouse” (Chi squared, p < 0.001)  (Table 
5.2, Figure 5.6). While out of 6,004 who were not prescribed a PELVA, there were 
43.1% (2,586) live “alone”, 3% (178) live in “a residential care”, and 3.7% (224) live 
in “a sheltered accommodation” compared to 29.5% (196) live alone, 0.6% (4) live in 
residential care, and 2% (13) live in sheltered accommodation of those who 
prescribed a PELVA (Chi squared, p < 0.05) (Table 5.2, Figure 5.6). Exclusion of 
children aged 18 years or younger did not significantly affect the results (Table 5.2).  
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Figure 5.6: The living situation of all patients who were prescribed a PELVA (n=664) 
and those who were not prescribed (n=6004).  
 
   
4) More likely to have poorer visual acuity: Visual acuity was not normally distributed 
(Kolmogorov Smirnov, p < 0.05). Median distance Log MAR visual acuity for those 
who were prescribed a PELVA was 0.90 compared to 0.60 for patients who were not 
prescribed (Mann Whitney U, p < 0.001) (Table 5.2, and Figures 5.7 A and B). The 
exclusion of children aged 18 years or younger did not affect the results (Table 5.2).  
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Figure 5.7: (A) Visual acuity of all patients who were prescribed a PELVA (median 0.90). 
The 13 patients that had a visual acuity worse than 2.00 Log MAR visual acuity are not 
included in this histogram (Hand Movements 9, Light perception 3, and No Light 
Perception 1). (B) Visual acuity of patients who were not prescribed a PELVA (Median 
0.60). The 53 patients that had a visual acuity worse than 2.00 Log MAR visual acuity 
are not included in this histogram (Hand movements 35, Light Perception 13, and No 
Light Perception 5). Counting fingers was not recorded in the service data set. A visual 
acuity of 2.00 Log MAR is equivalent to one letter seen at a distance of 0.5 metre i.e. 
1.98 which was approximated to 2.00 Log MAR in the service data set.   
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5) More likely to be registered as “sight Impaired” or ‘severely sight impaired’: 
Patients who were prescribed a PELVA [n=664] were more likely to be registered as 
“sight impaired” 27.3% (181), and “severely sight impaired” 26.5% (176) compared 
to 17.3% (1,040) “sight impaired” and 10.4% (623) “severely sight impaired” of those 
who were not prescribed (Chi squared, p < 0.001) (Figure 5.8 and Table 5.2). A total 
of 21.1% (140) of those prescribed a PELVA [n=664] were “not registered”, and 
25.2% (167) did not know if they were registered or not (Figure 5.8 and Table 5.2). 
Registration of visual impairment was self-reported; it was not confirmed by social 
services or hospital records. The exclusion of children aged 18 years or younger did 
not significantly affect these results (Table 5.2).  
 
Figure 5.8: The registration of visual impairment status of patients who were 
prescribed a PELVA (n=664) and those who were not prescribed (n=6,004). 
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6) Were diagnosed with different ocular conditions: 
The sum of percentages of all ocular conditions exceeded 100% (160.8%), because some 
patients had multiple ocular conditions (e.g. cataract and glaucoma; AMD and 
nystagmus).  
  
i) Age related macular degeneration (AMD): Out of 664 patients who were 
prescribed a PELVA, 47.4% (315) had AMD (including wet AMD, dry AMD, and 
not specified AMD) whereas out of the 6,004 patients who were not prescribed 
a PELVA 65.5% (3,931) had AMD (Chi squared, p < 0.001). Therefore patients who 
were prescribed a PELVA were less likely to have AMD.  
 
Patients who were prescribed a PELVA were more likely to have wet AMD 19.3% (128) 
[n=664] compared to 17.3% (1039) [n= 6,004] of those not prescribed (Chi squared, p = 
0.008). Patients who were prescribed a PELVA were less likely to have dry AMD 34% 
(226) [n=664] compared to 54.7% (3,282) of the 6,004 patients who were not prescribed 
(Chi squared, p < 0.001) (Figure 5.9 and Table 5.2). 
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Figure 5.9: The percentage of all patients with age-related macular degeneration (Wet, 
Dry, Not specified, and Total) for those who were prescribed a PELVA (n=664) and 
those not prescribed (n=6,004). 
 
 
ii) Cataract: Patients who were prescribed a PELVA were less likely to have 
cataract; 15.1% (100) of 664 patients who were prescribed a PELVA had 
cataract compared to 31% (1,862) of the 6,004 who were not prescribed (Chi 
squared, p < 0.001) (Figure 5.10 and Table 5.2).  
 
iii) Glaucoma: There was no significant difference in the prevalence of glaucoma 
between patients who were, and those who were not, prescribed a PELVA; 
10.8% (72) [n=664] and patients who were not prescribed 13.3% (797) 
[n=6,004] (Chi squared, p = 0.447) (Figure 5.10 and Table 5.2).  
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iv) Diabetic eye disease: Patients who were prescribed a PELVA were more 
likely to have diabetic eye disease; 9% (60) [n=664] compared to those who 
were not prescribed 6.7% (402) [n=6,004] (Chi squared, p = 0.002) (Figure 
5.10 and Table 5.2). 
 
v) Nystagmus:  Patients who were prescribed a PELVA were more likely to have 
nystagmus; 6% (40) [n=664] compared to those not prescribed 1.6% (98) 
[n=6,004] (Chi squared, p < 0.001) (Figure 5.10 and Table 5.2).  
 
vi) Other eye conditions: There were 24.4% (162) [n=664] of patients prescribed 
a PELVA who had other eye conditions/ disorders such as retinitis 
pigmentosa, optic nerve atrophy, cystoid macular oedema etc., compared to 
15.8% (947) [n=6,004] of those not prescribed a PELVA (Chi squared, p < 
0.001) (Figure 5.10 and Table 5.2).  
 
The distribution of ocular disorders for patients who were prescribed a PELVA compared 
to those not prescribed is shown in Figure 5.10 and Table 5.2. The exclusion of children 
aged 18 years or younger did not significantly affect these results (Table 5.2).  
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Figure 5.10: Ocular conditions for all patients who were prescribed a PELVA (n=664), 
and all patients who were not prescribed (n=6,004). 
 
Overall, there was a lower proportion of patients who had multiple ocular conditions of 
those prescribed a PELVA compared to those not prescribed. There were 36.6% (242) 
out of 664 patients who were prescribed a PELVA who had multiple ocular conditions 
compared to 52.5% (3,152) out of 6,004 who were not prescribed (Chi squared, p < 
0.001).  
 
There was no significant difference in the distribution of multiple ocular conditions at 
each category (e.g. one ocular condition, two ocular conditions) between patients who 
were prescribed a PELVA and those not.  Out of 664 patients who were prescribed a 
PELVA, 58% (395) had only one ocular condition (e.g. AMD only, cataract only, etc.) 
compared to 50.3% (3,022) out of 6,004 who were not prescribed (Chi squared, p > 0.05). 
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35% (117) out of 664 who were prescribed a PELVA had two ocular conditions compared 
to 32% (1,924) of those not prescribed (n=6,004) (Chi squared, p > 0.05). 6.6% (36) of 
those prescribed (n=664) had three ocular conditions compared to 5.8% (349) of 
patients who were not prescribed (n=6,004) (Chi squared, p > 0.05).  Also, 0.5% (3) of 
those prescribed (n=664) had four ocular conditions and 0.5% (30) (n=6,004) of those 
not prescribed (Chi squared, p > 0.05).  
 
5.3.3. Factors affecting prescribing for PELVAs for patients with visual impairment 
In the sample (n=6,668), there were more ‘older patients’. There was also twice as many 
females as males. Females live longer and are more likely to have visual impairment. 
Also, younger patients are more likely to live with a partner or a spouse. This may have 
affected other attributes. For example, older people are more likely to live alone.  
 
Therefore, multiple linear regression analysis was performed for. This showed that for: 
 
All patients:  
About 10% of the total variability in the prescribing for PELVAs for all patients included 
in this study (n=6,668) was explained by: age, gender, status of visual impairment 
registration, living situation, distance Log MAR visual acuity, and ocular conditions 
(including AMD, wet AMD, dry AMD, cataract, glaucoma, diabetic eye disease, and 
nystagmus)  (adjusted R-square = 0.100, p < 0.001).  
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Living situation, having glaucoma, having nystagmus, having diabetic eye disease, having 
not specified AMD, having dry AMD, having wet AMD, and having other eye conditions 
(each factor alone holding other factors constant) had no significant relationship with 
the prescribing of PELVAs (B-coefficient, p > 0.05), i.e. they had no predictive ability for 
patients being prescribed a PELVA (Table 5.3).   
 
Age, gender, distance Log MAR visual acuity, AMD, cataract, and status of visual 
impairment registration (each factor alone holding other factors constant) had a 
significant relationship with the prescribing  PELVAs (B-coefficient, p < 0.05), i.e. had a 
predictive ability for a patient being prescribed a PELVA or being not prescribed a PELVA 
(Table 5.3). 
 
Multiple linear regression analysis (Table 5.3) showed that the probability of a patient 
being prescribed a PELVA was: 1) increased by reducing age by a factor (i.e. B-
Coefficient) of 0.004, although there were more older patients in the sample [median 
age 83.37, OR = 3.079], 2) increased by being a male by a factor of 0.02, although there 
were twice as many females as males in the total sample [Female (65.7% (4,384)), Male 
(34.2% (2,282)) n=6,668, OR = 1.498], 3) increased by reduction in binocular distance 
visual acuity (i.e. worse vision) by a factor of 0.090, 4) decreased by having AMD by a 
factor of 0.04, 5) decreased by having cataract by a factor of 0.018, and 6) decreased by 
being not registered for visual impairment status by a factor of 0.037,  p < 0.05 for all of 
the above cases (Table 5.3).  
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Factor All patients 
(adjusted R square= 0.100 , p < 0.001, 
constant1 0.377) 
Adults 
(adjusted R square= 0.090 , p < 0.001, 
constant1 0.369) 
Children 
(adjusted R square= 0.003 , p = 0.430, 
constant1 -1.155) 
B-coefficient p-value B-coefficient p-value B-coefficient p-value 
Age  (Years) -0.004 <0.001* -0.004 <0.001* +0.021 0.234 
Gender +0.02 0.017* +0.018 0.026* +0.083 0.496 
AMD Total  -0.04 0.035* -0.04 0.035* -- -- 
AMD Wet  +0.018 0.209 +0.019 0.192 -- -- 
AMD Dry   -0.023 0.203 -0.022 0.199 -- -- 
AMD Not Specified  -0.014 0.745 -0.014 0.743 -- -- 
Diabetic Eye Disease  +0.004 0.810 +0.006 0.690 -- -- 
Cataract  -0.018 0.034* -0.018 0.034* +0.133 0.611 
Nystagmus   +0.034 0.250 +0.008 0.811 +0.058 0.703 
Glaucoma  +0.007 0.544 +0.006 0.578 +0.622 0.229 
Other Eye Conditions   +0.006 0.614 +0.010 0.403 -0.143 0.347 
Binocular Log MAR distance visual acuity +0.09 <0.001* +0.088 <0.001* +0.369 0.077 
Living Situation  +0.003 0.123 +0.003 0.107 NE -- 
Registration of Visual Impairment -0.037 <0.001* -0.039 <0.001* +0.097 0.260 
 
Table 5.3: Factors affecting the prescribing for PELVAs for ‘all patients’, adults (> 18 years), and children (=< 18 years).  Regression analysis was used 
to analyse data. * p-value is significant (p < 0.05). 1 Constant is the probability of a patient being prescribed a PELVA when all factors/ predictors (X) 
equal zero. The prescribing for PELVAs increases (+) or decreases (-) by *B-coefficient, for example the probability of a patient being prescribed a 
PELVA is increased by reducing age by a factor of 0.004 (B-coefficient = -0.004).  -- Not calculated as no patients had this condition.   NE = not 
evaluated; the analysis of children living situation was not appropriate because in the LVSW the record cards are designed for adults, and there is 
not an option 'living with family/ parents'.   
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Patients who were prescribed a PELVA were younger. There were 1.6% (104 out 6,668) 
patients aged 18 years or younger in the data set. Of the 10% (664 out of 6,668) patients 
who were prescribed a PELVA, there were 5.7% (38 of 664) children (aged 18 years or 
younger), and 94.3% (626 of 664) patients aged more than 18 years. Although the 
number of children was small, the data set excluding children aged 18 years or younger 
was analysed in order to find whether that affected the results.  
 
The characteristics of patients excluding children (i.e. adults) are shown in Table 5.1. The 
characteristics of adults who were prescribed a PELVA compared to those who were not 
prescribed are shown in Table 5.2.  
 
Adults:  
About 9% of the total variability in the prescribing of PELVAs for adults was explained 
by: age, gender, status of visual impairment registration, living situation, distance Log 
MAR visual acuity, and ocular conditions (including AMD, wet AMD, dry AMD, cataract, 
glaucoma, diabetic eye disease, and nystagmus)  (adjusted R-square = 0.090, p < 0.001).  
 
Excluding children aged 18 years or younger, the probability of an adult patient  being 
prescribed a PELVA was: 1) increased by reducing age by a factor of 0.004, 2) increased 
by being a male by a factor of 0.018, 3) increased by reduction in binocular distance 
visual acuity by a factor of 0.088, 4) decreased by having AMD by a factor of 0.04, 5) 
decreased by having cataract by a factor of 0.018, and 6) decreased by being not 
registered for visual impairment status by a factor of 0.039, p < 0.05 for all of the above 
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factors (Table 5.3). Therefore, the exclusion of children from the data set did not affect 
our conclusion.  
 
Children aged 18 years or younger:  
A higher proportion of children (36.5%) were prescribed a PELVA compared to adults 
(10%) (Chi-squared, p < 0.05). Children who were prescribed a PELVA were more likely 
to have cataract, glaucoma or other eye conditions such as cortical visual impairment 
and optic atrophy, and more likely to be registered as sight impaired or severely sight 
impaired. There were no significant differences in age and gender between children who 
were prescribed a PELVA and children who were not prescribed.  The characteristics of 
children who were prescribed a PELVA compared to those who were not prescribed are 
shown in Table 5.2.  
 
Multiple regression analysis showed that: age, gender, binocular Log MAR distance 
visual acuity, eye conditions (AMD, cataract, diabetic eye disease, glaucoma, nystagmus, 
and other eye conditions), and registration of visual impairment were not predictors for 
a child being prescribed a PELVA (adjusted R-square = 0.003, p = 0.430). B-coefficient, p 
> 0.05 for each of the above factors (Table 5.3).  
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5.4. Discussion  
In this study, despite PELVAs being available on loan free of charge at the LVSW, only 
10% (664) [n=6,668] patients were prescribed these devices. Patients who were 
prescribed a PELVA were significantly younger, more likely to be males, (although there 
were twice as many females as males in the data set), were more likely to live with a 
partner/ spouse, less likely to live alone or in a sheltered accommodation or in a 
residential care, had poorer visual acuity, more likely to be registered as sight impaired 
or severely sight impaired, were less likely to have AMD, less likely to have cataract, 
more likely to have diabetic eye disease, more likely to have nystagmus, and more likely 
to have other eye conditions compared to those not prescribed.  
 
The tendency to present PELVAs to younger males may be because males and younger 
people tend to use technology such as computers, tablets and smartphone more than 
females and older people. In 2013, 37% of people aged 65 and older used computers 
compared to (80 to 88%) of people aged less than 50 years (Office for National Statistics, 
2013). Smith and Necessary (1996) reported that compared to females, males had more 
positive attitudes towards using technology or computers (Office for National Statistics, 
2013).  There were 9% of UK household females used tablet computers compared to 
13% of UK households’ males (Ofcom Communications Market Report, 2012). 
Therefore, optometrists might be less likely to offer PELVAs to older patients and 
women, or it may be that older patients and women were more likely to turn them 
down.  
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An internal document (Ryan, 2011) outlined the 'prescribing patterns' for Compact+ (a 
PELVA) in the LVSW. She evaluated data set of about 4,300 low vision patients. The 
author reported that 12.25% (527) of patients were prescribed Compact+. This was 
slightly different to findings of this study where 10% (664) out of 6,668 patients with 
visual impairment were prescribed. This slight drop may be because there were more 
patients interested in PELVAs initially. She also found that patients who were prescribed 
Compact+ tended to be younger, male, and had poorer visual acuity, similar to the 
findings of this study. From experience in low vision practice, she suggested that 
prescribing Compact+ might be a suitable choice for patients with poor visual acuity (0.6 
Log MAR or worse). The findings are similar to this study in which patients who were 
prescribed a PELVA had poorer visual acuity (median binocular distance Log MAR visual 
acuity 0.90, interquartile range 0.60-1.20).  
 
Results from the Lighthouse National Survey on Vision Loss (1995) show that of study 
populations aged 45 years and older, 30% of patients with self-reported visual 
impairment used optical visual aids such as magnifiers or telescopes, whereas large print 
texts were used by 21% of patients, and about 5% used adaptive visual aids such as 
talking books and clocks. It was not clear if electronic low vision aids were included in 
the study (Lighthouse National Survey on vision loss 1995, Jutai et al. 2005). 
  
Crossland and Silver (2005) studied the change in the prescribing patterns for low vision 
aids over 30 years at Moorfields Eye Hospital. They found that younger patients (aged 
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60 years or less) tended to be prescribed more than one low vision aid.  Also, there was 
a linear increase in the number of prescribed hand magnifiers, bright field magnifiers, 
and illuminated hand magnifiers but a decline in the number of prescribed spectacle-
mounted telescopes with age. Their study did not include electronic low vision aids 
because they were not available for prescribing (only for demonstration). The authors 
explained that the decline in the number of prescribed spectacle-mounted telescopes 
could be explained by the increased availability of electronic low vision aids such as 
CCTVs, and the development of illuminated hand magnifiers besides the high cost of 
spectacle-mounted telescopes. 
 
From experience in low vision practice Ryan (2011) suggested that PELVAs may provide 
patients with more fluent reading as they have a wider field of view compared to optical 
magnifiers. The author also suggested that Compact+ might be useful for patients with 
low contrast sensitivity (Ryan, 2011). Although we did not have contrast sensitivity data, 
this was not consistent with our finding, that patients who were prescribed a PELVA 
were less likely to have cataract. This might be because of age; among those who had 
cataract, the median age of patients who were prescribed a PELVA was 81 years 
compared to 85 years of those not prescribed. The median age of ‘all patients’ who had 
cataract in our study was 84 years this is older than the median age of patients who 
were prescribed a PELVA (77 years). Also, information about the type and classification 
of cataract and if one eye or both eyes were affected was not included in patients 
records. Culham et al. (2004) found that contrast sensitivity of patients with visual 
impairment using CCTVs was not better than that using optical low vision aids. In 
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Chapter 4 of this thesis, luminance contrast was significantly improved for low contrast 
and high contrast texts using some PELVAs. This is an area that requires further 
investigation and in particular looking at whether patients with reduced contrast 
sensitivity are more likely to be prescribed a PELVA.   
 
Patients who were prescribed a PELVA had poorer visual acuity. This may be because 
PELVAs can be more useful for patients with severe reduction of vision. Li et al. (2002) 
found that of 203 patients with visual impairment who attended Chang Gung Memorial 
Hospital, 86.6% had improved their reading with optical low vision aids and 5.1% with 
CCTVs (Li et al., 2002). Those who benefited from using CCTVs had poorer visual acuity 
compared to those benefited from using optical low vision aids (Li et al., 2002).  The 
authors suggested that when optical low vision aids fail to improve vision of some 
patients, electronic low vision aids may be useful (Li et al., 2002). Nguyen et al. (2009) 
found that although 42%  of low vision patients show improvement in reading speed 
using CCTVs, patients with severe visual impairment (< 20/200) experienced significantly 
lower improvement in reading speed compared to patients with better visual acuity (>= 
20/200) (Nguyen et al., 2009). Culham et al. (2004) found that younger patients and 
those with better distance visual acuity experienced more improvement in reading small 
print using electronic low vision aids compared to optical low vision aids, and younger 
age was a predictor of faster reading speed (Culham et al., 2004). The authors found 
that the near visual acuity and contrast sensitivity of those using electronic low vision 
aids were the same as for those using optical low vision aids. Flipperport and Jordy 
(electronic head-mounted devices) significantly increased distance and intermediate 
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visual acuities compared to optical low vision aids (Culham et al., 2004). Optical low 
vision aids were more useful for the majority of visual tasks compared to electronic low 
vision aids (Culham et al., 2004). Patients with visual acuity of better than 1.2 Log MAR 
gained little benefit from using electronic vision enhancement systems, and many had a 
higher reading speed using optical low vision aids (Fonda et a. 1975, Jackson and 
Wolffsohn 2007). Compared to adults, young people were highly motivated to use 
electronic vision enhancement systems, but they were less likely to use them regularly 
(Fonda et al. 1975, Zabel et al. 1982, Jackson and Wolffsohn 2007). However, Watson et 
al. (1997) reported that age and visual acuity were not related to the continued use of 
electronic vision enhancement systems.   
 
Goodrich and Kirby (2001) found that reading speed and reading duration were 
significantly better using CCTVs compared to optical low vision aids in patients with 
central field loss (Goodrich and Kirby, 2001). This might be because larger CCTVs have a 
bigger screen which provides a larger field of view. 
 
Nguyen et al. (2009) reported that out of 530 patients (age 83±8 years) which is almost 
similar to our study population (median age 83.4 years, interquartile range 76-88) with 
AMD (different stages), visual rehabilitation was achieved mostly using optical low vision 
aids 58% (307) [n=530] and less by electronic low vision aids (CCTV) 42% (223) [n=530]. 
This is far higher than our study findings’ in which only 10% were prescribed a PELVA. 
The Nguyen et al. study represents the prescribing pattern from a private practice in the 
US. Also, this might be explained by the fact that the average distance visual acuity of 
  
207 
 
their study population was worse (0.80 Log MAR equivalent) than our study population 
(median = 0.60 Log MAR equivalent). Our study found that patients with poorer distance 
visual acuity were more likely to be prescribed a PELVA.  
 
Although patients who were prescribed a PELVA were more likely to live with a partner 
or a spouse, more likely to have nystagmus and diabetic eye disease they were not 
predictors for a patient being prescribed a PELVA. There were only a few factors found, 
using multiple linear regression analysis, that can be considered predictors for a patient 
being prescribed a PELVA. These include: being younger, being male, a reduction in 
binocular visual acuity, not having AMD, not having cataract, and being registered for 
visual impairment. 
 
Patients who live with a partner or a spouse, although living arrangement was not a 
predictor for prescribing a PELVA, were more likely to be prescribed a PELVA in this 
study. This might be because patients who were prescribed a PELVA, and live with a 
partner, have poorer binocular distance Log MAR visual acuity (median 0.90) than those 
who were not prescribed and live with a partner (median 0.60). Also, the use of a new 
device could be more convenient if a patient had someone to assist with the use of low 
vision aids at home.  
 
Patients who were prescribed a PELVA were more likely to have diabetic retinopathy 
and nystagmus, although neither were predictors for PELVAs prescribing. This might be 
explained by the fact that patients who were prescribed a PELVA and had diabetic eye 
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disease were younger in this sample (median age 66 years) compared to those who were 
not prescribed but had diabetic eye disease (median age 74 years). The median age of 
patients who had diabetic eye disease in this study was 73 years. Similarly, patients who 
were prescribed a PELVA and had nystagmus were younger (median age 34.50 years) 
compared to those who were not prescribed but had nystagmus median age (42.5 
years). The median age of patients who had nystagmus in this study was 41.50 years.  
 
Patients who were prescribed a PELVA were less likely to have AMD although two thirds 
of the study sample had AMD. AMD is more prevalent in females compared males (RNIB, 
2015). In this study, about 70% of those had AMD were females compared to 30% males. 
The median age of patients who had AMD in this study was 86 years (interquartile range 
81-89) this is older than the median age of patients who were prescribed a PELVA. 
 
There were twice as many females in this data set and according to RNIB statistics two 
third of patients with visual impairment are women (RNIB, 2015). Certain diseases such 
as AMD and cataract affect older people particularly women, and women live longer 
than men. 
 
Of the children aged 18 years or younger (n=104), 36.5% (38) were prescribed a PELVA. 
Children who were prescribed a PELVA were more likely to have cataract, glaucoma or 
other eye conditions such as cortical visual impairment and optic atrophy, and more 
likely to be registered as sight impaired or severely sight impaired. However, age, 
gender, binocular Log MAR distance visual acuity, eye conditions, and status of visual 
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impairment registration were not predictors (p > 0.05) of PELVAs prescribing among 
children aged 18 years or younger. This suggested that the prescribing patterns for 
PELVAs was different compared to adults, and other factors such as children preference 
or device ergonomics might affected PELVAs prescribing for children.  
 
In the LVSW, the record cards are designed for adults, and there is not an option 'living 
with family/ parents', so some practitioner may tick 'living with a partner/ a spouse' to 
mean relatives. Therefore, the analysis of children living situation was not appropriate 
in this study particularly that children do not live alone or in sheltered accommodation 
or residential care.   
 
Overall, the larger proportion of children aged 18 years and younger (36.5%) compared 
to adults (10%) were prescribed a PELVA might be explained by the fact that younger 
are more likely to use technology such as computers and tablet computers such as iPads 
(Office for National Statistics 2013, Anderson and Rainie 2012), or because ergonomics 
of PELVAs might draw less attention to children which might make more preference 
towards PELVAs, or possibly because they might have less fear of using technology. 
Nickson (2015) reported that children felt perfectly comfortable with new technology 
and they did not have fear about pushing buttons and trying new technology compared 
to older people.  
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Excluding children aged 18 years or younger (104 of 6,668), did not affect the results in 
this study. This is likely to be because there were a small number of children in the data 
set.  
 
Our study was important, because it is the first to describe the prescribing patterns for 
electronic low vision aids, the sample was also large. This will help those planning low 
vision services. It was difficult to develop a model for prescribing of PELVAs from the 
data set in this study, however we found a group of significant predictors for a patient 
to be prescribed a PELVA including age and gender.  
  
This study did not provide information about the tasks for which patients were 
prescribed a PELVA and if patients who were not prescribed a PELVA had more cognitive 
or physical limitations. Also, it was not clear what low vision aids other than (PELVAs) 
were prescribed. Moreover, it did not include an assessment of visual functions such as 
contrast and reading performance (with and without a PELVA) for patients who were 
prescribed a PELVA. However, each patient should be considered on an individual basis 
and factors such as patient’s expectations, and preferences should be considered.  The 
fact that there was no restriction on prescribing and yet only 10% of patients were 
prescribed a PELVA provides a holistic view of the need for these devices in NHS services.  
 
Although the number of children in the data set is small (n=104) and it is not 
representative of children with visual impairment, the fact that 36.5% of children were 
prescribed a PELVA suggests that PELVAs should be of considered for children.  
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There is evidence of deterioration of rehabilitation effect over time; the effect at two 
months was higher than at six months (Kuyk et al., 2008) and the effect at three months 
was higher than at 12 months (Stelmack et al., 2007).This study cannot conclude if 
patients still continue to use PELVAs. How many patients stopped using PELVAs? How 
do they rate them? What they are using them for? What things they think would 
improve these devices? Whether they use any other devices along with PELVAs? In the 
next chapter, patients’ self-reported satisfaction of PELVAs compared to optical 
magnifiers will be explored further.  
  
  
212 
 
5.5. Conclusion 
Despite Compact+ (a PELVA) being available for prescription for patients with visual 
impairment on loan free of charge, only 10% of patients attending the LVSW were 
prescribed these devices.  
 
Predictors (significant factors) for a patient being prescribed a PELVA include: younger 
age, being a male, poorer visual acuity, being registered as sight impaired or severely 
sight impaired, not having AMD or cataract. This will be useful for those planning 
services to consider the need in their patient base.  
 
Compared to adults, a higher proportion of children aged eighteen years and younger 
36.5% were prescribed a PELVA. Children who were prescribed a PELVA were more likely 
to have cataract, glaucoma or other eye conditions such as cortical visual impairment 
and optic nerve atrophy, and more likely to be registered as sight impaired or severely 
sight impaired. Device ergonomics or preference might affect PELVAs prescription 
among children.   
 
Other factors that could affect PELVAs prescribing such as patients rating and 
satisfaction, improvement of visual function (for example, contrast and reading 
performance), and low vision aid parameters (for example, field of view), devices 
ergonomics should be explored further.  
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CHAPTER 6: The use and self-reported satisfaction of pocket and portable 
electronic low vision aids, and optical low vision aids for patients with a 
visual impairment 
 
6.1. Introduction 
It is important to evaluate the outcomes of different low vision aids, to measure how 
much these devices are used and meet the needs or the aims of patients with a visual 
impairment, and to analyse benefits and limitations of these aids. 
  
The effectiveness of low vision aids for patients with visual impairment can be evaluated 
based on: 1) assessment of visual functions (visual acuity, contrast sensitivity, reading 
speed and comprehension) (Hiatt et al. 1963, Nilsson and Nilsson 1986, Rosenthal and 
Cole 1991, Whittaker and Lovie-Kitchin 1993, Leat et al. 1994, Harper et al. 1999, 
Margrain 2000, Culham et al. 2009, Markowitz et al. 2012), 2) assessment of quality of 
life reported by patients, aspects including mobility, orientation, functional status, 
mental status, self-care, social status (Hinds et al. 2003, Reeves et al. 2004, De-Boer et 
al. 2006, Lamoureux et al. 2007, Binns et al. 2012), 3) assessment of psychological status 
(Engel et al. 2000, Horowitz et al. 2005, Horowitz et al. 2006), 4) assessment of self-
reported ability to perform daily living tasks (i.e. functional ability) (Haymes et al. 2001, 
Pankow et al. 2004,  Eklund et al. 2008, Binns et al. 2012).  
 
Functional ability measures can be rated depending on the patients assessment of their 
functional ability, this approach can be called a ‘self-reported’ or patient rated 
assessment. Questionnaires that employ this approach include the Veterans Affairs LV 
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VFQ-48 (Stelmack et al. 2006, Stelmack et al. 2007), National Eye Institute Visual 
Function Questionnaire NEI VFQ-25 (Mangione et al. 2001, Stelmack et al. 2002, La-Grow 
2004, Kuyk et al. 2008), NEI-VFQ 51 (Scott et al., 1999),  the Manchester Low Vision 
Questionnaire (MLVQ) (Harper et al. 1999, Hinds et al. 2003), and 5) assessment of 
frequency and use of low vision aids (either at follow up or at variable periods of time) 
(Van-Rens et al. 1991, McIlwaine et al. 1991, Shuttleworth et al. 1995). 
 
Although clinical assessment of visual functions is very important, it does not necessarily 
reflects patients’ satisfaction. Because assessment of visual functions is usually 
performed in a clinic setting, it may not reflect patients’ capabilities at home. Leat et al. 
(1994) found that 75% of patients show good near visual acuity when it was measured 
in a clinical setting, but only 39% were able to read small print size at home. There may 
be a need for new outcome measures that could evaluate the outcome of provided 
services based on the quality of life assessment rather than clinical assessment. On the 
other hand, McKnight and Babcock-Parziale (2007) found that there was no significant 
difference between clinical rated and self-rated scores using the Functional Assessment 
of Self Reliance in Tasks (FAST).  
 
Hiatt et al. (1963), Virtanen and Laatikainen (1991), and Margrain (2000) assessed the 
improvement of visual functions such as reading ability of a newspaper print using the 
low vision aids, and found that the use of the low vision aids improved reading ability in 
90% of patients.   
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Nilsson and Nilsson (1986) found that the provision of distance and near low vision aids 
for patients who had diabetic retinopathy improved their distance visual acuity from 
0.78 to 0.14 Log MAR equivalent, and near visual acuity from N20.8 to N4.2. Telescopes 
were the most frequent distance low vision aids used with average magnification of 
4.8X, and near addition and hyperocular lenses were the most frequent near low vision 
aids used with average magnification of 5.6X. 
 
Nilsson and Nilsson (1986) found that there was an improvement in both distance (from 
0.76 to 0.20 Log MAR equivalent) and near visual acuity (from N20.9 to N4.9) of patients 
with age related macular degeneration after the provision of distance and near low 
vision aids. Telescopes were the most frequent distance low vision aids used with 
average magnification of 4.6X, and near addition and hyperocular lenses were the most 
frequent near low vision aids used with average magnification of 5.7X. 
 
Goodrich et al. (2006) found that there was a significant improvement in reading speed 
after the prescription of optical or electrical low vision aids with training sessions.  
 
McCabe et al. (2000) found an improvement of 50% in clinical functional outcomes using 
the Functional Visual Performance Test (FVPT), and 10% in self-reported functional 
abilities using the Functional Assessment Test (FAQ) after the provision of a 
comprehensive rehabilitation program  (training and low vision aids).  
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Hinds et al. (2003) used an interview-based questionnaire (MLVQ) to follow up patients 
6 months after attending an interdisciplinary low vision service. They found that patients 
used their low vision aids to accomplish different reading tasks such as reading 
instructions, and reading newspapers. They also found that 75% of patients who were 
prescribed low vision aids used or attempted to use them for reading ordinary print 
books, and 72% described low vision aids as extremely or moderately helpful (Hinds et 
al., 2003).  Reeves et al. (2004) used the MLVQ to follow up patients one year after the 
provision of a comprehensive rehabilitation program and found similar results.  
 
Crossland et al. (2007) analysed the response of 15 patients, by using open interview, 
before and after three months of the provision of magnifiers, and found that 40% of 
patients had experienced improvement in their quality of life.   
 
Scott et al. (1999) carried out telephone interviews, 3 months after the provision of low 
vision rehabilitation and found that 90% of patients rated the low vision service as 
helpful.  
 
Stelmack et al. (2006) and Stelmack et al. (2007) found a significant improvement in the 
performance of daily living activities (ADLs), 3 months and 12 months after the provision 
of an intensive Veterans Affairs rehabilitation program, using the VA LV VFQ-48. 
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Nilsson and Nilsson (1986) found that about 90% of patients who had diabetic 
retinopathy and discontinue their work because of visual impairment, return to work 
after the provision of low vision aids.  
 
Haymes et al. (2001) reported that there was a significant improvement in ADLs 
performance, after 1 week of the provision of a multidisciplinary rehabilitation program 
for 22 patients with visual impairment. The authors assessed the improvement of ADLs 
performance using the Melbourne Low Vision ADL Index (MLVAI).  
 
Pankow et al. (2004) found that the provision of a home based rehabilitation program, 
for 15 patients with visual impairment, significantly improved their functional abilities 
measured by using the Functional Independence Measure for Blind Adults (FIMBA), a 
clinical rated tool.  
 
De-Boer et al. (2006) found that, after the provision of a rehabilitation program, there 
was a small but significant improvement in vision related quality of life (including 
depression, safety, fear of vision deterioration, and anger) using the Vision Quality of 
Life Core Measure (VCM1), but no significant improvement was found using the Low 
Vision Quality of Life Questionnaire (LVQOL). Hinds et al. (2003) found that, 6 months 
after the provision of a rehabilitation program, there was a slight improvement in vision 
related quality of life using the VCM1.  
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Wolffsohn and Cochrane (2000) found a significant improvement in vision related 
quality of life, 1 month after the provision of a multidisciplinary rehabilitation program 
for 278 patients, assessed using the LVQOL tool.  The authors reported that reading and 
fine work were the most improved compared to general vision, mobility, and ADLs.  
 
Kuyk et al. (2008) found a significant improvement in vision related quality of life using 
the NEI-VFQ 25, after 2 and 6 months of intervention. Stelmack et al. (2002) found 
moderate improvement in vision related quality of life, after the provision of an 
intensive Veterans Affairs rehabilitation program using the NEI-VFQ 25.  On the contrary, 
La-Grow (2004) found that there was no significant improvement of vision related 
quality of life, 6 months and 1 year after the provision of comprehensive and standard 
low vision services; assessed using the NEI-VFQ 25. 
 
To date, there has been limited literature available on the effectiveness of electronic 
low vision aids particularly PELVAs (Goodrich et al. 1977, Harper et al. 1999, Goodrich 
and Kirby 2001, Li et al. 2002, Peterson et al. 2003, Culham et al. 2009, Virgili and Acosta 
2009, Dyment 2009).  
 
The aim of this study was to evaluate self-reported assessment of PELVAs compared to 
optical low vision aids for patients with visual impairment who attended the LVSW in 
the year 2011-2012, using the Manchester Low Vision Questionnaire (MLVQ).  The 
objectives were to:  
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1) Evaluate the tasks low vision aids (PELVAs and optical low vision aids) were used 
for, i.e. the purpose of using low vision aids.  
2)  Evaluate the usefulness of low vision aids for a group of visual tasks, e.g. reading 
newspaper print. 
3)  Evaluate the frequency and duration of reading that was achieved with the low 
vision aids.  
4) Compare PELVAs and optical low vision aids from the patients’ perspective in 
terms of use, rating, and reading frequency and duration.  
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6.2. Methods 
This is a pilot study that evaluated patients’ self-reported assessment of PELVAs 
compared to optical low vision aids for patients with visual impairment who attended 
the LVSW in the year 2011-2012, using the Manchester Low Vision Questionnaire 
(MLVQ). 
  
The MLVQ is a validated tool that measures the use of low vision aids. It consists of two 
parts (a total of 20 short questions) (Harper et al., 1999). The first part evaluates the 
purpose of using low vision aids for a group of tasks (18 tasks) such as reading 
newspapers, sewing, knitting, watching TV etc. To evaluate and to rate the usefulness 
of low vision aids for a specific visual task, a score from 1 to 4 is used (1 = not at all 
helpful, 2 = slightly helpful, 3 = moderately helpful, 4 = extremely helpful).  The second 
part is more specific for reading tasks and includes 2 questions; the first question 
evaluates the frequency of reading with low vision aids and the second question 
evaluates the duration of reading that can be achieved with low vision aids at any one 
time. Items of the MLVQ are included in Appendix (II). In this study we excluded tasks 
related to distance vision (watching TV, reading street signs, being on a trip) because we 
were interested in evaluating the near vision tasks such as reading for which PELVAs are 
used. We included tasks related to near vision (15), and we used the second part of the 
MLVQ twice; firstly to evaluate reading frequency and duration using PELVAs, and 
secondly to evaluate reading frequency and duration using optical low vision aids.  
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6.2.1. Ethics  
All study protocols, invitation letters, patient information sheets, and consent forms 
were approved by the School of Optometry and Vision Sciences Ethical Committee 
(Project no. 1351 4th July 2014) (Appendix III). The study was registered at Cardiff and 
Vale University Health Board as a Service Evaluation (27th June 2013) (Appendix III).  
 
6.2.2. Recruitment 
Records for those patients who attended the LVSW in the year 2011/2012 who 
consented to be contacted for research/ audit purposes were selected at random by the 
manager of the LVSW. The patients were sent an invitation to participate in this study. 
A total of 543 invitations were sent (279 invitations for patients who were prescribed a 
PELVA and 264 for those not prescribed a PELVA) by the LVSW by post. There was more 
consent received initially from patients who used optical low vision aids. Therefore in 
order to achieve almost equal number of participants of those who used PELVAs and 
those who used optical low vision aids, a reminder letter was sent by the LVSW to 159 
patients who had PELVAs (100 after 2 months, and 59 after 3 months of sending the 
initial invitations). Patients who consented to participate in the study were then 
telephoned in order to arrange a phone interview. Details of patients’ invitations and 
responses are included in the results section in this chapter. 
 
6.2.3. Phone interview 
Patients were interviewed by phone using 20 questions/ items (15 near vision tasks, and 
1 question about reading frequency using PELVAs, 1 question about reading duration 
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using PELVAs, 1 question about reading frequency using optical low vision aids, 1 
question about reading duration using optical low vision aids, and 1 question about 
types of low vision aids used by patients) taken from the MLVQ (Figure 6.1). Items/ 
questions related to distance vision of the original MLVQ were excluded. The original 
MLVQ is shown in Appendix II.  
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PARTICIPANT ID/ NAME:   --------------------------------------          TIME & DATE:           ------------------------------------ 
CALL DURATION:                 ---------------------------------                  PHONE NUMBER:  ------------------------------------- 
 
Appointment/ interview: 
Good AM/PM, I am ……………… calling from Cardiff University regarding LVSW service evaluation. We received 
your response and we appreciate your consent to participate in our study. The study is about evaluating 
magnifiers. The interview will take about 15 minutes; is this a good time for you or should I call you later?  
 
Outlines of the questionnaire: 
Firstly I would like to ask you, what type of magnifiers do you use? Is it an electronic or optical magnifier or do 
you use both? 
Magnifier  Comments 
Optical   
Electronic   
Others   
 
 Part I (The use and satisfaction of devices): 
 This part includes 15 short questions regarding the purpose of use and rating the satisfaction of devices.  
 
PART I. During the last 6 weeks, have you (15 tasks) --- (Task)--- ? (Answer yes/no)  If  yes:  
How helpful you found PELVA/ Optical device? (Answer: Extremely/  Moderately/ Slightly/ or not at all helpful) 
 Task YES 
PELV
A 
Rating YES 
OPTICA
L 
Rating NONE Comment
s 
1 Read ordinary print  books or newsprint/ 
magazines/ TV times 
 1/ 2/ 3/ 4  1/ 2/ 3/ 4   
2 Read large print books, large print 
newspapers, or newspaper headlines 
 1/ 2/ 3/ 4  1/ 2/ 3/ 4   
3 Read letters/ cards/ bank statements/ 
other correspondence 
 1/ 2/ 3/ 4  1/ 2/ 3/ 4   
4 Read your own writing  1/ 2/ 3/ 4  1/ 2/ 3/ 4   
5 Read instructions on packets, tins, 
bottles, medicines, etc. 
 1/ 2/ 3/ 4  1/ 2/ 3/ 4   
6 Read shop prices/ labels/ tickets  1/ 2/ 3/ 4  1/ 2/ 3/ 4   
7 Read the markings on dials—e.g., on the 
cooker, radio, hi-fi, washing machine, 
etc. 
 1/ 2/ 3/ 4  1/ 2/ 3/ 4   
8 Read the telephone directory to check 
numbers 
 1/ 2/ 3/ 4  1/ 2/ 3/ 4   
9 Read the time on your watch  1/ 2/ 3/ 4  1/ 2/ 3/ 4   
10 Filled in forms, cheques, cards, etc.  1/ 2/ 3/ 4  1/ 2/ 3/ 4   
11 Signed your own name  1/ 2/ 3/ 4  1/ 2/ 3/ 4   
12 Written your own letters  1/ 2/ 3/ 4  1/ 2/ 3/ 4   
13 Identified money  1/ 2/ 3/ 4  1/ 2/ 3/ 4   
14 Sewed/ knitted/ or mended   1/ 2/ 3/ 4  1/ 2/ 3/ 4   
15 Done a special hobby  1/ 2/ 3/ 4  1/ 2/ 3/ 4   
 
  
Part II: How often and how long you use your magnifier for reading? 
1.  How often do you use your optical magnifier for reading? 
Several times a day/ Once each day/ A few times each week/ Once each week/ Rarely/ Never 
2. How often do you use your PELVA for reading? 
Several times a day/ Once each day/ A few times each week/  Once each week/ Rarely/ Never 
3.  How long can your optical magnifier be used for reading at any one time? 
< 1 min/ 1-5 mins/ 6-10 mins/ 11-30 mins/ > 30 mins 
4.  How long can your PELVA be used for reading at any one time? 
< 1 min/ 1-5 mins/ 6-10 mins/ 11-30 mins/ > 30 mins 
 
** Personal responses from patients e.g. why they experienced or found this, how this can be improved, etc.? 
 
Figure 6.1: The interview form, questions taken from the MLVQ (Harper et al., 1999).  
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6.3. Results  
6.3.1. Invitations and response rate  
A total of 543 invitations were sent to patients (279 patients who were prescribed a 
PELVA and 264 patients who were not prescribed a PELVA). There were 113 replies 
returned; and 19 were unable to participate (2 had passed away, 4 were in hospital, 6 
had changed their addresses, 3 had hearing difficulty and could not arrange someone to 
assist them during the interview, and 4 envelopes were returned with no reply or 
comments or consent). In total, 94 of 543 (17.3%) patients were recruited to take part 
in the study. It was not possible to reach 6 of those that initially consented to take part 
by phone i.e. sample loss of 6 out of 95 (6.4%). Therefore, 88 out of 94 (93.6%) were 
interviewed (Figure 6.2). This was a pilot study, so there was no sample power 
calculation.  
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Figure 6.2: Patients recruitment and participation.  
Data set of  the LVSW 2011/2012 
N=6,668
543 randomly selected and invited
200 reminders were sent to acheive 
equal numbers of PELVAs and 
optical low vision aids users
113 replies returned
94 consented 
6 could not be 
reach on their 
telephone
88 
interviewed 
19 not consented 
2 passed away
4 in-hospital
6 changed address
3 had hearing 
difficulty and  
could not arrange 
one to help 
4 returned with no 
reply  or consent
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6.3.2. Low vision aids used  
A total of 88 patients were interviewed.  Patients used different types of low vision aids 
including PELVAs and optical low vision aids. Some patients used more than one low 
vision aid for example, a PELVA and optical low vision aids.  
 
PELVAs and optical low vision aids: 
There were 1) 51.1% (45 of 88) patients used a PELVA, 2) 81.8% (72 of 88) patients used 
optical low vision aids, and 3) 33% (29 of 88) patients used PELVAs and optical low vision 
aids. The use of PELVAs and optical low vision aids is shown in Figure 6.3.  
 
 
Figure 6.3: The use of PELVA and optical low vision aids, [n= 88]. Some patients used 
‘‘other low vision aids’’ along with PELVAs and/or optical low vision aids.  
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Patients who used optical low vision aids (n=72) used a variety of optical low vision aids. 
These include hand-held magnifiers 87.7% (63), stand magnifiers 27.8% (20), jewellers 
eye glasses (magnifiers clipped to spectacle lenses, they are used by jewellers and for 
watch repair and provide up to 20X magnification) 6.9% (5), and spectacle mounted 
telescopes 2.8% (2). Some patients 23.6% (17) used more than one optical magnifier. 
The distribution of the optical low vision aids used is shown in Figure 6.4.  
 
 
Figure 6.4: The distribution of the use of different types of optical low vision aids used 
(n=72) (some patients used more than one optical low vision aids e.g. hand-held and 
stand magnifier).  
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Other low vision aids (i.e. non-optical, substitution and electronic (excluding PELVAs) 
low vision aids):   
The term ‘other low vision aids’ refers to non-optical, substitution and electronic 
(excluding PELVAs) low vision aids. Of the total patients in this study [n=88], 42% (37) 
used ‘other low vision aids’: 43% (16) were optical low vision aid users, 19% (7) were 
PELVAs users, and 38% (14) were PELVAs and optical low vision aids users  (Chi squared, 
p < 0.001). The distribution of the use of ‘other low vision aids’ is shown in Figure 6.5.  
 
 
Figure 6.5: The distribution of patients (PELVA users and/ or optical low vision aid 
users) who used ‘other low vision aids’ along with PELVA and / or optical low vision 
aids (n=37).  
 
The use of non-optical devices, sight substitution devices, and electronic low vision aids 
(excluding PELVAs) is shown in Table 6.1.  
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Other low vision aids Percentage (number) 
Non-optical devices Appropriate lighting 10.8% (4) 
Pen 10.8% (4) 
Large print telephone directory 5.4% (2) 
Large print text 2.7% (1) 
Sight substitution devices Talking book 8.1% (3) 
Talking watch 5.4% (2) 
Electronic low vision aids 
(except PELVAs) 
CCTV 43.2% (16) 
Computer 16.2% (6) 
Electronic mouse magnifier 8.1% (3) 
Electronic book 5.4% (2) 
E-reader 5.4% (2) 
 
Table 6.1: The distribution of ‘other low vision aids’ by 37 patients. Some patients used 
more than one aid/ device.  
 
 
Patients who used a PELVA also used appropriate lighting and CCTVs. Patients who used 
optical low vision aids also used appropriate lighting, CCTVs, computers, e-readers, 
electronic books, large telephone directory, large print text, and talking books. Patients 
who used both a PELVA and optical low vision aids used also talking watches, computers, 
CCTVs, an electronic mouse magnifier (an electronic mouse magnifier has a magnifying 
camera incorporated inside the computer mouse which can be connected to a TV/ 
monitor), and a pen.  
 
6.3.3. The use and rating of using low vision aids for tasks performed 
Fifteen questions from the MLVQ asked about what low vision aids were used for and 
how helpful they were (rated from 1 to 4: 1= not helpful, 2= slightly helpful, 3= 
moderately helpful, and 4= extremely helpful).   The use and rating of optical low vision 
aids and PELVAs according to tasks performed are shown in Table 6.2 and Figure 6.6. 
Overall, it is clear that patients who were prescribed optical low vision aids (n=72) used 
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them for all of the 15 tasks in this study. Patients who were prescribed PELVAs (n=45) 
used them for 12 out of the15 tasks. They did not use PELVAs for ‘reading the time on 
their watch’, ‘writing their own letters’, or ‘sewing’, ‘knitting’, or ‘mending’.  
 
6.3.3.1. Tasks performed using low vision aids (PELVAs compared to optical low vision 
aids) 
Compared to  patients who used optical low vision aids, a larger proportion of those who 
used PELVAs used them to: 1) read shop prices/ labels/ or tickets, 2) read instructions 
on packets, tins, bottles, or medicines, 3)  sign their own name, 4) do a special hobby 
(Table 6.2). Chi squared test, p < 0.05 for each of the above cases. 
 
Compared to patients who used PELVAs, a larger proportion of those who used optical 
low vision aids used them to: 1) read ordinary print books, newsprint, or magazines, 2) 
read large print books, large print newspapers, or newspaper headlines, 3) read letters, 
cards, bank statements, or other correspondence, 4) read time on their watch, 5) fill in 
forms, cheques, or cards, etc., 6) write their own letters, 7) identify money, 8) read a 
telephone directory, 9) to read marking on dials, 10) sewing, knitting or mending (Table 
6.2). Chi squared test, p < 0.05 for each of the above cases.  
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Task 
Frequency of use % (Number) of patients who 
used them for named tasks) 
PELVAs 
(n= 45) 
Optical low 
vision aids 
(n= 72) 
p-value 
1. Reading ordinary print books, newsprint, 
magazines, TV times 
37.8% (17) 58.3% (42) <0.001* 
2. Reading large print books, large print 
newspapers, or newspaper headlines 
51.1% (23) 58.3% (42) <0.001* 
3. Reading letters, cards, bank statements/other 
correspondence 
31.1% (14) 58.3% (42) <0.001* 
4. Reading their own writing 6.7% (3) 6.9% (5) 0.871 
5. Reading instructions on packets, tins, bottles, 
medicines, etc 
57.8% (26) 48.6% (35) 0.032* 
6. Reading shop prices, labels, or tickets 82.2% (37) 37.5% (27) 0.028* 
7. Reading markings on dials—eg, on the cooker, 
radio, hi-fi, washing machine, etc 
6.7% (3) 13.9% (10) <0.001* 
8. Reading telephone directory to check numbers 11.1% (5) 25% (18) <0.001* 
9. Reading the time on their watch 0 13.9% 
(10) 
<0.001* 
10. Filling in forms, cheques, cards, etc 24.4% (11) 33.3% (24) 0.006* 
11. Signing their own name 31.1% (14) 29.2% (21) 0.016* 
12. Writting their own letters 0 15.3% (11) <0.001* 
13. Identifying money 22.2% (10) 26.4% (19) <0.001* 
14. Sewing, knitting,  or mending 0 9.7% (7) <0.001* 
15. Doing a special hobby 20% (9) 15.3% (11) <0.001* 
* p-value is significant (Chi-squared test, p-value < 0.05) 
 
Table 6.2: The use of PELVAs (n=45) and optical low vision aids (n=72) for each of the 
15 tasks performed.  
 
 
6.3.3.2. Rating of tasks performed using PELVAs compared to optical low vision aids  
Overall, patients who used PELVAs (n=45) described them as extremely helpful for the 
tasks they used them for; the median for PELVAs rating was 4. Patients who used optical 
low vision aids (n=72) described them as moderately helpful; the median for optical low 
vision rating was 3 (Mann Whitney U, P < 0.001). Rating of PELVAs compared to optical 
low vision aids for each individual task is show in Figure 6.6. 
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PELVAs (n=45) were significantly more helpful than optical low vision aids (n=72) for:  1) 
reading large print books, large print newspaper or newspaper headlines, 2) reading 
letters, cards, bank statements, 3) reading shop prices, labels, or tickets, 4) filling in 
forms, cheques, or cards, 5) signing their own name, 6) identifying money (Figure 6.6). 
Mann- Whitney U test, p < 0.001 for each of the above cases.  
 
Optical low vision aids (n=72) were significantly more helpful than PELVAs (n=45) for: 1) 
reading ordinary print books, newspapers, or magazines, 2) reading instructions on 
packets, tins, bottles, medicines, etc., 3) doing a special hobby (Figure 6.6). Mann 
Whitney U test, p < 0.001 for each of the above cases.  
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Figure 6.6: Rating of each individual task by patients who used PELVAs (n=45) and 
patients who used optical low vision aids (n=72) [1= not helpful, 2= slightly helpful, 3= 
moderately helpful, 4= extremely helpful]. Patients prescribed PELVAs did not use 
them to ‘sew/knit/mend’, ‘write their own letters’ or ‘read time on their watch’ 
therefore rating is not shown for PELVA users for these tasks.   
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There were no significant differences (Mann Whitney U test, p > 0.05) between PELVAs 
and optical low vision aids rating for: 1) reading their own writing, 2) reading marking 
on dials, 3) reading telephone directory. 
 
6.3.4. Reading frequency using low vision aids  
Reading frequency (i.e. how often a patient used PELVAs/or optical low vision aids for 
reading i.e. Part II of the MLVQ) was evaluated.  Optical low vision aids were used 
significantly more frequently for reading compared to PELVAs (Mann Whitney U, p < 
0.001). The median frequency of reading using optical low vision aids was ‘several times 
each day’ (IQR from ‘once each day’ to ‘several times each day’) i.e. patients who used 
optical low vision aids used them ‘several times each day’ to read.  The median 
frequency of reading using PELVAs was ‘once each day’ (IQR from ‘few times each week’ 
to ‘several times each day’) i.e. patients who used PELVAs used them once each day to 
read (Mann Whitney U, p < 0.001). Reading frequency using PELVAs compared to optical 
low vision aids is shown in Figure 6.7. 
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Figure 6.7: The frequency of reading of patients who used PELVAs (n=45) and patients 
who used optical low vision aids (n=72) (How often do you use your PELVA/ optical 
low vision aid for reading?, i.e. Part II of the MLVQ).   
 
6.3.5. Reading duration using low vision aids 
Reading duration (i.e. how long a patient used PELVAs/ optical low vision aids at any one 
time for reading i.e. Part II of the MLVQ) was evaluated.  PELVAs were used more for a 
longer reading duration (Mann Whitney U, p < 0.001). The median duration of reading 
using PELVA was ‘up to 30 minutes’ (IQR from ‘up to 10 minutes’ to ‘more than 30 
minutes’), i.e. on average patients prescribed a PELVA used it for up to 30 minutes at 
any one time for reading.  The median duration of reading using Optical low vision aids 
was ‘up to 5 minutes’ (IQR from ‘up to 5 minutes’ to ‘up to 30 minutes’), i.e. on average 
patients prescribed optical low vision aids used them for up to 5 minutes at any one time 
for reading. There was a significant difference in reading duration of patients who used 
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PELVAs compared to patients who used optical low vision aids (Mann Whitney U, p < 
0.001). Reading duration using PELVAs compared to optical low vision aids is shown in 
Figure 6.8. 
 
 
Figure 6.8: Duration of reading of patients who used PELVAs (n=45) and patients who 
used optical low vision aids (n=72) (How long can your PELVA/ optical low vision aid 
be used for reading at any one time?, i.e. Part II MLVQ). 
 
 
6.3.6. The use of PELVAs by patients who used both PELVAs and optical low vision 
aids  
 
The use and rating was compared for patients who used both PELVAs and optical low 
vision aids (n=29). Patients used PELVAs, but not optical low vision aids for all of the 
following tasks: doing a special hobby, identifying money, signing their own names, and 
reading markings on dials (Table 6.3).   
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The median rating of PELVAs (4 i.e. extremely helpful) was significantly higher than 
optical low vision aids (3 i.e. moderately helpful) for tasks performed (Wilcoxon signed 
rank test, p < 0.001).  
 
It seems that when patients had the choice whether to use PELVAs or optical low vision 
aids for a number of near vision tasks; they tend to use PELVAs rather than optical low 
vision aids in order to read shop prices, labels, or tickets (McNemar’s, p = 0.028), to read 
instructions on packets, tins, bottles etc. (McNemar’s, p = 0.032), to sign their own name 
(McNemar’s, p = < 0.001), and to do a special hobby (McNemar’s, p =  0.004) (Table 6.3). 
 
In comparison, significantly more patients used optical low vision aids compared to 
PELVAs in order to read large print books (McNemar’s, p < 0.001), and to read letters, 
cards, bank statements, etc. (McNemar’s, p < 0.001) (Table 6.3). 
 
Among 29 patients who used both PELVAs and optical low vision aids, the rating of 
PELVAs (median = 4) was significantly higher for reading shop prices, labels or tickets 
compared to optical low vision aids (median = 1) (Wilcoxon signed rank test, p < 0.001). 
Whereas, the rating of optical low vision aids (median = 4) was significantly higher than 
PELVAs rating (median = 3) for reading instructions on packets, tins, bottles, or 
medicines (Wilcoxon signed rank test, p < 0.001). The use and rating of using both 
PELVAs and optical low vision aids by 29 patients is shown in Table 6.3.  
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Task 
Frequency of use % (Number) of 
patients who used them for named 
tasks) 
Median rating 
PELVAs 
(n=29) 
Optical low 
vision aids 
(n=29) 
p-value PELVAs 
(n=29) 
Optical low 
vision aids 
(n=29) 
p-value 
 
1. Reading ordinary print books, newsprint, magazines, TV times 41.4% 
(12) 
41.4% (12) 1.000 3 3 0.564 
2. Reading large print books, large print newspapers, or newspaper headlines 31% (9) 41.4% (12) <0.001* 4 4 1.000 
3. Reading letters, cards, bank statements, other correspondence 31% (9) 41.4% (12) <0.001* 4 4 0.083 
4. Reading their own writing 0 0 - NE NE - 
5. Reading instructions on packets, tins, bottles, medicines, etc 41.4% 
(12) 
10.3% (3) 0.032* 3 4 <0.001** 
6. Reading shop prices, label, or tickets 72.4% 
(21) 
31% (9) 0.028* 4 1 <0.001** 
7. Reading the markings on dials—eg, on the cooker, radio, hi-fi, washing machine, etc 10.3% (3) 0 0.250 4 NE 
 
- 
8. Reading the telephone directory to check numbers 0 0 - NE NE 
 
- 
9. Reading the time on their watch 0 0 - NE NE 
 
 
10. Filling in forms, cheques, cards, etc 0 0 - NE NE - 
11. Signing their own name 41.4% 
(12) 
0 <0.001* 4 NE - 
12. Writting their own letters 0 0 - NE NE - 
13. Identifying money 10.3% (3) 0 0.250 4 NE - 
14. Sewing, knitting/ or mending 0 0 - NE 
 
NE - 
15. Doing a special hobby 31% (9) 0 0.004* 3 NE - 
Rating:  4= extremely helpful, 3= moderately helpful, 2= slightly helpful, 1 = not helpful 
0 = patients did not use the low vision aid for the task performed 
* p-value is significant (McNemar’s test, p < 0.05) 
** p-value is significant (Wilcoxon signed rank test, p < 0.05) 
–  not calculated 
NE: rating of low vision aids was not evaluated (NE) as patients did not used low vision aids (PELVAs and/ or optical) for these tasks 
 
Table 6.3: The use and median rating of PELVAs compared to optical low vision aids, by 29 patients who used both PELVAs and optical low vision 
aids.  
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The frequency of reading using PELVAs compared to optical low vision aids by 29 
patients who used both devices is shown in Figure 6.9. In terms of reading frequency 
(i.e. how often a patient used PELVAs/ optical low vision aids for reading i.e. Part II of 
the MLVQ),  patients tended to use optical low vision aids more frequently if they had 
both PELVAs and optical low vision aids. The median frequency for using optical low 
vision aids was ‘several times each day’ (IQR from ‘once each day’ to ‘several times each 
day’) compared to median frequency of ‘once each day’ for using PELVAs (IQR from 
‘once each day’ to ‘several times each day’) (Wilcoxon signed rank test, p < 0.001).  
 
 
Figure 6.9: The frequency of reading of patients (n=29) who used both PELVAs and 
optical low vision aids (How often do you use your PELVA/ optical low vision aid for 
reading?, i.e. Part II of the MLVQ).   
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The duration of reading (i.e. how long a patient used PELVAs/ optical low vision aids at 
any one time for reading i.e. Part II of the MLVQ) using PELVAs compared to optical low 
vision aids by 29 patients who used both devices is shown in Figure 6.10 and Table 6.4. 
Patients used PELVAs to read for a longer duration compared to optical low vision aids.  
Median reading duration using PELVAs at any one time for reading was more than 30 
minutes (IQR from 'up to 30 minutes' to 'more than 30 minutes') compared to median 
reading duration of up to 30 minutes (IQR from 'less than one minute' to 'more than 30 
minutes') for using optical low vision aids at any one time for reading (Wilcoxon signed 
rank test, p = 0.01). For example, 31% (9) of 29 used PELVAs to read for duration of more 
than 30 minutes compared to 17.2% (5) of 29 used optical low vision aids to read for the 
same duration.  
 
 
Figure 6.10: Reading duration of patients (n=29) who used both PELVAs and optical 
low vision aids (How long can your PELVA/ optical low vision aid be used for reading 
at any one time?, i.e. Part II MLVQ). 
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Table 6.4:  Reading duration of patients (n=29) who used both PELVAs and optical low 
vision aids (How long can your PELVA/ optical low vision aid be used for reading at any 
one time?, i.e. Part II MLVQ). 
 
  
Reading duration PELVAs 
Percentage (number) 
Optical low vision aids 
Percentage (number) 
Not used for reading 58.6% (17) 58.6% (17)  
Less than 1 minute 0 10.3% (3)  
Up to 5 minutes 0 0 
Up to 10 minutes 0 6.9% (2)  
Up to 30 minutes 10.3% (3) 6.9% (2)  
More than 30 minutes 31.0% (9) 17.2% (5)   
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6.4. Discussion 
This is an evaluation of the use and self-reported satisfaction of PELVAs and optical low 
vision aids for patients with a visual impairment attending the LVSW in the year 
2011/2012, using the MLVQ.  
 
Out of 88 patients who were interviewed, 18.2% had PELVAs but not optical low vision 
aids, 48.9% had optical low vision aids but not PELVAs, and 33% had both PELVAs and 
optical low vision aids.   
 
The majority of patients used their low vision aids daily and many used them several 
times a day. However, quite a large proportion of patients with PELVAs were not using 
them, e.g. 37.8% (17 out of 45) did not use their PELVAs for reading (Figure 6.9). 
Goodrich et al. (2006) found that there was a significant improvement in reading speed 
after the prescription of optical or electrical low vision aids with training sessions. No 
training was provided as part of the LVSW, and patients were just given basic 
instructions. Goodrich et al. (1976) also found that some PELVAs have technical faults 
after 2 years and so this may be a factor. Further investigation into why people have 
stopped using PELVAs is needed and the devices repaired or recovered as these are 
expensive devices, which could be loaned to other patients. Harper et al. (1999) 
reported that 81-90% of patients with visual impairment were prescribed at least one 
low vision aid, although it is known that many of them discontinue use after prescription 
and so follow-up is important. 
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Harper et al. (1999) found that patients that had optical devices often had more than 
one device and suggested this was because they were task specific; therefore patients 
would need more than one device to accomplish daily living tasks. This study found that 
most people 64.4% (29 out of 45) with PELVAs also had optical low vision aids. Therefore, 
although a PELVA can be used to perform a larger number of tasks because a range of 
magnifications is available, many patients use optical devices as well. This may be due 
to preference for a task or because of practical issues such as where they are positioned 
in their home, or delay in turning a PELVA on or charging it up.  
 
Goodrich et al. (1980) reported that patients used optical aids in order to find a specific 
item and CCTVs for detailed viewing. They found that optical low vision aids were used 
for 'spotting' tasks or in cases where portability is important (Goodrich et al., 1980). In 
this study the distinction was not so clear and patients used PELVAs and optical low 
vision aids for spotting tasks such as reading shop prices, labels or tickets; reading 
instructions on packets, tins, or medicines; signing their own name; and doing a special 
hobby. However for these tasks, PELVAs were significantly more frequently used (i.e. 
when they had both and the option many chose the PELVA for these tasks).  This might 
be because PELVAs are more portable than CCTVs and so have many of the advantages 
of optical low vision aids. PELVAs also provide contrast enhancing properties that optical 
devices don not and so would be useful for poor contrast tasks. However, there was not 
a clear preference for PELVAs and so other factors must be having an influence of their 
choice of device. It may be that patients who choose a PELVA for this type of task have 
reduced contrast sensitivity.  
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On the other hand, a greater percentage of people also chose to use optical devices 
compared to PELVAs for sustained reading tasks such as reading ordinary print books; 
reading large print books; and reading letters, cards and bank statements. Interestingly, 
patients used PELVAs less frequently but for a longer duration for reading compared to 
optical low vision aids. Optical low vision aids were also rated as more helpful than 
PELVAs for reading ordinary print books; reading instructions on packets; and doing a 
special hobby (Mann Whitney U, p < 0.05).  
 
Although optical low vision aids were rated as moderately helpful (the median rating of 
optical low vision aids for all tasks performed was 3) and can be used for different tasks 
as explained earlier in this study, as the magnification of optical low vision aids increases; 
aberrations increase and the field of view constricts, also optical low vision aids do not 
enhance contrast manipulation (Culham et al., 2004). This might explain why patients in 
this study tended to rate PELVAs higher for most tasks performed and to use them for a 
longer reading duration. Culham et al. (2009) reported that comfort of using low vision 
aids was important but magnification was predictive of rating low vision aids. 
 
Goodrich et al. (1980) found that there was no difference in reading speed between 
CCTVs and optical low vision aids, but reading duration was three times longer when 
patients used CCTVs compared to optical low vision aids. Goodrich and Kirby (2001) a 
higher reading speed and a longer reading duration were found using both of hand-held 
and stand-mounted CCTVs compared to optical low vision aids, and no differences were 
  
245 
 
found between both types of CCTVs.  Peterson et al. (2003) found that electronic vision 
enhancement systems improved reading speed and duration. Reading speed and 
duration were higher using stand electronic vision enhancement systems compared to 
optical low vision aids and head-mounted devices (Peterson et al., 2003). Peterson et al. 
(2003) found that map tracking and identification of medicine labels was faster when 
patients used optical low vision aids and stand electronic vision enhancement system. 
Patients found that locating a column task was faster using optical low vision aids 
compared to electronic vision enhancement systems. (Peterson et al., 2003). Electronic 
vision enhancement systems were described as helpful by patients in terms of improving 
reading speed and acuity. However, electronic vision enhancement systems with a head-
mounted device had a rating similar to optical magnifier for tasks including tracking from 
one column of print to the next, following a route on a map and locating a specific 
feature, and identifying specific information such as medication type (Peterson et al., 
2003).  
 
In this study 33% of patients had both PELVAs and optical low vision aids. Overall for all 
tasks performed, patients who had both PELVAs and optical low vision aids (n=29) found 
them useful. However, PELVAs were found to be slightly more helpful than optical low 
vision aids for tasks performed (median rating of PELVAs was ‘extremely helpful’, 
compared to ‘moderately helpful’ for optical low vision aids (Wilcoxon signed rank test, 
p < 0.001). 
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Of those interviewed who used optical low vision aids (n=72), the majority used hand-
held magnifiers (87.7%), the second most frequently used aids were stand magnifiers 
(27.8%), jewellers eye glasses (6.9%), and spectacle mounted devices (2.8%). Some 
patients (23.6%) used more than one optical low vision aid. Crossland and Silver (2005) 
found that patients were prescribed at least one low vision aid; hand-held magnifiers 
47%, spectacle mounted devices 2%, high reading additions 15%, stand magnifiers 34%, 
other low vision aids 2%. They also reported that illuminated magnifiers accounted for 
39% of hand-held magnifiers, and 40% off stand magnifiers. Electronic low vision aids 
were not included in the Crossland and Silver (2005) study as it was only available for 
demonstration. Our findings agree with Crossland and Silver (2005) in that the majority 
of the prescribed optical low vision aids were hand-held magnifiers. However, they 
found a larger proportion of patients who were prescribed optical magnifiers (84%) 
compared to our results (71%); as PELVAs and electronic low vision aids were not 
included in their study. In addition, this study sought to ensure a larger number of 
people with PELVAs were included and so the sample is not representative of the service 
users. 
 
In our study only 23.6% (16.7% illuminated hand-held, and 6.9% illuminated stand) of 
patients used illuminated optical low vision aids. This contradict the ere dispensed in the 
LVSW were illuminated, it also did not agree with the larger proportion of illuminated 
hand-held (39%) and illuminated stand (40%) magnifiers that were prescribed in the 
Crossland and Silver study. This might be because of the way the questions were asked. 
In the Manchester Low Vision Questionnaire there was not an option to choose an 
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illuminated hand magnifier hence people may have described an illuminated hand 
magnifier as a hand magnifier or an illuminated magnifier. Most illuminated magnifiers 
are hand or stand magnifiers; hence including these as options in the MLVQ is suggested. 
Also, our study was a pilot study which might not be representative of all patients with 
visual impairment.  
 
Out of 88 patients interviewed, there were 42% who used ‘other low vision aids’ 
including non-optical, substitution and electronic low vision aids along with PELVAs and/ 
optical low vision aids. The majority of patients who used ‘other low vision aids’ were 
optical low vision aids users (43%) compared to PELVAs users (19%) (Chi squared, p < 
0.001). This agree with the fact that optical low vision aid alone might not be appropriate 
for many tasks, and a patient might need more low vision aids to accomplish several 
tasks. Other low vision aids used by patients in this study included CCTVs, computers, 
appropriate lighting, pen, mouse, talking books, talking watches, large print telephone 
directory, electronic books, e-readers, and large print texts. Some patients used more 
than one of the ‘other low vision aids’. In our study, there were 16 of patients who used 
CCTVs; this is equivalent to 18.2% (n=88). This was lower than Goodrich et al. (1980) 
findings. Goodrich et al. (1980) found that 50% (48 of 96) of US veterans who used CCTVs 
used also optical low vision aids. It might be because patients in our study used different 
types of electronic low vision aids including PELVAs, computers, e-readers, e-books, etc. 
In addition veterans are often younger and more likely to be male than the low vision 
population in Wales.  
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Although the results may not be representative of all patients with a visual impairment 
using the LVSW, this study was important.  It compared the use and rating of both 
PELVAs and optical low vision aids from the users' perspective for a number of near 
vision tasks. Patients' feedback on the prescribed low vision aids was important in order 
to update clinicians on what they are used for. Experience and trying low vision aids is 
important in order to have a perspective of the practicability and limitations of existing 
low vision aids for a range of tasks and provide more realistic expectation of what can 
be achieved from using a particular low vision aid.  
 
The results haven’t shown any clear trends of use of PELVAs or optical devices and so it 
is important for clinicians to encourage patients to try using PELVAs and to discuss with 
them a range of tasks including reading books or newspapers, reading shop prices, 
instructions etc. that proved in this study to be helpful.   
 
The limitations of this study included the low recruitment rate which might be explained 
by: a) the cohort of study were elderly and many of them have other disabilities such as 
hearing loss or mobility restrictions besides visual impairment, b) lack of somebody to 
help them to arrange the interview, c) worsening of their vision, d) discontinuation of 
low vision aids usage, or e) the form of the MLVQ that was used in the interview 
excluded three tasks related to distance vision, therefore it might not have the same 
validity as if the original MLVQ was used. The prescribing for low vision aids was initially 
made in the year 2011/2012. This study was conducted in 2014; many patients could 
have discontinued the use of prescribed devices either because of change of vision, 
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limitations of prescribed aids to help them perform required tasks, or ergonomics of 
some devices. Patients' preference of using a low vision aid might be affected by several 
factors such as performance of visual aids including magnification and image quality, 
ergonomics, cost, size, weight, portability, ease of use, age of users, ocular conditions, 
or the onset of visual impairment (Culham et al., 2009). Those factors were not 
evaluated in this study and would be better explored using qualitative techniques such 
as a semi structured interview. 
 
Phone interviews can be less personal and more anonymous. However, they may be 
more convenient for elderly patients with visual impairment rather than conducting a 
face-to-face interview, because it could be difficult for most of them to arrange a visit 
to the clinic to be interviewed.   A phone interview has an advantage that any questions 
can be explained when necessary which is not possible if patients were asked to fill a 
questionnaire and return it in the post. However, some patients had hearing difficulty 
which might have prevented participating in phone-interviews. Semi-structured 
interviews may have been more valid, but they are time consuming, expensive, and they 
can be difficult to generalize (Opdenakker, 2006).   
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6.5. Conclusion 
A larger proportion of patients used optical low vision aids compared to PELVAs and a 
third of the patients used both PELVAs and optical low vision aids. Some patients used 
other low vision aids. PELVAs were used more frequently for reading shop prices, 
reading instructions on packets, signing their own names, and doing a special hobby 
compared to optical devices. PELVAs were significantly more helpful than optical low 
vision aids for the near vision tasks performed. PELVAs were used less frequently but for 
a longer duration when reading compared to optical low vision aids. Clinicians are 
encouraged to demonstrate the benefits of using these devices, and the group of tasks 
that can be performed using a PELVA.  Further investigations of the factors that affect 
patient preference for using low vision aids for each task should be explored. Also, the 
cost effectiveness of PELVAs and optical low vision aids should be compared.  
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CHAPTER 7: Investigation of the factors (visual functions and/ or devices 
parameters) that affect reading performance of people with simulated 
visual impairment using low vision aids (pocket and portable electronic 
low vision aids, and optical low vision aids) 
 
7.1. Introduction 
Reading difficulty is the most common complaint in people with visual impairment 
(Rubin, 2013). Rubin (2013) found that reading difficulty was the reason for 60% of 
patients to be referred to low vision practices. Literature available about the 
effectiveness of low vision aids has been focused on improvement in reading ability or 
speed by comparing the reading ability and/ or performance (e.g. critical print size, 
reading acuity and reading speed) with and without visual aids (Rubin, 2013).  
 
To our knowledge, no one has evaluated factors affecting reading performance using 
PELVAs, and no one has compared PELVAs to optical low vision aids in terms of reading 
performance. In Chapter 6, we reported that patients with visual impairment used 
PELVAs less frequently for reading, but for a longer reading duration at any one time. 
Therefore, it was important to explore factors affecting reading performance using 
PELVAs.  
 
In Chapter 4, we reported that some PELVAs significantly improved the luminance 
contrast of high and low contrast letters, and we hypothesize this will have an influence 
on reading performance. In addition, as PELVAs feature contrast enhancement and a 
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large screen compared to optical low vision aids, we hypothesize that PELVAs may 
provide a higher reading speed.  
 
The aim of this study was to investigate visual functions and/ or devices parameters that 
affect the reading performance of people with visual impairment using low vision aids 
(PELVAs and optical low vision aids).  
 
The objectives of this study were: 
1) To measure threshold near visual acuity of people with simulated visual 
impairment, using PELVAs and optical low vision aids.  
2) To measure high and low contrast visual acuities of people with simulated 
visual impairment, using PELVAs and optical low vision aids.  
3) To evaluate the field of view of people with simulated visual impairment (by 
counting the number of visible characters), using PELVAs and optical low vision 
aids.  
4) To measure the reading speed of people with simulated visual impairment, 
using both PELVAs and optical low vision aids.  
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7.2. Methods 
This pilot study aimed to investigate factors (visual functions and/ or device parameters) 
that affect reading performance of people with simulated visual impairment using low 
vision aids (PELVAs and optical devices).    
 
7.2.1. Ethics 
The study protocols, the Patient Information Sheets and Consent Forms were approved 
by the School of Optometry and Vision Sciences Ethical Committee (Project no. 1352 
24th October 2014) (Appendix IV).  
 
7.2.2. Participants 
A total of 10 normally sighted participants, aged between 20 and 30 years old were 
recruited. This age group was chosen to exclude the influence of age on reading 
performance. Participants were excluded if they had a history of abnormal ocular 
conditions, visual impairment or physical disability or limitation that could affect 
handling or use of low vision aids.  
 
7.2.3. Location 
Participants were examined in the Low Vision Clinic at the School of Optometry and 
Vision Sciences, Cardiff University. 
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7.2.4. Low vision aids used 
A PELVA (Compact+) (i.e. PELVA B in Chapters 3 and 4) with fixed magnification levels 
5X, 7.5X and 10X, and optical illuminated stand magnifiers (Eschenbach) with 
magnification 5X, 7X and 10X were used. The participants were asked to select the 
magnification level they were able to read with at the given distance (40 cm) using the 
PELVA, and the participant choose an illuminated stand magnifier themselves in the 
same way as the PELVA. The participants were advised to put the PELVA or the optical 
illuminated stand magnifier directly on the text/ chart. The accommodation was not 
controlled.  
 
7.2.4. Simulation of visual impairment 
Simulators 
Three simulator glasses were used to mimic visual impairment, these included:  
1) Moderate visual impairment simulator. This was achieved by adding plus 
lenses, to reduce participants distance visual acuity to 0.60 Log MAR. This was 
the median distance visual acuity of people who were not prescribed a PELVA 
(Chapter 5).  
2) Severe visual impairment simulator. This was achieved by adding plus lenses, 
to reduce participants distance visual acuity to 0.90 Log MAR. This was the 
median distance visual acuity of people who were prescribed a PELVA (Chapter 
5).  
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3) Reduced contrast sensitivity simulator (cortical cataract simulator). The 
contrast sensitivity reduction was achieved by using glasses with a semi-
transparent (cloudy) plastic filter.  
 
With all simulators participants’ near visual acuity was reduced.  
 
7.2.5. Clinical assessment   
Baseline (without simulators, without low vision aids)  
Baseline best corrected binocular Log MAR distance visual acuity at 2 metres, contrast 
sensitivity using Pelli-Robson chart at 1 meter, threshold near visual acuity using Bailey-
Lovie near visual acuity chart at 40 cm, and reading speed using IREST at 40 cm were 
measured for all participants. 
 
With simulators (without low vision aids) 
Binocular Log MAR distance visual acuity at 2 metres, contrast sensitivity using Pelli-
Robson chart at 1 meter, and threshold near visual acuity using Bailey-Lovie near acuity 
chart at 40 cm, high contrast Colenbrander near visual acuity at 40 cm, low contrast 
Colenbrander near visual acuity at 40 cm, and reading speed using IREST at 40 cm were 
measured with each simulator (without low vision aids, while the habitual correction 
was worn). 
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With simulators and low vision aids 
At 40 cm, threshold near visual acuity using a Bailey-Lovie near acuity chart, high and 
low contrast near visual acuity using a high and a low contrast Colenbrander chart, the 
number of visible characters seen (i.e. the edge of the PELVA screen/ or the edge of the 
optical low vision aid lens was placed at the beginning of the IREST text and participants 
were asked to count the number of characters including spaces that they were  able to 
see without moving their head), and reading speed using IREST were measured with 
both a PELVA and an illuminated stand magnifier. 
 
A fixed distance of 40 cm was chosen for all near charts for consistency because IREST 
reading chart were designed to be used at 40 cm (the distance at which most people 
read). The Bailey-Lovie near visual acuity was calculated in Log MAR for a distance of 40 
cm.  
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7.3. Results 
A total of ten normally sighted participants were tested (mean age 23.2±3.61 years, 
binocular distance visual acuity -0.30±0.00 Log MAR, contrast sensitivity 1.94±0.05, 
Bailey-Lovie near visual acuity was 0.08±0.07, reading speed 325.27±46.65 words/ 
minute). Data (age, binocular Log MAR distance visual acuity, Bailey-Lovie near visual 
acuity, high and low contrast, Colenbrander near visual acuities, reading speed, and 
number of visible characters) were normally distributed (Shapiro-Wilk test, p = 0.615). 
 
The moderate visual impairment (0.6 Log MAR distance visual acuity) was achieved by 
using plus lenses (mean +4.25 dioptres (D), range +3.75 to + 5.25). The severe visual 
impairment (0.90 Log MAR distance visual acuity) was achieved by using plus lenses 
(mean +7.50 D, range +6.00 to +9.50).  
  
Of the three magnification levels (5X, 7.5X, and 10X) of the PELVA, all participants chose 
the lowest magnification level (5X magnification), and they chose a 5X Eschenbach 
illuminated stand magnifier.   
 
It would not be appropriate to compare magnifiers with different equivalent power, 
because the 5X magnification of the PELVA is not equivalent to the 5X magnification of 
the stand magnifier.  With the fixed focus stand magnifier used in this study the lens to 
object distance was less than the focal length of the lens. The optics of the stand 
magnifier is described below.  
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The stand magnifier optics:  
The 5X Eschenbach illuminated stand magnifier was labelled by the manufacturer with 
5X magnification, and equivalent power of 20 D. In general, Eschenbach assumes an 
image to eye distance of 400 mm (Jonston 2003, Eschenbach Optik GmbH 2015).  
 
The focal length of a 20 D stand magnifier is 5 cm. For a stand magnifier the lens to 
object distance is less than the focal length of the lens and for the stand magnifier used 
in this study it was 3.6 cm. Therefore, the light leaving the stand magnifier will be 
divergent.  
 
The vergence of light reaching the stand magnifier from the text/ object (L) at a distance 
of 3.6 cm was: 
L = 1/ - stand height in metres                   (Jackson and Wolffsohn, 2007) 
L = 1/ -0.036 
L = -27.80 D. 
 
The vergence of light leaving the stand magnifier (L’) with lens power +20.00 D was: 
L’ = L + Fm                                                    (Jackson and Wolffsohn, 2007)  
L’ = -27.80 + (+20.00)                   
L’ = - 7.80 D.                                                                     
Where Fm is the dioptric power of the magnifier.  
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The image distance (I’) was: 
                     I’ = 1 / L’                                                      (Jackson and Wolffsohn, 2007) 
 I’ = 1 / -7.80                                              
 I’ = -12.80 cm.  
 
The enlargement was:  
                               = -12.80/ -3.60 
                               = 3.6X magnification. 
      
Therefore the stand magnifier labelled as 5X magnification, gave an equivalent 
magnification of 3.6X.  
 
With this, if the participant’s eye was against the stand magnifier (eye to magnifier 
distance (z) was zero), the image that was created by the stand magnifier alone would 
be at -12.8 cm in front of the eye and a 7.80 D addition/ accommodation would be 
required to neutralize the divergent light. The equivalent power (Fe) would be: 
 Fe = Fm + Fa – z * Fm * Fa                       (Jackson and Wolffsohn, 2007) 
 Fe = 20.00 + 7.80 - 0 * 20 * 7.80 
  Fe = 27.80 D.                 
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Where Fm is the magnifier power, Fa is the addition or accommodation, z is the 
magnifier to eye distance.  
   Enlargement ratio= Fe / 4                    (Jackson and Wolffsohn, 2007) 
                                                              = 27.80 / 4 
                                                              = 6.95 X. 
 
However, if the stand magnifier to the participant’s eye distance was 35 cm (40 cm eye-
to-text); the image would be positioned at: 
                    = z + I’                              (Jackson and Wolffsohn, 2007)  
                    = -35 + (-12.8)                                         
                    = -47.80 cm.                                        
 
The required accommodation/ add would be: 
                                                             = 1 / 0.478 
                                                             = 2.10 D.  
 
That means a 2.10 D would be needed to focus the divergent light on the retina. As all 
the participants are young, this would be achieved by participants’ accommodation, 
which was not controlled or measured in this study.  
 
Assuming 2.10 D of accommodation; the enlargement ratio of the accommodation 
system would be: 
  
261 
 
 
Fe = Fm + Fa – z * Fm * Fa            (Jackson and Wolffsohn, 2007) 
     = 20.00 + 2.10 – 0.35 * 20 * 2.10 
             Fe = 7.40 D.  
                    Enlargement = 7.40/ 4 
                                            = 1.85X.  
That means if participants used 2.10 D of their accommodation to focus the image on 
the retina, the accommodation would give an additional 1.85X.  
 
The accommodation/ addition cannot be greater than the divergence of light leaving the 
stand magnifier lens, or a blurred image of the text/ object would be formed on the 
retina. Participants would still accommodate. The accommodation was not controlled in 
this study.  
 
Assuming participants would not use their accommodation to focus the image and the 
required 2.10 D to focus the image was used of the +4.25 D that was added as moderate 
visual impairment simulators; with the remaining +2.15 D the participants Baily-Lovie 
near visual acuity was blurred to 0.54±0.3 Log MAR. This means the moderate visual 
impairment simulator was enough to blur near visual acuity.  
 
7.3.1. Moderate visual impairment simulator (0.60 Log MAR distance visual acuity) 
With the 0.60 Log MAR simulator, near visual acuity measured using a Bailey-Lovie near 
acuity chart significantly improved with the PELVA and the optical low vision aid; from 
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0.77±0.16 Log MAR to 0.04±0.08 using the PELVA (Paired sample t-test, p < 0.001) and 
0.54±0.30 using the optical low vision aid (Paired sample t-test, p < 0.001) (Table 7.1).  
 
 
Table 7.1: Visual assessment with moderate visual impairment simulator, with and 
without low vision aids. P-value¹ the significance of difference between the PELVA and 
without low vision aids (Paired sample t-test). P-value² the significance of difference 
between the optical low vision aid and without low vision aids (Paired sample t-test). 
* The difference is significant (p-value < 0.05). NM = not measurable.  
 
 
 
High contrast near visual acuity using a Colenbrander chart significantly improved from 
0.52±0.18 Log MAR equivalent to -0.08±0.04 Log MAR equivalent using the PELVA 
(Paired sample t-test, p < 0.001) and to 0.03±0.12 Log MAR equivalent using the optical 
low vision aid (Paired sample t-test, p < 0.001) (Table 7.1).  
 
Low contrast near visual acuity using a Colenbrander chart significantly improved from 
0.88±0.22 Log MAR equivalent to 0.03±0.12 using the PELVA (Paired sample t-test, p < 
M
o
d
e
ra
te
 v
is
u
al
 im
p
a
ir
m
e
n
t 
(0
.6
0
 L
o
g 
M
A
R
 d
is
ta
n
ce
 
vi
su
a
l a
cu
it
y)
 s
im
u
la
to
r 
 
 
Assessment 
Without 
low 
vision 
aids 
With PELVA (5X 
magnification) 
With optical low vision 
aid (3.6X equivalent 
magnification) 
mean±SD mean±SD P-value¹ mean±SD P-value² 
Distance visual acuity (Log 
MAR) 
0.6±0.006 - - - - 
Contrast sensitivity at 1 
meter (Pelli-Robson) 
1.50±0.09 - - - - 
Bailey-Lovie near visual 
acuity (Log MAR) 
0.77±0.16 0.04±0.08 < 0.001* 0.54±0.30 < 0.001* 
High contrast Colenbrander 
near visual acuity ( Log MAR 
equivalent) 
0.52±0.18 -0.08±0.04 < 0.001* 0.03±0.12 < 0.001* 
Low contrast Colenbrander 
near visual acuity ( Log MAR 
equivalent) 
0.88±0.22 0.03±0.12 < 0.001* 0.3±0.19 < 0.001* 
Reading speed (words/ 
minute)  
NM 169.91±33.56 - 120.16±32.21 - 
Number of visible characters  - 21.8±1.69 - 13.50±2.17 - 
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0.001) and to 0.03±0.19 using the optical low vision aid (Paired sample t-test, p < 0.001) 
(Table 7.1). 
 
With 0.60 Log MAR simulator, participants could not see clearly enough to be able to 
read the IREST passages at 40cm, therefor reading speed could not be measured at 
40cm, but the reading speed was significantly improved using the PELVA to 169.9±33.56 
words/ minute, and with the optical low vision aid to 120.16±32.21 words/ minute 
(Table 7.1). The reading speed was significantly faster using the 5X magnification PELVA 
compared to the 3.6X magnification optical low vision aid (Paired sample t-test, p < 
0.001).  
 
The number of visible characters including spaces was 21.8±1.69 characters using the 
PELVA and 13.5±2.17 characters using the optical low vision aid (Table 7.1).  
 
7.3.2. Severe visual impairment simulator (0.90 Log MAR distance visual acuity) 
With the 0.90 Log MAR simulator, near visual acuity measured using a Bailey-Lovie near 
acuity chart significantly improved from 1.22±0.97Log MAR to 0.46±0.12 using the 
PELVA (Paired sample t-test, p < 0.001) and to 0.83±0.22 using the optical low vision aid 
(Paired sample t-test, p < 0.001) (Table 7.2).  
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Table 7.2: Visual assessment with severe visual impairment simulator, with and 
without low vision aids. P-value¹ the significance of difference between the PELVA and 
without low vision aids (Paired sample t-test). P-value² the significance of difference 
between the optical low vision aid and without low vision aids (Paired sample t-test). 
* The difference is significant (p-value < 0.05). NM = not measurable.   
 
 
High contrast near visual acuity using a Colenbrander chart significantly improved from 
0.69±0.24 to 0.00±0.01 Log MAR equivalent using the PELVA (Paired sample t-test, p < 
0.001), and to 0.34±0.25 Log MAR equivalent using the optical low vision aid (Paired 
sample t-test, p < 0.001) (Table 7.2).  
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Assessment  
Without  
low 
vision 
aids 
With PELVA (5X 
magnification) 
With optical low vision 
aid (3.6X equivalent 
magnification) 
mean±SD mean±SD P-value¹ mean±SD P-value² 
Distance visual acuity (Log 
MAR) 
0.90±0.01 - - - - 
Contrast sensitivity at 1 
meter (Pelli-Robson) 
1.32±0.16 - - - - 
Bailey-Lovie near visual 
acuity (Log MAR) 
1.22±0.1 0.46±0.12 < 0.001* 0.83±0.22 < 0.001* 
High contrast Colenbrander 
near visual acuity ( Log MAR 
equivalent) 
0.69±0.24 0.00±0.1 < 0.001* 0.34±0.13 < 0.001* 
Low contrast Colenbrander 
near visual acuity ( Log MAR 
equivalent) 
0.98±0.31 0.31±0.20 < 0.001* 0.94±0.13 0.521 
Reading speed (words/ 
minute)  
NM 110.62±35.03 - 56.38±3.78 - 
Number of visible 
characters  
- 22.89±2.42 - 9.78±1.72 - 
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Low contrast near visual acuity using a Colenbrander chart significantly improved from 
0.98±0.31 to 0.31±0.20 Log MAR equivalent using the PELVA (Paired sample t-test, p < 
0.001), but did not significantly change 0.94±0.13 Log MAR equivalent (Paired sample t-
test, p = 0.521) using the optical low vision aid (Table 7.2). 
 
With 0.90 Log MAR simulator, participants did not see clearly enough to be able to read 
the IREST passages at 40cm, therefore reading speed could not be measured at 40cm, 
but the reading ability was significantly improved using the PELVA (110.62±35.03 words/ 
minute), and the optical low vision aid (56.38±3.78 words/ minute) (Table 7.2). The 
reading speed was significantly faster using the 5X magnification PELVA compared to the 
3.6X magnification optical low vision aid (Paired sample t-test, p < 0.001).  
 
The mean number of visible characters was 22.89±2.42 characters using the PELVA and 
9.78±1.72 characters using the optical low vision aid (Table 7.2).  
 
7.3.3. Cataract simulator (contrast reduction) 
With the cataract simulator, near visual acuity measured using a Bailey-Lovie near acuity 
chart significantly improved from 1.17±0.10Log MAR to 0.24±0.11 using the PELVA 
(Paired sample t-test, p < 0.001), and 0.50±0.12 using the optical low vision aid  (Paired 
sample t-test, p < 0.001) (Table 7.3).  
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Table 7.3: Visual assessment with cataract visual impairment simulator, with and 
without low vision aids. P-value¹ the significance of difference between the PELVA and 
without low vision aids (Paired sample t-test). P-value² the significance of difference 
between the optical low vision aid and without low vision aids (Paired sample t-test). 
* The difference is significant (p-value < 0.05). NM = not measurable.  
 
 
High contrast near visual acuity using a Colenbrander chart significantly improved from 
0.81±0.09 to 0.02±0.07 Log MAR equivalent using the PELVA (Paired sample t-test, p < 
0.001), and 0.16±0.16 Log MAR equivalent using the optical low vision aid (Paired sample 
t-test, p < 0.001) (Table 7.3).  
 
Low contrast near visual acuity using a Colenbrander chart significantly improved from 
1.16±0.16 to 0.52±0.29 Log MAR equivalent using the PELVA (Paired sample t-test, p < 
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Assessment  
Without  
low vision 
aids 
With PELVA 
(5X magnification) 
With optical low vision 
aid (3.6X equivalent 
magnification) 
mean±SD mean±SD P-value¹ mean±SD P-value² 
Distance visual acuity (Log 
MAR) 
0.66±0.12 - - - - 
Contrast sensitivity at 1 
meter (Pelli-Robson) 
0.9±0.08 - - - - 
Bailey-Lovie near visual 
acuity (Log MAR) 
1.17±0.1 0.24±0.11 < 0.001* 0.50±0.12 < 0.001* 
High contrast Colenbrander 
near visual acuity ( Log MAR 
equivalent ) 
0.81±0.09 0.02±0.07 < 0.001* 0.16±0.16 < 0.001* 
Low contrast Colenbrander 
near visual acuity ( Log MAR 
equivalent ) 
1.16±0.16 0.52±0.29 < 0.001* 1.09±0.29 0.087 
Reading speed (words/ 
minute)  
NM 152.94±32.6 - 117.39±21 - 
Number of visible characters  - 21.67±2.78 - 11.33±3.24 - 
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0.001), but did not improve significantly using the optical low vision aid (Paired sample 
t-test, p = 0.087) (Table 7.3).  
 
Participants did not see clearly enough to be able to read the IREST at 40 cm with the 
cataract simulator, therefore reading speed could not be measured at 40cm, but the 
reading speed was significantly improved to 152.94±32.61 words/ minute using the 
PELVA, and 117.39±20.1 words per minute using the optical low vision aid (Table 7.3). 
The reading speed was significantly faster using the PELVA (5X magnification) compared 
to the lower magnification (3.6X) optical low vision aid (Paired sample t-test, p < 0.001).  
 
The mean number of visible characters was 21.67±2.78 characters using the PELVA and 
11.33±3.24 characters using the optical low vision aid (Table 7.3).  
 
The significance of difference between the PELVA and the optical low vision aid was not 
compared because different equivalent magnification was used 5X magnification with 
the PELVA and 3.6X with the optical low vision aid.  
 
For both the PELVA and the optical low vision aid, the reading speed with the severe 
visual impairment simulator was significantly lower compared to moderate visual 
impairment and cataract simulators (Multiple paired sample t-test, p < 0.001) (Figure 
7.1). However, there was no significant difference (Multiple paired sample t-test, p > 
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0.05) between reading speed using the cataract and moderate visual impairment 
simulators with the PELVA and the optical low vision aid.  
 
Figure 7.1: Reading speed using IREST reading chart for the three different visual 
impairment simulators, with the PELVA and the optical low vision aids.   
 
 
Although the PELVA’s Bailey-Lovie near visual acuity, high contrast Colenbrander near 
visual acuity, low contrast near visual acuity, reading speed, and number of visible 
characters were higher/ better compared to that of the optical low vision aid for all 
simulators (Paired sample t-test p < 0.001), the relationship between the 3.6X optical 
low vision aid and the 5X PELVA was not linear for all of: Bailey-Lovie near visual acuity 
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(Pearson Correlation Coefficient = 0.002, p = 0.989), high contrast Colenbrander near 
visual acuity (Pearson Correlation Coefficient = 0.134, p = 0.298), low contrast 
Colenbrander near visual acuity (Pearson Correlation Coefficient 0.221, p = 0.091), 
reading speed (Pearson Correlation Coefficient = 0.215, p = 0.071), and number of visible 
characters (Pearson Correlation Coefficient 0.051, p = 0.670). Therefore, the comparison 
between the PELVA and the optical low vision aid was not appropriate in this study. 
 
7.3.4. Factors affecting reading speed  
All parameters (Bailey-Lovie near visual acuity, high contrast near acuity, low contrast 
near acuity, reading speed, and the number of visible characters) measured in this study, 
were improved with the PELVA (Paired sample t-test, p < 0.05) using all simulators 
(Tables 7.1, 7.2, and 7.3). Finding the factor(s) that significantly affected reading 
performance with the PELVA was important, therefore, multiple regression analysis was 
performed. 
 
Reading speed with simulators using the PELVA and the optical low vision aid 
All of the Bailey-Lovie near visual acuity, high contrast Colenbrander near visual acuity, 
low contrast Colenbrander near visual acuity, and the number of visible characters were 
significant predictors/ factors (B-coefficient, p < 0.05) of reading speed.  This was the 
case for the PELVA and the optical low vision aid with all simulators (Table 7.4). The 
statistical significance of each predictor/ factor is show in Table 7.4.  
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Low 
vision 
aid 
Simulator Predictor  
(X)  
B-coefficient 
(B) 
P-value 
P
EL
V
A
  (
5
x 
m
ag
n
if
ic
at
io
n
) 
Moderate visual impairment 
simulator  (adjusted R 
square= 0.960, p < 0.001, 
constant4  156.22) 
Bailey-Lovie near visual acuity¹ -231.97 < 0.001* 
High contrast Colenbrander acuity² -104.23 < 0.001* 
Low contrast Colenbrander acuity³ -333.95 < 0.001* 
Number of visible characters +15.53 < 0.001* 
Severe visual impairment 
simulator  (adjusted R square 
= 0.955, p < 0.001, constant4 
90.867) 
Bailey-Lovie near visual acuity¹ -187.89 < 0.001* 
High contrast Colenbrander acuity² -125.44 < 0.001* 
Low contrast Colenbrander acuity³ -301.98 < 0.001* 
Number of visible characters +10.13 < 0.001* 
Cataract simulator (adjusted 
R square = 0.981, p < 0.001, 
constant4 120.74) 
Bailey-Lovie near visual acuity¹ -210.44 < 0.001* 
High contrast Colenbrander acuity² -35.83 < 0.001* 
Low contrast Colenbrander acuity³ -259.83 < 0.001* 
Number of visible characters +12.27 < 0.001* 
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Moderate visual impairment 
simulator  (adjusted R square 
= 0.853, p < 0.001, constant4 
75.68) 
Bailey-Lovie near visual acuity¹ -199.44 < 0.001* 
High contrast Colenbrander acuity² -105.83 < 0.001* 
Low contrast Colenbrander acuity³ -279.35 < 0.001* 
Number of visible characters +10.27 < 0.001* 
Severe visual impairment 
simulator  (adjusted R square 
= 0.82, p < 0.001, constant4 
52.82) 
Bailey-Lovie near visual acuity¹ -172.81 < 0.001* 
High contrast Colenbrander acuity² -93.56 < 0.001* 
Low contrast Colenbrander acuity³ -104.49 < 0.001* 
Number of visible characters +8.37 < 0.001* 
Cataract simulator (adjusted 
R square = 0.811, p < 0.001, 
constant4 72.65) 
Bailey-Lovie near visual acuity¹ -191.76 < 0.001* 
High contrast Colenbrander acuity² -107.10 < 0.001* 
Low contrast Colenbrander acuity³ -85.23 < 0.001* 
Number of visible characters +9.25 < 0.001* 
 
 
Table 7.4: Predictors of reading speed of participants with simulated visual 
impairment (moderate visual impairment, severe visual impairment and cataract 
simulators). * P-value is significant (p < 0.05).¹ Bailey-Lovie near visual acuity in Log 
MAR. ² High contrast Colenbrander near visual acuity in Log MAR equivalent. ³ Low 
contrast Colenbrander near visual acuity in Log MAR equivalent. Regression analysis 
was used to analyse data. 4 Constant is the predicted reading speed when all factors/ 
predictors (X) equal zero. B-coefficient: The predicted reading speed increases (+) or 
decreases (-) by *B-coefficient, for example with the optical low vision aid, the Bailey-
Lovie near visual acuity in Log MAR decrease the predicted reading speed by a factor 
of 191.76.  
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Using data in Table 7.2, for each simulator using the PELVA or the optical low vision aid 
reading speed can be predicted by applying:  
 
Y = Constant + B* Bailey-Lovie near visual acuity in Log MAR + B* High contrast 
Colenbrander visual acuity in Log MAR + B* Low contrast Colenbrander visual acuity 
in Log MAR + B* Number of visible characters for each simulator, where Y is the 
predicted reading speed in words/ minute, the constant is the predicted reading speed 
when all factors (X) equal zero. For example, one the study participants with a cataract 
simulator and using the PELVA, had Bailey-Lovie near visual acuity of 0.30 Log MAR, high 
contrast Colenbrander visual acuity of 0.20 Log MAR equivalent, low contrast 
Colenbrander visual acuity of  0.63 Log MAR equivalent, and a number of visible 
characters of 22 characters. The predicted reading speed (Y) for this participant will be: 
 
Y= 120.74+ 0.30*(-210.44) + 0.20*(-35.83) + 0.63*(-259.83) + 22*(12.27) 
Y= 156.68 words/ minute. 
 
The best and worst predictor would depend on the individual patient’s Bailey-Lovie near 
visual acuity, high and low contrast Colenbrander near visual acuities, and the number 
of visible characters. The best predictor of reading speed in the example above was the 
number of visible characters which increased the reading speed by 223.6%, followed by 
the low contrast Colenbrander near visual acuity which decreased the reading speed to 
135.6% of the initial reading speed, and the Bailey-Lovie near visual acuity which 
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decreased the reading speed to 52.3% of the initial reading speed. The worst predictors 
was the high contrast Colenbrander near visual acuity decreased the reading speed by 
5.9%.   
  
273 
 
 
7.4. Discussion 
This study was intended to investigate factors affecting reading performance of people 
with visual impairment. Ethical approvals from the Research Ethics Committee were 
gained (Appendix IV). An honorary contract was required to gain approval from Cardiff 
and Vale University Health Board, but it took much longer than expected. Therefore, 
with time constraints, patients with visual impairment were replaced with people with 
simulated visual impairment in this study.  
 
Simulation of visual impairment has been employed in several research studies (Wood 
and Troutbeck 1995, Latham et al. 2011, Butt et al. 2014). Although results of simulated 
visual impairment cannot be generalized to all patients with visual impairment such as 
patients with age related macular degeneration (Butt et al., 2014), it can be relevant to 
some conditions such as contrast sensitivity reduction in patients with cataract, and 
uncorrected presbyopia (Latham et al., 2011). Aballea and Tsuchiya (2007) suggested 
that simulation of visual impairment is feasible and a promising method for future 
research. However, they explained that simulation might be practically difficult and not 
all conditions can be ethically simulated. Patients with a visual impairment usually have 
multiple ocular conditions; therefore the advantage of simulated visual impairment is 
that it is possible to evaluate the effect of each factor/ visual function such as contrast 
reduction and reduced visual acuity, separately.   
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Latham et al. (2011) assessed the legibility of pharmacy labels for participants with visual 
impairment. They included 20 normally sighted participants aged 22.4±3.6 years, with 
simulated visual impairment (0.41 and 0.69 Log MAR distance visual acuity). Participants 
read pharmacy labels with their habitual correction and with both simulator spectacles. 
The authors measured reading speed and accuracy of label reading. They evaluated 
distance visual acuity using a Log MAR chart, and contrast sensitivity using a Mars chart. 
Reading acuity, critical print size, and reading speed were assessed using MNRead chart.  
They found that using large print pharmacy labels accurate reading speed improved by 
100% in patients with mild visual impairment, and by 80% in participants with moderate 
visual impairment (Latham et al., 2011). In our study, we could not find the ratio of 
improvement because the reading speed without low vision aids was not known to us. 
Because participants were not able to read IREST reading chart using three visual 
simulators without low vision aids. Participants were able to read with both the PELVA 
and the optical low vision aid. Their reading speed with the PELVA and the optical low 
vision aid was more than 88 words/ minute (i.e. the fluent reading speed as defined by 
Whittaker and Lovie-Kitchin (1993)) using the three visual simulators, except that using 
the severe visual impairment simulator participants were able to read with the optical 
low vision but they did not reach the fluent reading speed of 88 words/ minute.    
  
Butt et al. (2014) assessed the differences between contact lenses-simulated visual 
impairment, and visual impairment due to AMD. The authors assessed visual acuity, 
contrast sensitivity, and the visual fields of 5 normally sighted participants with and 
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without simulator contact lenses. The contact lens had a 6mm black (opaque) central 
pupil. They found that the simulator contact lens was useful in reducing visual acuity (17 
letters on average), and reducing contrast sensitivity (7 letters on average) but not in 
fixation stability. The authors concluded that a contact lens with opaque centre 
simulated retinal blur, and caused a reduction in contrast sensitivity but it could not 
simulate the effect of AMD (Butt et al., 2014).  
 
In this pilot study, we found that the PELVA significantly improved all the Bailey-Lovie 
near visual acuity by equivalent of 4 to 9 lines, high contrast Colenbrander near acuity 
by equivalent of 5 to 8 lines, and low contrast Colenbrander near acuity by equivalent 
of 6 to 8 lines, and reading speed with all visual impairment simulators.  
 
 The optical low vision aid significantly improved the Bailey-Lovie near visual acuity by 
equivalent of 2 to 7 lines, high contrast Colenbrander near visual acuity by equivalent of 
3 to 6 lines, and reading speed with all visual impairment simulators. The optical low 
vision aid improved the low contrast Colenbrander only with moderate visual 
impairment simulator by equivalent of 5 lines, but did not improve it with severe visual 
impairment and cataract simulators. In Chapter 6, patients reported that they used 
PELVAs for a longer reading duration, and for near tasks that had reduced contrast such 
as instructions on packets. Also, the findings in Chapter 4 showed that PELVAs improved 
luminance contrast. These finding supporting this study finding; PELVAs might be more 
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useful compared to optical low vision aids for patients with low contrast or tasks that 
require high luminance contrast. 
 
The difference between Bailey-Lovie near visual acuity in Log MAR and high contrast 
Colenbrander near visual acuity (converted into Log MAR equivalent), might be 
attributed by chart characteristics such as text difficulty or subjective differences, or due 
to the conversion of the Bailey-Lovie near visual acuity to 40 cm, and the Colenbrander 
near visual acuity from decimal to Log MAR equivalent.  
 
A comparison between the PELVA and the optical low vision aids in this study was not 
appropriate, because different magnifications were used with the PELVA (5X) and with 
the optical low vision aid (3.6X).  However, the PELVA was significantly better for all 
simulators. It is important in future to compare the reading performance of PELVAs and 
optical low vision aids.   
 
However it should be noted that the PELVA significantly improved low contrast 
Colenbrander near visual acuity with all simulators, whereas the optical magnifier did 
not. This may well be due to the fact that a contrast enhancement is a feature of the 
PELVA (as shown in Chapter 4).   
 
As magnification increases to the maximum the field of view will be restricted to the 
minimum (Schurink et al., 2011). Den-Brinker and Bruggeman (1996) reported that the 
  
277 
 
 
field height and width had a significant effect on reading speed. The window size was 
found to affect reading speed with and without navigation in patients with a visual 
impairment (Legge et al. 1985, Fine et al. 1996). Legge et al. (2001) suggested that if the 
visual span is reduced the reading rate will be lower. A field of view of 4 to 5 characters 
was found sufficient for fluent reading (88 words/ minute) (Legge et al. 1985, Whittaker 
and Lovie Kitchin 1993). However, Rayner et al. (1982) found that a window size of 15 
characters to the right of the fixation point increased the reading speed. Also, Den-
Brinker and Bruggeman (1996) reported that a large field of view was required for page 
navigation. In our study, the number of visible characters ranged from 21.67 to 22.89 
characters with the PELVA, and from 9.78 to 13.50 characters with the optical low vision 
aid.  The higher reading speed with the 5X magnification PELVA was associated with 
larger number of visible characters seen compared to the 3.6X magnification optical low 
vision aid. The 9.78 characters achieved with the optical low vision aid was associated 
with a reading speed of 56.38 words/ minute; this did not achieve the fluent reading of 
88 words/ minute in the Whittaker and Lovie Kitchin (1993) study. Therefore, the PELVA 
produces a greater magnification with field of view, both of which aided the fluency of 
reading.  
 
 In optical low vision aids, high magnification levels restrict the field of view which 
significantly reduced reading speed (Dickinson and Fotinakis, 2000). This might be due 
to higher magnification that was not accompanied with a proportional increase in the 
number of saccades (Dickinson and Fotinakis, 2000). In comparison, Lowe and Drasdo 
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(1990) suggested that the field of view of patients with a visual impairment using CCTVs 
was approximately equal to the normal field of view, for manual scanning. Den-Brinker 
and Bruggeman (1996) found that when the window size (width and height) with CCTVs 
increased the time required to read a line was decreased, and the number of the 
required saccades was decreased. In this study, the field of view evaluated by counting 
the number of visible characters and this was a significant predictor of higher reading 
speed. Also, a larger field of view was found using the 5X PELVA compared to the 3.6X 
illuminated stand magnifier.  This was expected as the PELVA’s screen diameter is larger 
than that of the optical low vision aid. Also, with optical low vision aids, as magnification 
increases the field of view constricts and the aberration increases.  
 
Nguyen et al. (2009) found that low vision aids (CCTVs and optical low vision aids) 
significantly improved reading ability, and no difference was found in reading ability 
between optical and electronic low vision aids. Our findings agree with all of Margrain 
(2000), Bowers (2000), and Nguyen et al. (2009) in that low vision aids improved reading 
ability. 
 
Peterson et al. (2003) found a higher reading speed with mouse and stand EVES 
compared to the reading speed with optical magnifiers and the reading speed with stand 
EVES was higher compared to the reading speed with mouse EVES. Also, Goodrich and 
Kirby (2001) reported a higher reading speed and duration with the CCTV systems 
compared to optical low vision aids. In our study, the comparison was not appropriate 
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because of different magnification used with the PELVA and the optical low vision aid, 
although reading speed was higher using the PELVA for each simulators. 
 
On the contrary, Nguyen et al. (2009) did not find a significant difference in reading 
speed between optical and electronic low vision aids. Dickinson and Shim (2007) found 
a lower reading speed with low vision aids (hand-held optical magnifiers). Ahn and Legge 
(1995) found a lower reading speed with low vision aids compared to without low vision 
aids, however a higher reading speed was found with spectacle mounted magnifiers, 
followed by hand-held magnifiers, CCTVs and then stand magnifiers.  
 
Whittaker and Lovie-Kitchin (1993) found that reading needed a print size larger than 
acuity threshold, and that the effectiveness of a low vision aid depended largely on 
acuity reserve. They found that near visual acuity was predictive of higher reading rate. 
An acuity reserve of 1.5:1 achieved a ‘fluent’ reading speed (88 words/ minuet) and an 
acuity reserve of 3:1 achieved a ‘high fluent’ reading (174 words/ minute) (Whittaker 
and Lovie-Kitchin, 1993). A reading speed of 118 words/ minute was achieved with an 
acuity reserve of 2:1 (Latham and Tabrett, 2012).  Harper et al. (1999) found that 
reduced visual acuity was associated with lower reading ability. Visual acuity was 
associated with a higher reading speed (Lovie-Kitchin et al., 2000).  The authors found 
that the average oral reading speed, with low vision aids, of patients with near visual 
acuity of 1.0 Log MAR was 56 words/ minute, and 113 words/ minute for patients with 
near visual acuity of 0.2 Log MAR (Lovie-Kitchin et al., 2000). This agrees with our 
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findings; we found that near visual acuity was a significant predictor of reading speed 
using both PELVA and optical low vision aid using all simulators. On the other hand, 
visual acuity was not predictive of reading performance (Cummings et al. 1985, Legge et 
al. 1992, Sunness et al. 2007, Fletcher et al. 1999, Ergun et al. 2003).  
 
In this study, we found that better low contrast acuity was a significant predictor of 
higher reading speed using both PELVA and illuminated stand magnifier with all visual 
impairment simulators including moderate and severe visual impairment, and cataract. 
This agrees with Whittaker and Lovie-Kitchin (1993) who found that, in patients with 
visual impairment, a contrast reserve of 10:1 was required for reading at ‘high fluent’ 
reading speed of 174 words/ minute; a contrast reserve of 4:1 for reading speed of 88 
words/ minute, and a contrast reserve of 3:1 reserve for reading speed of 44 words/ 
minute i.e. spot reading. However these findings were upper-bound values, which might 
not be true for every patient (Whittaker and Lovie-Kitchin, 1993).  
 
Ginsburg (1978) reported that small characters need a higher contrast level for 
identification rather than detection. Crossland et al. (2005) found that the baseline 
contrast measurements were predictive of future reading speed for patients with AMD.  
Legge et al. (1987) found that reading rates were highest for letters ranging in size from 
0.25 to 2 degrees, within this range, reading was very tolerant to contrast reduction for 
1” letters, reading rate decreased by less than a factor of two for a tenfold reduction in 
contrast. Brown (1981) reported that higher contrast was more critical to cataract 
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patients compared to AMD patients, in terms of reading performance with CCTVs. The 
authors also found that word recognition speed in patients with visual impairment was 
more predicted by contrast sensitivity (measured by Arden plates) than visual acuity.  
On the other hand, Van-Nes and Jacobs (1981) found that the accuracy of letters 
recognition did not decrease with lowering contrast to 0.12 Michelson contrast but did 
with further contrast reduction. Therefore,   PELVAs might be useful for patients with 
contrast reduction such as patients with cataract because, the low contrast near acuity 
was significantly improved using the PELVA in this study. Also, PELVAs significantly 
improved the luminance contrast of a low contrast text (Chapter 4).  
 
Legge et al. (1992) found a slower reading rate in patients who had AMD compared to 
other conditions. Brown (1981) found that patients who had AMD needed more 
magnification and more time to recognize texts compared to cataract patients. Central 
visual field status and ocular media status were not predictors of reading speed (Ahn 
and Legge, 1995). In older patients, glaucoma was associated with a lower reading speed 
(Ramulu et al., 2009). Mohammed and Omar (2011) found a lower reading speed in 
young patients (aged 13-19 years) with visual impairment (different ocular conditions) 
compared to a normally sighted age matched group. We did not assessed the effect of 
ocular conditions on reading speed. We found that using the PELVA and the optical low 
vision aid, reading speed was significantly lower with severe visual impairment (0.9 Log 
MAR) compared to moderate visual impairment and cataract simulators. No significant 
difference was found between cataract simulator and moderate visual impairment 
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simulator. However, the findings of this study might not be representative of patients 
with visual impairment, and therefore it is important to evaluate reading speed of 
patients with visual impairment (different ocular conditions).  
 
This study was important because it evaluated factors that might affect reading 
performance using PELVAs. Bailey-Lovie near visual acuity, high contrast and low 
contrast Colenbrander near acuities, and the number of visible characters were 
significant predictors of reading speed. The best and worst predictors might be difficult 
to generalize for patients with visual impairment, because it would depend on the 
individual patient. However, relying on the B-Coefficient found on regression analysis; 
the Bailey-Lovie near visual acuity was the best predictor and the number of visible 
characters was the worst predictors.  
 
The limitations of this pilot study included the small sample (n=10) (Professor Garry 
Rubin advised that 25 patients with visual impairment would be appropriate), and the 
simulation of visual impairment which might not be a true representation for patients 
with visual impairment, although findings do agree with previous studies. Also, only one 
PELVA was evaluated. It might be important to evaluate reading performance with other 
types of PELVAs and with a larger sample of patients with different ocular pathologies. 
A comparison between the PELVA and the optical low vision aid was not possible, 
because of the optics of the optical low vision aids as explained earlier, as we cannot 
compare 5X magnification using the PELVA to 3.6X equivalent magnification using the 
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optical low vision aid. Using a stand magnifier with a higher magnification (5X 
equivalent) could have made it possible to compare between the PELVA and the optical 
low vision aid in this study. Blurring visual acuity using plus lenses were used in this 
study, because it was difficult to reduce visual acuity without affecting contrast; other 
methods of reducing visual acuity by non-optical means should be used in future. The 
use of contact lenses to simulate visual impairment can be considered, however this 
would require an ethical approval.  
 
The use of filters (e.g. Cambridge filters, Bangerter filters, or Vistech light scattering 
filters) would simulate a general blurring (image defocus, reduced visual acuity and 
contrast reduction) (Odell et al., 2009), but they would not simulate the effect of 
reducing one visual acuity alone (e.g. visual acuity reduction without contrast reduction) 
or a particular eye condition. However, other filters could be explored.   
 
A fixed working distance of 40 cm (the distance at which most people read at) was used 
in this study. This might restrict participants to choose a closer/ more comfortable 
distance to read at.  
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7.5. Conclusion 
Both PELVA and optical low vision aid significantly improved Bailey-Lovie near visual 
acuity, high contrast Colenbrander near visual acuity, and reading speed for participants 
with simulated visual impairment. Low contrast near visual acuity was improved 
significantly using the PELVA with all visual impairment simulators, the optical low vision 
aid improved the low contrast near acuity with one simulator only (moderate visual 
impairment simulator). The reading speed was significantly faster with the PELVA (5X 
magnification) than that achieved with the low magnification (3.6X) provided by the 
optical low vision aid. Better near visual acuity, better low contrast near acuity, and a 
higher number of visible characters were significant predictors/ factors of a higher 
reading speed using the PELVA and the optical low vision aid for all simulated visual 
impairment. 
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CHAPTER 8: Summary of thesis findings 
 
This thesis aimed to inform those who prescribe or choose PELVAs about the functions 
or attributes that are most important when considering their use for people with a visual 
impairment.  
 
We evaluated PELVAs from different aspects: 1) agreement between the reported 
PELVAs parameters' (including display screen size and magnification) and those 
measured in an independent setting, 2) estimation of PELVAs contrast enhancement 
features and resolution, 3) the prescribing patterns for PELVAs by clinicians already using 
them, 4) the use and satisfaction of these devices among patients with visual 
impairment, and 5) reading performance of participants with simulated visual 
impairment using PELVAs.  
 
8.1. Main findings of the thesis 
There were statistically significant differences between PELVAs measured screen 
diameter and reported diameter, although these differences were small (-0.03±0.07 
inch) and considered unlikely to have any clinical implications. 
 
We found that variations between reported manufacturers magnification of PELVAs and 
those measured in an independent setting were statistically significant. For the vast 
majority of PELVAs, the magnification was outside the ISO standard for magnifiers 
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tolerance. Clinicians should be aware that variations may occur between manufacturers 
reported magnification and those measured in an independent setting to ensure they 
meet their patients’ requirements.   
 
Some PELVAs (A, B, F, G, I, J, and K) were shown to significantly enhance the luminance 
contrast of a high contrast letter. All PELVAs (A-L) lie within the minimum recommended 
luminance contrast ratio of text and background by the ISO9241 Part3 (2008) which is 
3:1, except PELVA D which was also found to give higher than expected magnification 
compared to manufacturers reported data (106%). This might be explained by 
manufacturing error, or technical faults.  
 
Some PELVAs (A, B, F, I and K) lie within the preferred contrast ratio by Ware (2013) of 
10:1. For a patient with reduced contrast sensitivity such as patients with glaucoma or 
cataract, PELVAs will be useful to improve a low contrast scene or target. However, 
whilst some PELVAs (B, C, and E) significantly improved (almost doubled) the luminance 
contrast of a low contrast letter, the contrast was not the same as a high contrast letter. 
So, for people with very much reduced contrast sensitivity it may not improve it enough. 
 
Illumination conditions had no significant effect on the luminance contrast of PELVAs. 
There was no significant difference between black-on-white and white-on-black 
contrast viewing modes on the luminance contrast of PELVAs. The dynamic viewing 
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conditions (refreshed image) had an advantage over the static viewing conditions in 
terms of significant increase of luminance contrast.  
 
The estimated resolution limit of some PELVAs was comparable to the resolution of a 
general computer screen. The resolution limit was increased with increasing 
magnification. High resolution is an important factor to maintain a good quality image, 
particularly for patients with visual impairment. 
  
Despite PELVAs being available for prescription for patients with visual impairment on 
loan free of charge, only 10% of (6,668) patients attending the LVSW were prescribed 
these devices. Predictors for a patient (all patients) being prescribed a PELVA include: 
younger age, being a male, having poorer visual acuity, being registered as sight 
impaired or severely sight impaired, and not having AMD or cataract. These were similar 
to the prescribing of PELVAs in adults (> 18 years) with visual impairment. Optometrists 
might be less likely to offer PELVAs to older patients and women, or it may be that older 
patients and women were more likely to turn them down. The fact that there was no 
restriction on prescribing and that only 10% of patients were prescribed a PELVA 
provides a holistic view of the need for these devices in NHS services. These results will 
be useful for those planning services, and for clinicians to recognise those patients most 
likely to benefit from being prescribed a PELVA.   
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Interestingly, a larger proportion of children aged 18 years and younger were prescribed 
a PELVA (36.5%) compared to 10% of adults. Factors affecting this should be investigated 
in the future. Children age or gender did not affect the prescribing of PELVAs. Children 
who were prescribed a PELVA were more likely to have cataract, glaucoma or other eye 
conditions such as cortical visual impairment and optic nerve atrophy, and more likely 
to be registered as sight impaired or severely sight impaired.  However, none of these 
was a predictor for a child being prescribed a PELVA. Other factors such as ergonomics 
of the devices or preference might affect the prescribing of PELVAs among children.  
 
A larger proportion of patients used optical low vision aids compared to PELVAs and a 
third of the patients used both PELVAs and optical low vision aids. Some patients used 
other low vision aids and substitution aids. PELVAs were used more frequently than 
optical low vision aids for reading shop prices, reading instructions on packets, signing 
their own names, and doing a special hobby compared to optical devices. PELVAs were 
significantly more helpful than optical low vision aids for the near vision tasks 
performed. PELVAs were used less frequently but for a longer duration of reading 
compared to optical low vision aids. It would be beneficial for clinicians to demonstrate 
to patients (particularly younger males with poor binocular distance Log MAR visual 
acuity, who are registered as sigh impaired or severely sight impaired and do not have 
AMD or cataract) the benefits, and tasks that can be performed using a PELVA and how 
helpful they might be for a specific task. For example, reading instructions on packets 
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where contrast matters and reading for longer duration where a patient comfort 
matters.   
 
For patients with simulated visual impairments, the PELVA and the optical low vision aid 
significantly improved Bailey-Lovie near visual acuity, high contrast Colenbrander near 
visual acuity and reading speed. Low contrast Colenbrander near visual acuity was 
improved significantly with the PELVA using all of the three visual impairment 
simulators. Low contrast Colenbrander near visual acuity did not improve with the 
optical low vision aid using severe visual impairment simulator and cataract simulator, 
but improved using moderate impairment simulator. Participants reading speed was 
higher and the number of visible characters was larger with the 5X magnification PELVA 
compared to the 3.6X magnification optical low vision aid. A better near visual acuity, a 
better low contrast near acuity, and a higher number of visible characters were 
significant predictors of a higher reading speed. The best and worst predictors of a 
higher reading speed might depend on the individual patients. PELVAs features such as 
contrast enhancement and a larger screen diameter of PELVAs are likely to explain the 
higher reading speed and the larger number of visible characters achieved with the 5X 
magnification PELVA compared to the lower magnification (3.6X) optical low vision aid.   
 
8.2. Limitations of thesis  
The magnification measurements were limited by manufacturers’ loan period and a 
different sample of PELVAs was not provided to us, therefore in many cases we only 
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used one device. The later was a good reason not to disseminate the names of the 
devices.  
 
Also, we were not able to obtain any information on the manufacturers’ methodology 
of measuring magnification, contrast and resolution in order to be followed in our study. 
Only one observer measured the luminance contrast and estimated the resolution limit.  
 
The data set provided by the LVSW had some limitations such as the lack of contrast 
sensitivity and near visual acuity data, and the fact that several optometrists inserted 
the original data set. It also required a lot of time to be cleaned.  
 
The use of the MLVQ and the way questions were asked might limited our results in 
Chapter 6. In the MLVQ, the patients were asked what type of low vision aid(s) they have 
been using (PELVA, optical low vision aid, or other aids). In addition, there was not an 
option to choose an illuminated hand magnifier or stand magnifier. Hence people may 
have described an illuminated stand magnifier as a hand magnifier or an illuminated 
magnifier. Most illuminated magnifiers are hand or stand magnifiers; hence including 
these as options in the MLVQ is suggested. Patients with a visual impairment might have 
some restrictions that would deter them from accepting the phone interview such as 
hearing difficulty. The phone interview, although useful, might not be informative as 
other interview methods such as semi-structured or focused interviews (may be better).  
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Although these might be more valid for such studies, they are time consuming and 
expensive.  
 
Ethical approvals from different committees were required for a number of studies 
(Chapter 6 and Chapter 7). Our original plan for Chapter 7 was to investigate factors 
(visual functions and/ or devices parameters) that affect reading performance of 
patients with a visual impairment using PELVAs and optical low vision aids. However, it 
took more than one year to gain an ethical approval for the study, but the honorary 
contract for one of the researchers was not issued. This forced us to change the original 
study (a cross-over study with 25 patients with a visual impairment) into 10 of patients 
with simulated visual impairment in the last 2 months of the PhD.  
 
The small sample size and the simulation of visual impairment which might not be a true 
representation for patients with visual impairment was a limitation, although findings 
do agree with previous studies. Also, only one type of PELVA was evaluated. We could 
not compare the performance of the PELVA to the optical low vision aid as they had 
different magnification levels (the 5X PELVA, and the 3.6X optical low vision aid). 
 
Blurring visual acuity using plus lenses were used in this study was a limitation, although 
it was difficult to reduce visual acuity without affecting contrast.  
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8.3. Future work 
In future, it is important to repeat the magnification measurements again with an 
increased number of observers, and batch test PELVAs from each manufacturer, as only 
one of each type of PELVA was measured in the study.  
 
It is recommended that luminance contrast should be measured with more observers 
and different methods such as manufacturers’ methods (if they can be acquired), and 
resolution using a different method such as the SFRplus/ IMAtest software which will 
provide objective measures.  
 
It is important to study factors that might affected the prescribing for PELVAs for 
children as a larger proportion of children (36.5%) compared to adults (10%) were 
prescribed a PELVA.  
 
In order to obtain more specific results about the types of low vision aids used by 
patients with a visual impairment, the inclusion of hand-held illuminated and stand 
illuminated optical low vision aids as options in the MLVQ is suggested.  
 
Evaluating the use and satisfaction of the low vision aids using a semi-structured 
interview instead of a phone interview is suggested because it might be more 
informative for such studies.  
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Further investigations of the factors (other than the benefit for reading or doing near 
vision tasks) that affect patient preference of using a particular low vision aid for a 
specific task such as devices ergonomics or comfort should be explored. Also, the cost 
effectiveness of PELVAs and optical low vision aids should be compared. 
 
Other methods of reducing visual acuity by non-optical means should be considered in 
the future such as the use of contact lenses, or filters. However the use contact lenses 
has ethical issues, and the use of filters would simulate a general blurring (image 
defocus, reduced visual acuity and contrast reduction) and it would not simulate the 
effect of reducing visual function alone (e.g. visual acuity reduction without contrast 
reduction) or a particular eye condition.  
 
It would be beneficial to evaluate reading performance with other types of PELVAs and 
using a larger sample of patients with different ocular pathologies or causes of visual 
impairment.  
 
This thesis was important because it has been the first that evaluated the use and 
prescribing for PELVAs for patients with a visual impairment, and it assessed various 
PELVA parameters including magnification, contrast enhancement features and the 
resolution limit. In addition it is the first that found factors that affect the reading 
performance using PELVAs. It also compliments a randomized control trial being 
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conducted currently by Taylor et al. (2014) to determine the impact and cost 
effectiveness of prescribing PELVAs.  
 
With technological development and increasing access for people in all age groups to 
computers and high-tech devices, electronic low vision aids might supersede 
conventional low vision aids. The prescribing patterns for low vision aids might change 
dramatically in the near future, with increased prescribing for PELVAs. Features such as 
affordability, ease of use, devices ergonomic, small size, portability, contrast 
enhancement, variable magnification, and large field of view would probably make 
PELVAs the low vision aids of choice for an increasing number of patients with a visual 
impairment. Issues such as patients’ preference and comfort, and devices durability 
might affect the uptake of PELVAs, and these are important factors to be studied in 
future. Practitioners are advised to demonstrate PELVAs and their features, and give 
patients some time to trial them before prescribing a low vision aid. Studying the cost 
effectiveness of PELVAs is another important issue to be explored in order to guide 
services of the funding costs for patients with a visual impairment.  
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Appendix I: A sample of the LVSW Compact+ prescribing data set, 2011-2012 
A sample of Compact+ prescribing data set as received from the LVSW. Type = type of visit, VA Dist = distance visual acuity in Snellen 6 metres notation, AMD = age-related 
macular degeneration, Diabe Eye Dis = diabetic eye diseases, Other = other ocular conditions, Not known = the diagnosis is not known/ not confirmed yet, Prescribed = 
prescribed a Compact+ or not, Registered = registration of visual impairment status, 0 = No, 1 = Yes, N = No, Y = Yes, VA = visual acuity 
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Appendix II: The Manchester Low Vision Questionnaire (MLVQ) 
 
 
 
  
Part I: Tasks and difficulty: 
Have you used/ or tried to use your low vision aid to (1-18)? If you have tried to use your magnifier(s) for 
this how helpful have you found them? 
 
1. Read or tried to read ordinary print books/newsprint/ magazines/TV times 
2. Read or tried to read large print books, large print newspapers, or newspaper headlines 
3. Read or tried to read letters/cards/bank statements/other correspondence  
4. Read or tried to read your own writing  
5. Read or tried to read instructions on packets, tins, bottles, medicines, etc.  
6. Read or tried to read shop prices/labels/tickets  
7. Read or tried to read the markings on dials - e.g. on the cooker, radio, hi-fi, washing machine,etc. 
8. Read or tried to read the telephone directory to check numbers 
9. Read or tried to read the time on your watch  
10. Tried to fill in forms, cheques, cards, etc.  
11. Signed or tried to sign your own name  
12. Written or tried to write your own letters  
13. Identified or tried to identify money  
14. Sewed/knitted/mended or attempted to sew, knit, or mend  
15. Done or tried to do a special hobby  
16. Watched or attempted to watch TV  
17. Read or attempted to read street signs/bus numbers/ directions, etc. 
18. Been on a trip or special day out 
 
Part II: Frequency and duration of reading: 
 
a. How often do you use your preferred low vision aid  for reading? 
b. How long can your preferred low vision aid be used at any one time for reading? 
 
Source: Harper et al. 1999, Hinds et al. 2003 
 
  
 331 
 
Appendix III: Ethics applications for Chapter 6 
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Appendix IV: Ethics applications for Chapter 7 
  
 
 
 
 
SCHOOL RESEARCH ETHICS AUDIT COMMITTEE  
   
Project Number:   1352  
  
Amendment No.     2  
 
Project title:  Investigation of the factors (visual functions and/or device parameters) that affect reading 
performance of people with visual impairment using portable electronic low vision aids (PELVA)  
  
Lead Investigator(s):   Prof Rachel North    
  
Date:     24/10/2014                               Project expiry date: 24/10/2015    
_______________________________________________________________________________  
  
With reference to the above application, I am pleased to confirm that the request to amend the above 
ethics application has been granted.    
  
These amendments include:   
1) 10 normally sighted people (male and female)   
2) Participant age: between 20 and 30 years old) normally sighted 
2) Cognitively unimpaired  
3) Extend until 24/10/2015  
Simulators:  
Simulator glasses will be used to mimic visual impairment (instead of patients with macular 
degeneration):   
 
1) Refractive error (DVA Snellen equivalent of 6/12 and 6/30 
2) Reduced contrast (nuclear cataract)   
3) Reduced contrast (cortical cataract)   
4) AMD (central scotoma)   
  
Please inform the School Research Ethics Audit Committee immediately of any changes to 
the protocol, changes to personnel involved, or of any unforeseen circumstances arising from the 
study.  
  
Please note the data retention periods specified by the University  
• For non-funded non-clinical research, data shall be retained for no less than 5 years, 
or 2 years post-publication  
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Approval form 2014_0809  
  
  
  
• Undergraduate project data shall be retained at least until the end of the  University 
appeals process  
  
  
  
  
  
  
  
Signed:   
Dr Julie Albon, Chairperson   
Approval form 2014_0809 
School of Optometry and Vision Sciences  
Ysgol Optometreg a Gwyddorau’r Golwg  
College of Biomedical and Life Sciences  
Cardiff University  
Maindy Road  
Cardiff   
Head of School Pennaeth Yr Ysgol Professor Yr Athro Marcela Votruba   CF24 4HQ Wales  
UK  
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School of Optometry and Vision Sciences 
Ysgol Optometreg a Gwyddorau’r Golwg 
 
Head of School Pennaeth Yr Ysgol Professor Yr Athro Marcela V. Baxter 
College of Biomedical and 
Life Sciences 
Cardiff University 
Maindy Road 
Cardiff  
CF24 4HQ 
Wales  UK 
 
Tel Ffôn  +44(0)29 2087 
4374 
Fax Ffacs  +44(0)29 2087 
4859 
http://www.cardiff.ac.uk/
optom/ 
 
Prifysgol Caerdydd 
Heol Maindy 
Caerdydd  
CF24 4HQ 
Cymru, Y Deyrnas Gyfunol 
 
Participant Information Sheet 
 
Study Title: Investigation of the factors (visual functions and/ or device 
parameters) that affect reading performance of people with visual impairment 
who are using pocket and portable electronic low vision aids (PELVAs) 
 
Approval No: 2014-0809 
 Version 3.0 (24/10/2014) 
 
 
 
We would like to invite you to take part in our research study. Before you decide we would like you to 
understand why the research is being done and what it would involve for you. One of our research team 
will go through the information sheet with you and answer any questions you have. We would suggest 
this should take about 10-15 minutes.  
 
('Part 1' tells you the purpose of this study and what will happen to you if you take part. 'Part 2' gives you 
more detailed information about the conduct of the study). 
 
Please, ask us if there is anything that is not clear. 
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Part 1 of the information sheet:  
 
1.1 What is the purpose of the study? 
Portable electronic low vision aids (PELVAs) have now become a prescribing option in Low Vision Service 
Wales (LVSW). This study will evaluate how we can predict who will find PELVAs useful and the factors 
that affect their usefulness. 
 
1.2 Why have I been invited? 
You are invited to take part in this study because you are 20 -30 years old and you are normally sighted.   
 
1.3 Do I have to take part?  
It is entirely up to you to decide if you wish to volunteer for the study. We will describe the study and go 
through this information sheet. If you agree to take part, we will ask you to sign a consent form. You are 
free to withdraw at any time, without giving a reason.  
 
1.4 What will happen to me if I take part? 
This study involves a visit to Low Vision Clinic at Cardiff University (the visit will take about 90-120 
minutes).  
 
You will be asked to wear simulator glasses and you will undergo a number of visual tests. These include:  
Visual acuity test, contrast sensitivity test, and reading performance test with and without low vision aids 
(electronic and optical device).  
 
1.5 Expenses and payments: 
- No payment will be provided towards your expenses for this study.  
 
1.6 What will I have to do? 
You are expected to a visit at the Low Vision Clinic, Cardiff University (the visit will take about 90-120 
minutes). 
 
1.7 What are the possible disadvantages and risks of taking part? 
There are no risks involved in this study.  
 
1.8 What are the possible benefits of taking part? 
This study will help us to identify who is most likely to benefit from portable electronic low vision aids 
(PELVAs) and help us to develop guidance for clinicians about prescribing these devices. 
 
1.9 What happens when the research study stops? 
You do not need to do anything.  
 
1.10 What if there is a problem? 
Any concern/ complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. The details are included in 'Part 2' of this information sheet. 
 
1.11 Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in confidence. 
The details are included in 'Part 2' of this information sheet. 
 
If the information in 'Part 1' has interested you and you are considering participation, please read the 
additional information in 'Part 2' before making any decision. 
 
Part 2 of the information sheet:  
 
2.1 What if relevant new information becomes available? 
If this occurs you will be contacted.  
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2.2 What will happen if I don't want to carry on with the study? 
You can withdraw from the study and you can keep in contact with us to let us know your progress. 
Information collected may still be used.  
 
2.3 What if there is a problem? 
If you have a concern about any aspect of this study, you should contact the researchers who will do their 
best to answer your questions [their contact details are provided at the bottom of the information sheet].  
 
2.4 Will my taking part in this study be kept confidential? 
Yes, your results will remain confidential. All procedures are compliant with the Data Protection Act 1998. 
Also, in accordance with the Data Protection Act this information may be retained indefinitely. 
Researchers will not access your personal/ medical information at any point. Data collected during the 
study will be kept anonymous and will be stored in a password-protected computer. 
 
2.5 What will happen to the results of the research study?  
Study results will be kept anonymous. Results may be used in subsequent publications (e.g. a PhD thesis, 
and peer reviewed journals) and conference presentations. 
 
2.6 Who is organising and funding the research?  
The sponsor of this study is Cardiff University. Researchers will not be paid for including you in this study. 
 
2.7 Who has reviewed the study? 
This study has been approved by School of Optometry and Vision Sciences Ethics Committee.   
 
2.8 Further information and contact details: 
For general/ specific information about research and advice as whether you should participate, please 
contact: 
 
Areej Okashah, School of Optometry and Vision Sciences, Maindy Rd, Cardiff CF24 4HQ Tel. +44 
(0)29 2087 0247 
 
For concerns/ complaints about research, please contact research team who will be happy to raise/ solve 
any problem that you have: 
 
Areej Okashah, School of Optometry and Vision Sciences, Maindy Rd, Cardiff CF24 4HQ Tel. +44 
(0)29 2087 0247 
 
Prof. Rachel North School of Optometry and Vision Sciences,Maindy Rd, Cardiff CF24 4HQ Tel. +44 
(0)29 2087 5114  
 
Dr. Barbara Ryan / School of Optometry and Vision Sciences, Maindy Rd, Cardiff CF24 4HQ Tel. 
+44 (0)29 2087 0561 
 
 
Thank you for taking time to read this information. 
Please, sign attached consent form if you agree to participate in this study. 
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Consent Form 
 
Study Title: Investigation of the factors (visual functions and/ or device 
parameters) that affect reading performance of people with visual 
impairment who are using pocket and portable electronic low vision aids 
(PELVAs) 
 
Approval No: 2014-0809 
Version 3.0 (24/10/2014) 
 
 
Name of Researchers: Rachel North, Barbara Ryan, Areej Okashah 
Please initial box 
1 I confirm that I have read and understand the Participant Information Sheet Version 3.0 
(24/10/2014) for the above study. One of the research team went through the information sheet 
with me and I have had the opportunity to ask questions, and have had these answered 
satisfactorily. 
 
 
2 I understand that participation is entirely voluntary and that I can withdraw at any time without 
giving a reason. 
 
 
3 I understand that relevant sections of data collected during the study may be looked at by the 
named researchers I give permission for these individuals to have access to this data. 
 
 
4 I understand that data collected during the study will be kept anonymous. The results will be 
used in subsequent publications (e.g. a PhD thesis, and peer reviewed journals) and conference 
presentations and to inform the development of Low Vision Service Wales. 
 
 
5 I agree to take part in the above study. 
 
 
6 I wish to receive a report of study findings. 
 
 
 
Name of Participant                                                      Date                                     Signature 
 
Name of Person taking consent  
(If different from researcher)                                       Date                                     Signature 
 
Researcher                                                     Date                                     Signature 
School of Optometry and Vision Sciences 
Ysgol Optometreg a Gwyddorau’r Golwg 
 
Head of School Pennaeth Yr Ysgol Professor Yr Athro Marcela V. Baxter 
College of Biomedical and Life 
Sciences 
Cardiff University 
Maindy Road 
Cardiff  
CF24 4HQ 
Wales  UK 
Tel Ffôn  +44(0)29 2087 4374 
Fax Ffacs  +44(0)29 2087 4859 
http://www.cardiff.ac.uk/opto
m/ 
Prifysgol Caerdydd 
Heol Maindy 
Caerdydd  
CF24 4HQ 
Cymru, Y Deyrnas Gyfunol 
 353 
 
To: School of Optometry Human Science Ethical Committee 
 
Project Number: 1352 
Investigation of the factors (visual functions and/ or device parameters) that affect reading performance 
of people with visual impairment using portable electronic low vision aids (PELVA) 
 
Areej Okashah, Prof Rachel North, Dr Barbra Ryan 
 
We would like to make the following amendments to the above project: 
Subjects to be recruited: 
1) 10 normally sighted people (male and female)  
2) Participant age: between 20 and 30 years old) normally sighted  
 
Simulators: 
Simulator glasses will be used to mimic visual impairment (instead of patients with macular degeneration):  
1) Refractive error (DVA Snellen equivalent of 6/12 and 6/30  
2) Reduced contrast  
 
Low vision aids/ magnifiers: 
Compact+ (a PELVA) with fixed magnification levels 5x, 7.5x, and 10x, and illuminated hand-held optical 
magnifiers with magnification (the required magnification level will be chosen by participant). 
 
Clinical assessment:  
Subjects who consent will undergo the following assessment (with and without simulators): 
1) Distance visual acuity using LogMAR chart  
2) Contrast sensitivity using a Pelli-Robson chart  
3) Threshold near visual acuity using high and low contrast Bailey Lovie near 
LogMAR chart (with and without PELVA)   
4) Reading speed using IRest test with and without low vision aids (PELVA and 
optical magnifiers) 
5) Field of view by counting the number of characters seen with PELVA and 
optical magnifiers 
6) Magnification and contrast settings used by patients will be recorded, if applicable.   
 
One visit lasting approximately 45 minutes. 
 
Analysis: 
The reading speed and accuracy ‘with’ and ‘without’ simulators will be compared between ‘with’ 
and ‘without’ PELVAs (using two way ANOVA). Of the factors that affect the reading speed and 
accuracy including contrast sensitivity, VA at distance and near, central scotoma, field of view, 
or magnification will be determined using multiple regression analysis. 
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Appendix V: Poster presentation (BCOVS, HOAC, OPTOM poster day)  
BCOVS September 2012, Bradford, UK. (Published abstract: Okashah A, North R, Wood I, Ryan B. 2012. 
Pocket and portable electronic low vision aids (PELVAs): Do the manufacturers provide an accurate 
description?, OPO (33), 2012). 
HOAC September 2012, Chester, UK. 
OPTOM poster day May 2014, School of Optometry and Vision Sciences, Cardiff, UK.    
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Appendix VI: Poster presentation (AAO)   
AAO October 2014, Seattle USA.  
 
 
